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ABSTRACT 
Although monocyte margination to the lungs is enhanced during endotoxemia, little is 
known of their role in sepsis-associated acute lung injury (ALI).  Moreover, monocytes 
exists as two functionally distinct subsets ‘inflammatory’ Gr-1high and ‘resident’ Gr-1low, 
which exhibit heterogeneous inflammatory responses upon LPS stimulation both in vivo 
and in vitro but, the signalling mechanisms regulating their differential responses are 
unknown. 
The objective of this research was to define the role of monocyte-endothelial 
interactions during pulmonary microvascular injury, in response to LPS challenge, using 
an in vitro monocyte-endothelial coculture model. The specific aims were to: establish a 
primary lung endothelial cell line culture; investigate priming and enhancement of 
monocyte pro-inflammatory response; investigate the role of the p38 MAPK pathway in 
the differential monocyte subset cytokine response, and investigate the role of LPS-
mediated TLR4 signalling for monocyte-endothelial reciprocal activation. 
 Primary mouse lung endothelial cells (MLEC), that were successfully cultured, 
displayed typical morphological and phenotypic properties of the vascular endothelium.  
During coculture with MLEC, monocytes produced significantly higher levels of TNF 
when treated with a single high dose of LPS when compared with monocytes cultured 
alone. Also, upon LPS stimulation, Gr-1high monocytes expressed significantly higher 
levels of TNF, IL-6, COX-2, and iNOS in comparison to Gr-1low monocytes.  Furthermore, 
significantly higher levels of p38, a critical regulator of inflammatory cytokines, were 
induced in Gr-1high monocytes in comparison to Gr-1low monocytes. Finally, using a 
chimeric system of TLR4+/+ (LPS responsive) and TLR4-/- (LPS unresponsive) 
monocytes and endothelial cells, it was demonstrated that monocytes could activate 
endothelial cells through TNF-dependent signalling, while endothelial cells could induce 
TNF production in monocytes. 
 These data indicate an important role for monocytes, especially the Gr-1high 
subset in the pathogenesis of ALI, and suggest that the p38 MAPK pathway could play a 
pivotal role in regulating monocyte-induced pulmonary inflammation during sepsis-
associated ALI. 
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Acute lung injury (ALI) and its more severe manifestation, acute respiratory distress 
syndrome (ARDS) are frequent complications of sepsis. Sepsis induces the activation of 
endothelial cells, and also initiates the sequestration and margination of leukocytes to 
the lung microvasculature. Activated, lung-marginated leukocytes, release a plethora of 
inflammatory mediators which promote the disruption of endothelial cell 
junctions/contractile functions, culminating in the development of pulmonary oedema – 
the hallmark of ALI 
 Investigations into the cellular mediators involved in the pathogenesis of sepsis-
induced ALI have focussed mainly on neutrophils. Consequently, researchers have 
accumulated substantial evidence that illustrate the central role neutrophil-endothelial 
interactions within the pulmonary microvasculature play in the development of 
ALI/ARDS. However, monocytes, another group of leukocytes, which are also recruited 
to the pulmonary microvasculature during sepsis, have largely been disregarded and as 
such, little is known of their role in the pathophysiology of ALI.  
Despite this, recent studies using mouse models of endotoxin-induced ALI have 
demonstrated that large of amounts of bone marrow derived monocytes are recruited 
to the lung microvasculature, where they induce activation of lung endothelial cells in a 
tumour necrosis factor (TNF-α)-dependent manner. In addition, during subclinical 
endotoxemia, these bone marrow derived monocytes marginate to the lung 
microvasculature, and are ‘primed’ such that in response to secondary endotoxin 
challenge they produce even greater amounts of TNF-α. However, the mechanisms 
responsible for this priming-induced enhancement of the monocyte inflammatory 
responses have not been studied. Furthermore, monocytes are now known to exist as 
two subsets in mice: Gr-1high and Gr-1low monocytes. In vivo studies in mouse models of 
endotoxemia have illustrated that the Gr-1high subset produces higher levels of TNF than 
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the Gr-1low subset within the lung microvasculature. In stark contrast, other studies 
have demonstrated that Gr-1low monocytes produce higher levels of TNF upon 
lipopolysaccharide (LPS) stimulation of whole blood in vitro. The reasons for this 
discrepancy in pro-inflammatory responses of the monocyte subsets between in vivo 
and in vitro studies have not been investigated. Moreover, the signalling mechanisms 
regulating their differential inflammatory cytokine responses have not been elucidated.   
This introduction chapter will address the current understanding of the 
molecular and cellular mechanisms involved in the pathogenesis of sepsis-induced ALI, 
and particular attention will be paid to the mechanisms involved in leukocyte-mediated 
lung endothelial injury. This chapter will also address the current knowledge of 
monocyte subset biology, their inflammatory responses in various models of injury, and 
their potential roles/contribution to the development of lung endothelial injury during 
sepsis. Signalling mechanisms regulating cytokine production in monocytes, and their 
potential involvement in the differential monocyte subset responses will also be 
discussed. Finally, the aims and objectives of this project will be outlined. 
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1.1 Acute Lung Injury (ALI) 
ALI is a condition that is characterised clinically in patients by the presence of impaired 
gas exchange, pulmonary oedema and chest radiographic abnormalities, which occur in 
the absence of heart failure. It was originally described as acute respiratory distress 
syndrome (ARDS) by Ashbaugh and colleagues in 1967, when 12 patients who had a 
variety of underlying conditions ranging from pneumonia to multiple traumas 
presented with similar lung pathologies upon chest radiography (1). In order to 
improve diagnostic consistency and allow comparison of epidemiological and treatment 
studies, the American-European Consensus Conference (AECC) proposed standard 
criteria to define ALI and ARDS (2). According to the AECC definitions, ALI can be 
described as a syndrome of non-cardiogenic origin that is characterised by increased 
capillary permeability, arterial hypoxemia (PaO2/F1O2≤300 mmHg), diffuse pulmonary 
infiltrates on chest radiography, and the need for mechanical ventilation (2). ARDS on 
the other hand is associated with similar chest radiographic abnormalities, but a more 
severe hypoxemia (PaO2/F1O2≤200 mmHg) (2).  
Although the exact incidence of ALI and ARDS are uncertain, it is estimated in the 
United States (US) that around 17–64 per 100,000 (person/years) develop these 
conditions (3). The incidence in the US is slightly higher than in Europe, Australia, and 
other developed countries which is estimated at around 17–34 per 100,000 
(person/years) (3). Generally, approximately 5–15% of patients admitted to the 
intensive care unit (ICU) develop ARDS. Mortality is reported to be in the range of 35–
60% when patients who meet the AECC criterion for ARDS are included (3, 4). Although 
there has been a progressive decline in ALI/ARDS incidence and mortality (5), mainly 
16 
 
due to improvements in supportive care therapy, ARDS especially remains one of the 
major causes of morbidity and mortality in the ICU. 
ALI can be caused by a variety of underlying conditions (Table 1.1), which have 
been divided into two main groups based on pathophysiological mechanisms. They 
include: direct (pulmonary) insult (infectious, mechanical or chemical) and indirect 
(extra-pulmonary) insult (sepsis or trauma, pancreatitis) (6). After direct insults, the 
pulmonary epithelium is the primary structure injured, while the main target of damage 
after indirect insults is the pulmonary endothelium. 
 
Direct (pulmonary) insults Indirect (extra-pulmonary) insults 
Frequent causes 
Pneumonia 
Aspiration  
Frequent causes 
Sepsis 
Severe trauma 
Less frequent causes 
Fat emboli 
Inhalation injury 
Reperfusion 
Less Frequent causes 
Acute pancreatitis 
Drug overdose 
Transfusion 
 
Table 1.1. Underlying conditions associated with the development of ALI/ARDS (Ware L and Matthay M, 2000) 
 
 
Clinical features  
The pathophysiological process of ALI is similar in patients regardless of whether the 
underlying condition arises from a direct or an indirect insult. The pathologic features 
of the lungs in ARDS occur due to severe injury to the alveolar-capillary bed – the main 
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site of gaseous exchange. There are three main phases of ALI/ARDS; these include an 
inflammatory or exudative phase, a proliferative phase, and a fibrotic phase (7). 
 The inflammatory phase is characterised by the development of hypoxemia, 
bilateral infiltrates on the chest radiograph, and a reduction in pulmonary compliance, 
which lasts up to 7 days from onset. Histological features include dense eosinophilic 
hyaline membranes and alveolar collapse, and loss of barrier function of capillary 
endothelial cells leading to capillary leak and oedema formation. Type I pneumocytes 
also become swollen with cytoplasmic vacuoles, and eventually detach from the 
basement membrane. This results in the influx of leukocytes, erythrocytes, fibrin, and 
other cell debris. 
 The sub-acute or proliferative phase can start from as early as day 5. Persistent 
hypoxemia, increased dead space, and reduced lung compliance are some of the 
characteristic features of this phase. Also present are interstitial fibrosis, proliferation 
of type 2 alveolar cells, and disruption of capillary function due to microvascular 
thrombus formation. In some patients these changes resolve and clinical improvement 
follows whereas other patients progress into the fibrotic phase. 
 The genesis of the fibrotic stage is not clearly defined but may begin as early as 
day 7 and last for many weeks. It results from widespread pulmonary fibrosis, and loss 
of the normal lung structure leading to deterioration in lung compliance, and an 
increase in dead space. Clinically, this presents as a reduction in carbon dioxide 
excretion, which may be accompanied by an improvement in oxygenation. 
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Treatment  
The management of ALI/ARDS mainly involves supportive care and mechanical 
ventilation. The general principles of supportive care for patients include identifying 
and treating underlying causes of ALI/ARDS, preventing secondary lung injury such as, 
aspiration or nosocomial infections; maintaining adequate oxygenation; maintaining 
fluid balance, and nutritional support. 
 As sepsis is commonly associated with ALI, treatment usually includes 
antimicrobial therapy. This initially involves the administration of a broad spectrum of 
antibiotics pending the establishment of a formal microbial diagnosis, after which a 
narrow spectrum antibiotic therapy ensues. 
Owing to the altered capillary permeability in ALI, excessive fluid administration 
leads to a deterioration in gas exchange. This occurs because excess fluid increases the 
capillary hydrostatic pressure, which in turn causes pulmonary oedema and a 
worsening in oxygenation and carbon dioxide elution. On the other hand, the benefits of 
a more liberal fluid strategy are an increase in cardiac output with a possible 
improvement in non-pulmonary organ perfusion thus; fluids are also usually 
administered to patients. In patients with sepsis associated ARDS, therapy usually 
involves the administration of sufficient fluid volume to achieve a high-normal oxygen 
delivery. In the absence of sepsis, fluids should be restricted such that the lowest 
possible pulmonary capillary wedge pressure can be achieved whilst maintaining 
adequate carbon monoxide levels (8). 
 The major physiological abnormalities in ARDS are hypoxemia due to reduced 
lung compliance from increased extravascular water. Patients are often mechanically 
ventilated to maintain adequate gas exchange until cellular damage resolves.  
Mechanical ventilation is carefully monitored in patients to prevent the development of 
19 
 
ventilator-induced lung injury – a condition that constitutes the tetrad of barotraumas, 
volutrauma, atelectrauma, and biotrauma. Mechanical ventilation is conventionally 
delivered as positive pressure ventilation with positive-end expiratory pressure (PEEP).  
PEEP can help to reverse alveolar collapse and allow a lower oxygen concentration to be 
administered, and thus oxygen induced lung can injury can be avoided. Currently, ARDS 
patients are ventilated using a strategy that focuses on protecting the lungs. This 
approach involves limiting plateau pressures to 30cm H2O, adjusting tidal volumes to 
6mL/kg (based on ideal body weight), and applying adequate levels of PEEP. Thus far, 
the optimal level of PEEP has not been determined. Data from previous studies suggest 
that at PEEP levels above 5–12cm H2O, the risk of alveolar collapse can be reduced, 
especially in patients with severe lung injury (9). In patients with mild lung injury, high 
PEEP levels are associated with adverse effects such as lung overdistension (10). PEEP 
levels should therefore be assessed separately for each patient. FiO2 should also be 
maintained at non-toxic levels (8). 
 Due to the dysregulated production of inflammatory mediators in ARDS, other 
therapies have included the modulation of inflammatory response. Drugs that block 
individual factors in the inflammatory cascade for example TNF, IL-1, PAF, adhesion 
molecules or NO synthase have been developed but, on the whole they have been 
unable to improve survival (11). A meta-analysis of 10 sepsis trials, however, showed a 
reduction in mortality of patients using anti-TNF drugs (11). Nitric oxide is implicated 
as the major cause of hypotension during septic shock, and antagonizing its activity 
would be anticipated to lead to patient benefit. However, a clinical trial using a specific 
inhibitor of nitric oxide synthase inadvertently increased patient mortality (12). The 
excessive activation and migration of circulating neutrophils from blood to the alveolar 
space is one of the crucial events in the early development of ALI. Blocking β2 integrins 
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has been shown to protect against lung injury in many experimental studies (13, 14). 
However, the clinical relevance of these animal models remains unclear, and translation 
into clinical studies is difficult. Other potential novel therapies include blocking high 
mobility group box 1 (HMGB1) – a cellular protein involved in facilitating gene 
transcription (15). Secreted HMGB-1 is a potent inflammatory mediator that appears 
late in the septic cascade, and induces the expression of inflammatory cytokines (16). 
Experimental studies show that inhibition of HMGB1 with ethyl pyruvate improves 
survival in septic models of mice when administered 24h after the onset of sepsis (17), 
although, the mechanism of action of HMGB1 is not fully known. Finally, other targets 
include macrophage migration inhibitory factor (MIF), components of the complement 
cascade C5a and C5aR, and the family of caspases that are involved in apoptosis. 
 
 
, 
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1.2 Sepsis-induced ALI 
Sepsis can be defined as the systemic inflammatory response to infection. It is 
characterised clinically by the presence of two or more of the following conditions: body 
temperature >380C or <360C, tachycardia >90 beats/min, tachypnea >20 breaths/min 
or PaCO2 <32 mm/Hg and or leukocyte count >12x103 cells/mm3, <4x103 cells/mm3 or 
>10% immature (band) forms (18). The annual incidence of sepsis in the US has 
recently been estimated at around 50–95 cases per 100,000 (19) and in the UK at 66 
cases per 100,000 (20). Recent data from the Sepsis Occurrence in the Acutely ill Patient 
(SOAP) study additionally suggest that sepsis accounts for around 37% of hospital 
admissions in European hospitals with overall ICU and hospital mortality rates as high 
as 19 and 24% respectively (21). 
Sepsis as a consequence of both pulmonary and extra-pulmonary insults has 
been identified as the most common predisposing factor for ALI. It accounts for 25–50% 
of ALI/ARDS cases (22), with mortality rates in patients as high as 53% (21). ALI can 
occur as a consequence of either gram-negative or gram-positive bacterial infections. In 
gram-negative sepsis, lipopolysaccharide (LPS, endotoxin), a component of the bacterial 
cell wall is the triggering factor for ALI, whereas in gram-positive sepsis, other cell wall 
constituents including lipoteichoic acids are the causative factors. Previous studies by 
Fein et al showed that 23 and 8% of patients with gram-negative and gram-positive 
bacteraemia respectively developed ARDS (23). Thus signifying that gram-negative 
bacteraemia accounts for a considerable proportion of ARDS cases. 
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Cellular & molecular mechanisms of lung injury 
Gram negative sepsis resulting in the development of ALI is considered to be the 
consequence of a dysregulated systemic inflammatory response to circulating LPS. LPS 
induces an inflammatory response via Toll-like receptor (TLR)-4-dependent 
mechanisms that result in the activation of pulmonary endothelial cells, and the 
sequestration of leukocytes into the microvasculature of many organs including the 
lung. Activated leukocytes release a plethora of inflammatory mediators including 
cytokines (TNF-α, IL-1β), reactive oxygen/nitrogen species (ROS/RNS) and proteases 
(elastase), which promote the disruption of endothelial cell junctions leading to 
interstitial oedema as a consequence of increased capillary permeability (24).  
 
Host recognition of LPS 
LPS is made up of three main regions known as the O-antigen, the core region and lipid 
A (25) (Figure 1.1). The O-antigen consists of repeating polysaccharide subunits, which 
vary among gram-negative bacteria while the core region links the O-antigen to the lipid 
A moiety. This moiety is considered to be the bioactive or toxic portion of the LPS 
molecule – early studies demonstrated that synthetic lipid A is able to elicit endotoxic 
and biological activity (26). 
 
Figure 1.1. Structure of LPS. LPS consists of three main components; the O-specific chain, containing repeating 
polysaccharide units, the core region, which links the O-chain to the biologically active lipid A region (Beutler and 
Rietschel Nat rev 2003). 
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In mammalian cells, LPS is recognised by a complex of proteins, the components of 
which include LPS binding protein (LPB), CD14, TLR4 and MD-2. These proteins have 
been described as the “LPS receptor complex”. The main function of LBP in LPS 
signalling is to catalyse the transfer of LPS on to CD14 present on host cells (27). CD14 
is expressed on the membrane of cells of monocytic origin, and to a lesser extent on 
neutrophils as a glycerophosphatidylinositol (GPI)-anchored molecule (membrane 
CD14, mCD14). It also exists as a soluble protein present in the circulation (soluble 
CD14, sCD14). In certain cell types, such as endothelial cells where mCD14 is lacking, 
sCD14 serves as the signalling receptor for surface recognition of the LPS-LBP complex 
(28). As CD14 lacks an intracellular cytoplasmic domain and essentially no intrinsic 
signalling capabilities, it transduces LPS signals through TLR4, a member of the TLR 
signalling family. TLR4 is responsible for the recognition of most gram-negative bacteria 
and its binding to LPS is enhanced by the accessory protein MD-2 (29). 
Ligation of LPS with its receptor complex on host cells results in signal 
transduction mechanisms that activate the nuclear factor (NF)- κB, and the mitogen-
activated protein kinase (MAPK) family through a series of phosphorylation events (30) 
(Figure 1.2). Under resting conditions, NF-κB is confined to the cytoplasm in an inactive 
form bound to inhibitory κ (Iκ)-B. In inflammatory conditions, phosphorylation of Iκ-B 
by Iκ-B kinase occurs, resulting in the release and translocation of NF-κB into the 
nucleus, where it activates genes that promote the production of inflammatory 
mediators. The MAPK family, especially p38 MAPK, play a crucial role in the 
biosynthesis and release of certain cytokines, and other inflammatory mediators from 
monocytes and macrophages (31). Its role in monocyte cytokine biosynthesis will be 
described later. 
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 The susceptibility of mammalian cells to LPS stimulation differs among species. 
Humans and sheep for example are considered to be sensitive to LPS, whereas baboons 
and rodents are highly resistant (32). Across mouse strains however, differences also 
exist – whereas the C57BL/6 strain are resistant, the BALB/c strain are relatively 
sensitive (33). 
 
 
Figure 1.2. LPS induced TLR4 signalling (Takeda K and Akira S. Semin Immunol 2003). Ligation of LPS with its 
co-receptors LPB and CD14 induces the activation of downstream signalling cascades via the TLR4 that results in the 
activation of NF-kB and MAPK kinase signalling pathways. 
 
Inflammatory mediators 
The inflammatory response is driven in part by cytokines including tumour necrosis 
factor (TNF)-α, interleukin (IL)-1β, IL-6, and IL-8. These mediators have been identified 
in BAL fluid and plasma of patients with ARDS (34-36). Other mediators including 
monocyte chemoattractant protein (MCP)-1, platelet activating factors (PAF), 
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prostaglandins and nitric oxide (NO) have also been implicated in the pathogenesis of 
ARDS (37). 
 TNF-α and IL-1β can be regarded as early response cytokines as they are 
produced within the first 30–90 min after exposure to LPS predominantly by 
mononuclear phagocytes (38). Upon their release, TNF and IL-1β induce the activation 
and production of several other cytokines, lipid mediators, and reactive oxygen species. 
They also induce the activation and up-regulation of adhesion molecules on endothelial 
cells. The activation of endothelial cells results in their release of chemotactic factors for 
neutrophils and monocytes, including IL-8 and MCP-1, which induces further 
sequestration and accumulation of leukocytes within the pulmonary microvasculature, 
ultimately culminating in capillary injury. Both TNF and Il-1β are elevated in the BAL 
fluid of ARDS patients (39). Circulating TNF levels are also increased in septic patients, 
and this increase is associated with the development of ARDS (40). Based on the high 
levels of TNF found within the microvasculature and circulation, many animal studies 
using specific antagonists to TNF and IL-1β, including anti-TNF antibodies and IL-1 
receptor antagonist have been performed, in a bid to ameliorate tissue injury in 
ALI/ARDS (41). Despite promising results in these pre-clinical models, anti-TNF and 
anti-IL-1 strategies have been unsuccessful in the clinical setting (42, 43). 
IL-6 is secreted by a variety of cells, including monocytes, lymphocytes, 
fibroblasts and endothelial cells, in response to stimulation by endotoxin, IL-1β, and 
TNF (44). It induces T and B-cell proliferation and the production of acute phase 
proteins such as C - reactive protein, serum amyloid and protease inhibitors in the liver 
(45). IL-6 is an essential part of the cytokine cascade which can activate the coagulation 
system (46), and up-regulate the expression of TNF receptors (47). Circulating levels of 
IL-6 have been shown to predict the severity of ARDS of different aetiologies including 
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sepsis (48) and acute pancreatitis (49). In addition, increased levels of TNF and IL-6 
correlate with fatal outcomes in septic patients (50) 
 Eicosanoid lipid mediators, prostaglandins and leukotrienes are metabolites of 
arachidonic acid that are required for homeostasis but have been implicated in the 
pathogenesis of sepsis (51). These mediators promote inflammation; modify vasomotor 
tone, and increase blood flow and vascular permeability (52). They are synthesised by 
cyclooxgenase (COX) isoenzymes and 5-lipoxygenase respectively. Two distinct COX 
enzymes namely COX-1 and COX-2, have been identified; COX-1 is constitutively 
expressed in most tissues whereas, upon stimulation by inflammatory cytokines and 
LPS, COX-2 is rapidly activated in inflammatory cells including monocytes (53, 54). 
Inhibition of COX-2 has been shown to reverse inflammation in some tissues (55), and 
in addition, COX-2-deficient mice are protected from sepsis-induced inflammation and 
death (56). Leukotrienes, mainly LTB4, increase IL-6 production by monocytes (57), and 
also induce the production of other cytokines by stimulating early gene transcription in 
monocytes (58). It also induces neutrophil chemotaxis, production of mediators and 
superoxides, and enhances neutrophil-endothelial interactions in inflammation (59). 
PAF is produced by different cells including monocytes (60), neutrophils (61) and 
endothelial cells (62). It has been implicated in the pathogenesis of endotoxin shock and 
multiple organ dysfunction syndrome (MODS) in rats (63), and in septic patients, 
increased levels of intravascular PAF have been detected (64). In vitro, PAF enhances 
the permeability of cultured human endothelial cell monolayers, and induces changes of 
the cell cytoskeleton leading to cell retraction and formation of intracellular gaps (65).  
NO involved in sepsis is produced by inducible NO synthase (iNOS), an enzyme 
induced in response to LPS or inflammatory cytokines (66). iNOS is expressed in a 
variety of cells including epithelial cells (67), neutrophils (68), monocytes (69), and 
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macrophages (70). Increased iNOS activity has been detected in inflamed tissues and 
vessel walls of septic patients (71) and in macrophages, which mediate the induction of 
pulmonary microvascular protein leak in septic mice (72). NO production has been 
implicated as a crucial cause of vasopressor-resistant vasodilation and myocardial 
depression characteristic of septic shock (73) as well as MODS (74). Evidence regarding 
the role of iNOS and NO in inflammatory responses has largely been gathered from 
studies investigating the responses of rodent macrophages to inflammatory cytokines, 
particularly IFN-γ and LPS (75). In human macrophages however, such evidence has 
been controversial. A study by Schneemann and colleagues demonstrated that human 
monocytes stimulated with either IFN-γ, TNF, GM-CSF or LPS were unable to produce 
NO (76). In another study by Weinberg et al, it was contrarily shown that human 
peritoneal macrophages were capable of expressing high levels of iNOS, and 
subsequently producing NO upon stimulation by LPS and IFN-γ (77). Despite this, it is 
well acknowledged that human macrophages (75) and hepatocytes (78) express 
considerably lower levels of iNOS, and consequently produce lower levels of NO than 
rodents.  
Chemokines are a family of low molecular weight proteins (8-14kDa) that signal 
through G-protein-coupled receptors, and induce the sequestration of leukocytes, 
particularly monocytes and neutrophils, into inflamed tissues (79, 80). Although 
chemokines are crucial for host defence against bacteria, excessive generation of these 
proteins has been demonstrated to contribute to the pathogenesis of sepsis (44). IL-8 
and MCP-1 are the main chemokines that have been implicated in the pathogenesis of 
sepsis (44). IL-8 acts as a chemoattractant for the recruitment of neutrophils to 
inflammatory sites (81, 82). Systemic administration of LPS induces significantly 
increased levels of IL-8 in humans (83). MCP-1 plays a crucial role in the recruitment of 
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monocytes during endotoxemia (84), and also induces the adhesion of monocytes to the 
inflamed endothelium (85, 86). In mouse cecal ligation and puncture (CLP) sepsis 
models, it has been demonstrated that MCP-1 levels are significantly increased in 
tissues such as the lung and liver (87, 88), and KC, the mouse IL-8 homologue, is 
increased in the lungs and plasma during sepsis (89). 
 While sepsis is associated with a high production of pro-inflammatory cytokines 
at the local site of infection, elevated levels of anti-inflammatory cytokines particularly 
IL-1RA, IL-4, IL-10 and IL-13 are observed in the plasma of patients, and is often 
associated with a poor outcome (90, 91). These cytokines can suppress gene expression 
and synthesis of IL-1 and TNF and other pro-inflammatory cytokines. In addition, when 
administered to rats or mice, they can protect animals from sepsis or endotoxin-induced 
shock (92). IL-10 has been shown to decrease mortality in septic mice (93), and 
suppress inflammatory responses in humans (94). In comparison to the administration 
of other anti-inflammatory cytokines, IL-10 appears to be the safest as it is associated 
with little or no side effects (95). 
 
Leukocytes 
Leukocytes, particularly neutrophils, are considered to play a central role in the 
pathogenesis of ALI as they are the prevalent leukocyte population found in BAL fluid, 
and in histological samples from patients with ARDS (96). In animal models of LPS-
induced ALI, there is a considerable increase in neutrophil infiltration into the lungs, 
and the severity of lung injury is reduced if neutrophils are depleted (97, 98). In vitro 
studies have shown that LPS directly stimulates neutrophils to produce serine 
proteinases and superoxide ions (98-100), which mediate capillary endothelial damage 
in the lung. Adoptive transfer studies have further shown that neutrophils stimulated 
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with LPS ex vivo cause lung injury when administered to naive animals (101). LPS also 
‘primes’ neutrophils to produce an augmented respiratory burst with increased release 
of superoxide, elastase, and arachidonic acid metabolites when they are re-challenged 
by a second stimulus (102). The importance of neutrophil priming by endotoxin has 
been observed in experimental animal models. In rabbits for example, administration of 
low-dose endotoxin does not cause lung injury, but pre-treating neutrophils ex vivo with 
LPS and subsequently adoptively transferring them into animals treated with 
chemotactic factors results in the retention of neutrophils within the lungs, and the 
development of capillary permeability (103). In spite of the evidence from patients and 
animal studies, which demonstrate the importance of neutrophils, it has been observed 
that ARDS can occur in neutropenic patients (104). This indicates that while neutrophils 
are important, they are dispensable for the propagation of the inflammatory response 
and other cellular mediators may be involved. Recent studies in animal models of lung 
injury have indicated that monocytes can be primed by LPS to produce increased levels 
of tumour necrosis factor (TNF)-α upon re-challenge by secondary LPS stimulation. 
Moreover, monocyte depletion results in an attenuation of lung injury. Thus, suggesting 
that monocytes may also play a crucial role in the development of ALI (105, 106). The 
precise mechanisms by which monocytes contribute to the pathogenesis of ALI have 
however, not been extensively elucidated. 
 
Leukocyte sequestration into the lungs 
The principal site of leukocyte emigration in response to inflammation within the lung 
is the alveolar capillary bed (107). A unique characteristic of this bed is the complex 
interconnecting network of short capillary segments where the path from arteriole to 
venule intersects several alveolar walls and often contains 40-100 capillary segments 
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(108). The pulmonary capillaries contain around 40-65 times more neutrophils and 
significantly more monocytes and lymphocytes than is found in large vessels within the 
systemic circulation (108). Studies of these vessels revealed that the transit time of 
neutrophils through the capillary network required a median and mean time of 26s and 
6.1s respectively, which is significantly more than that of erythrocytes which require 
between 1.4-4.2s (108). The longer transit time has been attributed to the larger 
diameter of the leukocyte, which in the case of neutrophils is approximately 6-8 µm and 
in monocytes is approximately 10-18 µm as opposed to the capillaries which have a 
diameter of 2-15 µm. Due to their larger size, leukocytes have to deform i.e. change their 
shape in order to pass through the capillary beds (109). Recent studies suggest that the 
transit time of neutrophils through pulmonary capillaries may be grossly 
overestimated. This suggestion has arisen because experimental data from leukocyte 
scintigraphy experiments perfomed in human lungs show that relatively little amounts 
of marginated neutrophils are present (110). In view of this, it been suggested that 
previous adoptive transfer studies, which have been perfomed to study neutrophil 
margination, have employed techniques that activate neutrophils in the isolation 
process, and inadvertently enhances their retention and transit time through 
microvessels (110). 
 In much of the systemic microvasculature, leukocyte sequestration and 
transendothelial migration takes place within the postcapillary venules and is initiated 
by selectin-mediated rolling (108). In the lung, however, neutrophil sequestration and 
emigration occurs through the pulmonary capillaries, which as described above are 
very narrow in comparison to the neutrophil. Consequently, rolling does not occur and 
in fact, physical trapping is enough to stop the neutrophil (111). Therefore, selectins are 
not required for the initial sequestration of neutrophils within the pulmonary 
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capillaries. Evidence for this comes from studies, which showed that L-selectin (present 
on leukocytes) was not required for sequestration of neutrophils within the pulmonary 
capillaries. However, once sequestered, both L-selctin and CD11/CD18 (β-2 integrin) 
were required to keep these neutrophils within the capillary bed (112). On a side note, 
recent studies have indicated that during LPS-induced lung injury, the endothelium is 
the main cell required to induce leukocyte sequestration. Apparently, the presence of 
TLR-4 on the surface of the activated endothelium induces the sequestration of 
leukocytes within the pulmonary microvasculature (113). This study reveals a more 
important role for the capillary endothelium in the pathogenesis of lung injury than was 
previously appreciated. 
 During inflammation, sequestration and infiltration also occurs through the 
narrow capillaries (107, 113, 114). Activation of leukocytes through chemokines, 
complement fragments, cytokines and LPS, induces a transient loss of deformability in 
the leukocyte as a result of actin filament reorganization. This further prolongs transit 
times, and increases the concentrations of leukocytes within the alveolar capillary bed 
(115). 
While sequestration occurs independently of the selectin family of adhesion 
molecules, the events following the sequestration of leukocytes within alveolar capillary 
beds are dependent on other adhesion molecules, particularly integrins and their 
corresponding ligands (111). Leukocytes adhere to capillary endothelial cells 
predominantly through interactions between β-2 integrins on the leukocyte surface and 
intercellular adhesion molecule (ICAM)-1 located on the endothelial surface (108). TNF-
α and LPS induce the expression of ICAM-1 on the surface of endothelial cells. In a 
model of peritonitis-induced lung injury, anti-CD18 antibodies reduced neutrophil 
infiltration and reactive oxygen species release, thereby preventing capillary damage 
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and significantly reducing mortality (116). When neutrophils adhere to endothelial cells 
through β-2 integrins-ICAM-1 interactions, a series of signalling events are initiated 
within the pulmonary microvascular endothelial cells that results in cytoskeletal 
remodelling. These changes allow neutrophils migrate to endothelial cell junctions, and 
transmigrate through the endothelial layer. 
 
Leukocyte-mediated endothelial injury  
The sequestration of neutrophils within the pulmonary microvasculature is a key event 
in the pathogenesis of lung injury. Adherence of neutrophils to the capillary 
endothelium results in their release of large quantities of oxidants, including ROS such 
as, superoxide, hydrogen peroxide and hydroxyl radicals, and RNS such as peroxynitrite, 
nitryl chloride and chloramines (117). These reactive species play a significant role in 
endothelial dysfunction and disruption, responsible for the development of capillary 
leak and pulmonary oedema (118). ROS can also act as signalling molecules to induce 
activation of kinases and transcription factors that up-regulate gene expression (119). A 
role for ROS as important mediators of the pathophysiological events in ARDS is 
supported by studies, which have demonstrated that prior exposure to endotoxin and 
cytokines enhance free radical synthesis and release by neutrophils upon further 
stimulation (120, 121). Inflammatory cytokines produced by neutrophils or 
macrophages could also change the endothelial cells from their normal anticoagulant 
state to a more procoagulant state with the initiation of disseminated intravascular 
coagulation (DIC) (122), and also induce their production of NO (123). In addition to 
inducing hypotension during septic shock (124), NO also impairs tissue metabolism via 
inhibition of mitrochondrial enzymes (125), an effect augmented by the further 
production of NO by the neutrophils themselves (126). Neutrophils additionally secrete 
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substantial amounts of proteases which damage the extracellular matrix of the lung to 
facilitate migration of neutrophils from the capillary endothelium into the alveolar 
airspace (127). The principal protease released by neutrophils in ALI/ARDS is 
neutrophil elastase. An increased level of this protease has been found in plasma and 
bronchoalveolar lavage fluid in patients with ARDS (128, 129). Lung failure eventually 
results from alveolar denudation, basement membrane destruction and damage of the 
typical alveolar fluid-clearance mechanism (7). 
As research into the cellular mediators of sepsis-induced lung injury has 
focussed on the neutrophils present in the pulmonary vasculature as well as in the 
alveolar compartment, little attention has been paid to the monocytes, a component of 
the mononuclear phagocyte system also present in the pulmonary vasculature. 
Monocytes readily marginate to the lungs (130), and are capable of producing a range of 
crucial pro-inflammatory mediators (TNF-α, IL-1β) that are important for the 
propagation of the inflammatory response (43, 131, 132). However, little is known of 
their role in ALI. Research in pigs and sheep has shown that these animals possess 
highly responsive resident macrophage populations, known as ‘pulmonary 
intravascular macrophages’ (PIM), that are bound to the endothelium of pulmonary 
capillaries (133). The presence of PIM in pigs and sheep predisposes them to pulmonary 
dysfunction after intravascular administration of small amounts of endotoxin or 
bacteria (133). In other species such as humans and rodents where PIMs are absent, it 
has been proposed that monocyte accumulation within the lungs under sustained 
systemic inflammatory conditions could eventually give rise to a population with a PIM-
like phenotype (134, 135) that would play crucial roles in the pathogenesis of lung 
injury.  
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1.3  The Mononuclear Phagocyte System 
The mononuclear phagocytic system (MPS) which essentially consists of monocytes, 
macrophages and dendritic cells (DCs) was originally discovered by Metchnikoff in 
1883 (131) but was later described by van Furth and Cohn in the late 1960s (136). They 
are essentially a group of bone marrow-derived myeloid cells that circulate in the blood 
as monocytes and enter tissues to become tissue resident macrophages and antigen 
presenting dendritic cells during homeostasis and inflammation (136). The 
development of the MPS is dependent on the growth factor, colony-stimulating factor 
(CSF)-1 also known as M-CSF. Its ligand CSF-1R (M-CSFR, CD115) is expressed on 
monocytes, macrophages, DCs and their precursors (137). Monocytes will be described 
in detail in the next section. 
Macrophages are tissue resident cells that play crucial roles in the preservation 
of tissue homeostasis through various mechanisms including the production of growth 
factors, elimination of apoptotic cells, production of inflammatory mediators, and in the 
remodelling and repair of injured tissues after inflammation (138). Macrophages 
possess a vast array of pattern associated recognition receptors (PARRs) as well as 
scavenger receptors that make them more proficient at the phagocytosis and clearance 
of micro-organisms (138, 139). They also exhibit a diverse range of functional 
properties that are greatly defined by their microenvironment as exemplified by the 
ability of osteoclasts to remodel bone, and the capacity of alveolar macrophages to clear 
pathogens through their high expression of PAMPS and scavenger receptors (138, 139).  
Upon activation by stimuli, macrophages become ‘polarized’ such that their effector 
functions are dependent on the cytokine composition of their milieu (140). Polarized 
macrophages are classified either as M1 or M2 macrophages. Classically activated or M1 
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macrophages are mainly responsive to IFN-γ and microbial products; they release 
inflammatory mediators including TNF-α, and IL-1β, and are thus referred to as the 
inflammatory group. The alternatively activated or M2 macrophages are mainly induced 
by IL-4, IL-13 or IL-10 and are more anti-inflammatory (131). The M2 group consists of 
at least three subsets known as M2a, M2b and M2c, which are distinguished on the basis 
of cytokines or molecules that activate them. M2a macrophages are mainly induced by 
IL-4 or IL-13, M2b by immune complexes and agonists of TLRs or IL-1 receptors, and 
M2c by IL-10 and glucocorticoid hormones (141). 
DCs can be classified into two main groups known as the Classical DCs (cDCs) 
and Plasmacytoid DCs (PDCs). CDCs are specialized in antigen processing and antigen 
presenting to T-cells. They are generally short-lived cells which are present in the 
human circulation, but rare in mouse blood, and play crucial roles in phagocytosis and 
cytokine production during inflammation (142). CDCs are highly migratory cells that 
can move from tissues to the T-cell and B-cell zones of lymphoid organs via afferent 
lymphatics and high endothelial venules. They also regulate T-cell responses both 
during homeostatic and inflammatory conditions. PDCs are relatively long-lived cells, 
and are present in the bone marrow and all peripheral organs (142). They are also 
important for antigen presentation but are specialized to respond to viral infection, and 
produce large amounts of type I interferons (IFNs) (143). 
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1.4  Monocytes 
Monocytes are morphologically characterised as having bean-shaped nucleuses, 
cytoplasmic vesicles, and a high cytoplasm-to-nucleus ratio both in humans and mice 
(137). Monocytes constitute around 10 and 4% of peripheral blood leukocytes in 
humans and mice respectively(144), and have relatively short half-lives, which is 
around 1 day in mice, but 3 in humans(144). It is thought that their short half-life allows 
them to act as reservoirs of myeloid precursors so that they can continuously replenish 
and maintain tissue macrophage and dendritic populations during homeostasis and 
inflammation (145). A wealth of evidence, however, suggests that during homeostasis, 
macrophages in some organs, such as the alveolar macrophages of the lung, kupffer 
macrophages of the liver as well as the brain microglia, self-renew without input from 
blood monocytes (146-148). Despite these findings, under inflammatory conditions, it is 
well-acknowledged that monocytes give rise to tissue specific macrophages (149, 150). 
In addition to being able to differentiate into macrophages and DCs, blood monocytes 
play an important role in maintaining homeostasis through their removal of senescent 
or apoptotic cells. They contribute to the pathogenesis of inflammatory diseases 
especially atherosclerosis (151) as they contain an array of scavenger- and pattern-
associated receptors that facilitate their recognition of pathogens and bacterial 
fragments, including LPS. Recognition of these molecules inadvertently results in their 
production of effector mediators, including cytokines (TNF-α, IL-1β, IL-6) and 
prostaglandins that are involved in the propagation and pathogenesis of inflammatory 
responses (132). 
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Heterogeneity of monocytes 
Monocytes can generally be defined by their expression of M-CSFR, also known as 
CD115. In addition to CD115, human monocytes are characterised by their expression of 
CD11b, CD14 and CD16. In mice, monocytes are characterised by their expression of 
CD115, CD11b and F4/80. Monocytes are distinct from neutrophils, natural killer (NK) 
cells, B or T cells as they lack some of the markers typically expressed by these cells, 
including NK 1.1, CD19 and CD4/8 respectively. Considerable evidence has been 
accumulated over the last 25 years that show that monocytes, not only in humans but in 
mice, rats and pigs, exist as phenotypically and functionally distinct subsets (139). 
Consequently, monocyte subsets may play differential roles in the pathophysiology and 
resolution of inflammation, the full extent of which is still currently being studied.   
 
Human monocyte subsets 
Human monocyte subsets can be distinguished into three subsets on the basis of their 
size, their expression of CD14, a component of the lipopolysaccharide receptor complex, 
and CD16, the Fcγ RIII immunoglobulin receptor (139). The two major subsets consist 
of ‘classical’ CD14+CD16- and ‘non-classical’ CD14-CD16+ monocytes. These monocyte 
subsets express divergent immunoglobulin, chemokine adhesion, and scavenger 
receptors (139).  
 CD14+CD16- monocytes constitute around 80-90% of circulating monocytes and 
are approximately 18 µm in diameter. CD14-CD16+ monocytes on the other hand, 
constitute around 10% of circulating monocytes and are approximately 14 µm in 
diameter. These CD14-CD16+ monocytes express higher levels of MHC class II molecules 
than CD14+CD16- monocytes, and their numbers are increased in the blood of patients 
during acute inflammation (152) and sepsis (153). It has been observed that they also 
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produce higher levels of TNF in response to LPS stimulation in vitro. As a result of these 
observations, especially their higher productions of TNF, CD14-CD16+ monocytes are 
classified as ‘pro-inflammatory’ (154). CD14+CD16- monocytes produce higher levels of 
IL-10 and therefore have more of an anti-inflammatory potential (155). However, the 
cytokine production profiles of these monocyte subsets upon activation with 
inflammatory stimuli in vitro have not been corroborated with in vivo studies. 
CD14+CD16- monocytes express high levels of CCR1, CCR2 and CXCR2 but 
express low levels of CX3CR1, whereas CD14-CD16+ monocytes express higher levels of 
CX3CR1 but low levels of CCR2 (139). As a result of this differential chemokine receptor 
expression, they respond to different chemokine signals. CD14+CD16- respond to MCP-1, 
while CD14-CD16+ respond to fractalkine (CX3CL1) (156). In terms of adhesion 
molecule expression, CD14+CD16- express higher levels of L-selectin (CD62L) and 
CD11b than CD14-CD16+ (139). In the presence of granulocyte-macrophage colony-
stimulating factor (GM-CSF) and IL-4, both monocyte subsets have the ability to 
differentiate into macrophages and DCs (157). However, data from in vitro coculture 
studies of peripheral blood mononuclear cells (PBMCs) and human umbilical vein 
endothelial cell (HUVEC) show that CD14-CD16+ monocytes have a greater propensity 
than CD14+CD16- monocytes to become DCs. Although this suggests that CD14-CD16+ 
monocytes may be precursors for DCs, it does not necessarily give a definite 
representation of what happens in the in vivo setting (139); as cytokine compositions of 
local microenvironments play a significant role in defining the differentiation potentials 
of monocytes. 
In addition to the two main subsets, another group of monocytes that are defined 
as CD14+CD16+CD64+ have also been recently identified (158). These cells have the 
ability to produce vast amounts of inflammatory cytokines, and also exhibit phagocytic 
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activity. They display high expression of CD86 and HLA-DR, and also stimulate T-cells 
suggesting that they have DC-like properties (159). Although the origins and functions 
of this subset have not been fully determined, it has been postulated that these cells 
could be an intermediate or transitional population between monocytes and DCs, and 
could play an immune-regulatory role (139). 
The majority of the data concerning the inflammatory cytokine response of 
human monocyte subsets have been derived from in vitro studies of LPS-stimulated 
whole blood (154). It is established that the inflammatory responses of circulating 
monocytes as a whole are much less within the circulation in comparison to within the 
microvasculature of tissues, where inflammatory responses are significantly enhanced 
due to interaction with the endothelium (160) Thus far, no studies have been done to 
determine the migratory patterns or the functional roles of these subsets in sepsis-
induced ALI. It is however stipulated that data from animal models could provide an 
insight into the potential role of these subsets in the development of ALI in humans. 
 
Mouse monocyte subsets 
Monocytes in mouse blood constitute around 6% of circulating leukocytes (161). 
Although they are CD11b-expressing cells, like granulocytes, monocytes can be 
distinguished by their high expression of CD115 and F4/80, and thus are primarily 
defined as CD115+F4/80+CD11b+ cells (145). They can be further characterised by their 
expression of Ly6C, a GPI-anchored differentiation antigen that is expressed not only by 
monocytes but also by granulocytes, some NK cells, and plasmacytoid dendritic cells 
(137, 162). Gr-1 is another GPI-linked differentiation antigen that recognises Ly6C as 
well as Ly6G, an antigen that is expressed exclusively on granulocytes. Either Ly6C or 
Gr-1 antibodies can therefore be used to identify mouse monocytic cells (137).  
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Monocytes in mice originate from bone marrow as Gr-1highCD115+F4/80+CD11b+ cells 
but once they enter the circulation, they exist as subpopulations. Engineered expression 
of green fluorescent protein (GFP) into the CX3CR1 gene in mice, and the subsequent 
isolation and transfer of monocytes from these mice into naive mice enabled the initial 
identification of monocyte subpopulations (163). According to their expression of Gr-
1/Ly6C, CCR2, L-selectin and CX3CR1, mouse monocytes are subdivided into two main 
subsets (163). The first subset known as Gr-1highCCR2+CD62L+CX3CR1- (hereafter 
referred to as Gr-1high) express high levels of Gr-1 (or Ly6C), CCR2, CD62L and a low 
level of CX3CR1 and can be regarded as phenotypic orthologs of human CD14+CD16- 
monocytes. The second subset known as Gr-1lowCCR2-CD62L-CX3CR1+ (Gr-1low) 
expresses low levels of Gr-1 and do not express CCR2 or CD62L but express high levels 
of CX3CR1. They can be regarded as phenotypic orthologs of human CD14-CD16+ (132). 
A third subset that expresses intermediate levels of Gr-1 (Gr-1int) also exists but 
constitutes only a small percentage of circulating monocytes. It is thought that it 
corresponds to the human CD14+CD16+CD64+ population (161). 
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Figure 1.3. Phenotypic and functional characteristics of mouse monocyte subsets. (A) Gr-1high monocytes arise 
from the bone marrow and are released into the peripheral blood. They are characterised as high expressing CC-
chemokine receptor 2 (CCR2) cells (B) Under steady-state conditions, they are thought to adopt a Gr-1int which is 
associated with the expression of CCR7 and CCR8 (C) after which they differentiate into Gr-1low monocytes that are 
characterised by their high expression of CX3C-chemokine receptor 1 (CX3CR1). (D) Under inflammatory conditions, 
Gr-1high monocytes are recruited to sites of inflammation where they are important for the release of inflammatory 
mediators, clearance of pathogens and for the resolution of inflammation. (E) Under steady-state conditions, Gr-
1lowCX3CR1+ monocytes migrate into tissues and are precursors for tissue-resident macrophage & dendritic cells. 
(Adapted from Gordon S and Taylor P in “Monocyte & Macrophage Heterogeneity 2005) 
 
 
Gr-1high monocytes 
Gr-1high monocytes are short-lived cells, approximately 10-14 µm in diameter and 
account for around 60% of circulating monocytes in steady-state. Early adoptive 
transfer experiments by Geissmann et al in 2003 showed that these monocytes were 
selectively recruited to inflamed tissues and lymph nodes in vivo, where they induced 
the activation and proliferation of naive T-cells, and were thus named the 
‘inflammatory’ subset (163, 164). Recent studies using various models such as the 
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inflamed retina (164), infection with Listeria monocytogenes (165) or Salmonella (166), 
and carbon tetrachloride (CCL4)-induced liver injury (167) have further shown that due 
to their high expression of CCR2, Gr-1high monocytes are recruited both from the bone 
marrow and circulation in a CCL2-dependent manner into inflamed tissues, where they 
produce high levels of pro-inflammatory cytokines such as TNF-α (105, 166, 168, 169), 
are involved in the phagocytosis of microbes (166), and possess high protease 
activity(168). However, it was recently found in a mouse model of Listeria 
monocytogenes-induced liver injury that although CCL2 was required to induce the 
mobilization of Gr-1high monocytes from the bone marrow, it was not sufficient to 
mediate the sequestration of these monocytes into the infected tissues. Instead, ICAM-1 
expression on inflamed tissues was required (170). Thus indicating that in different 
models of inflammation, distinct mechanisms may be required for the sequestration of 
Gr-1high monocytes into local sites of inflammation. 
Gr1high monocytes in inflamed tissues are capable of differentiating into TNF and 
iNOS-producing DCs (Tip-DCs) which further contribute to the inflammatory response 
(132, 167, 171, 172). Tip-DCs, as their name suggests, secrete high levels of TNF and 
rapidly migrate to T-cell zones in the spleen where they also express high levels of iNOS 
that generates NO radicals (171). Although they have DC-like properties, it has been 
suggested that the primary function of Tip-DCs is to kill bacteria rather than to activate 
and induce proliferation of T cells (137). In a model of liver injury, Gr-1high monocytes 
differentiate into iNOS producing macrophages that induce T-cell activation, and 
produce transforming growth factor (TGF)-β, which activates hepatic stellate cells 
(167). In addition to CCR2, it has been shown that Gr-1high monocytes can be recruited 
to inflamed sites in the skin via the chemokine receptor CCR6 and its ligand CCL20. In 
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this scenario, Gr-1high monocytes are responsible for the priming of CD8+ cytotoxic T-
cells (173). Converse to other data, Gr-1high monocytes have also been implicated to play 
a role in the suppression of T-cell responses in the spleen of tumour-bearing mice (174). 
In these mice, Gr-1high monocytes are expanded and activated as part of a myeloid-
derived suppressor cell population (MDSC) that mediate the impairment of antigen-
specific T-cell responses. Further evidence from human studies suggests that monocytes 
are recruited to tumour sites in a CCR2-MCP-1-dependent fashion (175). 
Based on data from depletion and repopulation studies, it has been proposed 
that, under steady-state conditions, Gr-1high monocytes mature in the circulation by 
down-regulating their Gr-1 expression, and subsequently progress through the Gr-1int 
phenotype to become Gr-1low monocytes (161). Although the Gr-1int population have not 
been extensively studied, it has been suggested that they could represent precursors of 
DCs (172). It was shown that in comparison to the other two subsets, Gr-1int monocytes 
express higher levels of the chemokine receptors, CCR7 and CCR8, which were found to 
be crucial for the mobilization of monocyte-derived DCs from the skin to draining lymph 
nodes (172). 
 
Gr-1low monocytes 
Gr-1low monocytes are approximately 8-12 µm diameter and account for around 40% of 
circulating monocytes (163). They are known as the ‘resident’ subset in mice because 
data from early adoptive transfer experiments in vivo showed that they were relatively 
long-lived cells that persisted in the blood, brain, liver, lungs, and spleen of recipient 
mice for up to four days after transfer (163). It was also shown that Gr-1low monocytes 
possessed the capacity to differentiate into DCs under steady-state conditions as they 
had higher expression levels of CD11c and MHC Class II molecules (163). Due to their 
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high expression of CX3CR1, it was proposed that Gr-1low monocytes could play an 
important role in the replenishment of resident populations of macrophages and DCs in 
tissues under steady-state conditions (161, 163). This suggestion arose due to data from 
in vitro experiments in humans, which showed that the CD14-CD16+ monocytes 
transmigrate across the endothelium in a CX3CR1-dependent manner (176). This 
hypothesis however has not been extensively corroborated in vivo. In spite of this, one 
piece of evidence that supports this speculative role of Gr-1low  monocytes has come 
from adoptive transfer studies, which have focused on the differentiation pattern of 
monocyte in the lung (177). It was observed that Gr-1low monocytes could differentiate 
into DCs in the lungs of naive mice under steady-state conditions, but not into 
macrophages. In macrophage/DC-depleted recipient mice however, donor Gr-1low 
monocytes could differentiate into both macrophages and dendritic cells (177). Further 
supporting evidence has come from an in vivo real-time intravital microscopy study of 
blood monocytes within capillaries and post-capillary vessels in the dermis and 
mesenteric vessels of mice (178). Data from these studies revealed that in steady-state 
conditions, Gr-1low monocytes within the dermal blood vessels exhibited a constitutive 
patrolling behaviour, via long-range crawling on the luminal side of the endothelium, 
which was mediated in part by CX3CR1; of note is the fact that in these conditions 
crawling Gr-1low monocytes did not migrate into tissues. Under inflammatory conditions 
however, these monocytes extravasated into tissues where they transiently produced 
high levels of inflammatory cytokines, and differentiated into macrophages that 
expressed markers associated with M2-macrophages (178). Finally, a recent study has 
shown that during the healing phase of experimentally induced myocardial infarctions 
in mice, Gr-1low monocytes are recruited into the myocardium where they express 
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vascular endothelial growth factor; induce myofibroblast accumulation, deposition of 
collagen and angiogenesis (168).  
Collating the data, the current concept about monocyte subsets and their 
functions can be summarized as follows: Mouse monocytes with the phenotype Gr-
1highCCR2+CX3CR1- originate and are released from the bone marrow into the 
circulation. In the absence of inflammation, Gr-1high monocytes alter their functional and 
phenotypic characteristics to become another subpopulation characterised as Gr-
1intCCR2+CCR7+CCR8+. In inflammatory conditions, Gr-1high and Gr-1int monocytes, 
possess the capacity to migrate into inflamed sites, and differentiate into inflammatory 
DCs. In the absence of inflammation, Gr-1int monocytes subsequently modify their 
phenotype through a mechanism that has not been established to become Gr-1low 
monocytes, which are proposed to enter tissues, and replenish resident populations of 
macrophages and DCs. Under inflammatory conditions, they have a greater propensity 
to differentiate into macrophages, although, they can also differentiate into dendritic 
cells. Gr-1high monocytes typically possess a higher propensity to produce inflammatory 
mediators, although, whether this is intrinsically predetermined or whether it is 
influenced by their microenvironment is yet to be investigated. The reason for this 
uncertainty is because, although in several in vivo models of inflammation such as in the 
myocardium (168) and in the gut (166), where Gr-1high monocytes have been shown to 
migrate to the sites of inflammation and produce higher levels of TNF, Gr-1low 
monocytes derived from the peritoneum produce higher levels of TNF upon stimulation 
ex vivo, and also upon LPS stimulation of whole blood. Moreover, irrespective of what 
their proinflammatory cytokine profiles are, the mechanisms regulating their 
differential cytokine release are yet to be elucidated.   
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TNF-α 
TNF is a pleiotropic cytokine that is predominantly produced by activated mononuclear 
cells but it can also be produced by a variety of other cells including granulocytes and 
mast cells (179). TNF plays a role in a wide range of biological activities, including 
apoptosis, induction of adhesion molecule expression and chemokine production by 
endothelial cells, and the induction of other inflammatory molecules. It is initially 
synthesised as a 26 kDa transmembrane protein (memTNF) that is subsequently 
cleaved by the matrix metalloprotease TNF alpha converting enzyme (TACE; ADAM17) 
into a soluble 17 kDa protein. Both memTNF and soluble TNF (solTNF) are biologically 
active and possess the ability to interact with TNF receptors, TNFR1 and TNFR2 (179). 
TNFR1 is constitutively expressed in most cell types, whereas TNFR2 is found 
predominantly on immune and endothelial cells (179). Both forms of TNF differ in their 
ability to stimulate signalling through TNFR1 and TNFR2. While memTNF induces 
signalling via both receptors, soluble TNF preferentially activates TNFR1. Both TNFRs 
bind intracellular adaptor proteins that induce the activation of diverse intracellular 
signalling pathways (180). 
 MemTNF plays a key role in local inflammation as it has been shown to exert its 
biological function in a cell-contact -dependent fashion. This mechanism of action is 
quite different from that of solTNF, which acts at sites distal to its production. Since 
memTNF possess potent biological activity, prolonged accumulation on the cell surface 
could potentially result in deleterious local effects. Consequently, memTNF is normally 
rapidly cleaved into its soluble form. Previous in vitro studies using pulse-chase analysis 
have indicated that memTNF in monocytes has a half-life of ~ 20 min but in the 
presence of a broad-spectrum metalloprotease inhibitor, it is extended to ~60 min and 
after this time point is rapidly degraded (181). MemTNF can additionally function as a 
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receptor that transmits outside-to-inside signals into TNF producing cells. In various 
models of disease including pulmonary inflammation and arthritis, memTNF has been 
shown to be sufficient to induce inflammation (160, 182, 183). 
 
 
MAPK signalling in the regulation of monocyte cytokine biosynthesis 
MAPKs (Mitogen-activated protein kinase) comprise a family of highly conserved 
serine/threonine protein kinases that regulate key cellular processes including gene 
induction, cell survival/apoptosis, proliferation, differentiation, cellular stress and 
inflammatory responses (184). Three major groups of MAPKs have been characterised 
in mammals. They include the extracellular signal regulated kinases (ERKs); the c-jun N-
terminal kinases (JNK), and p38. MAPKs are activated via a three-tiered signalling 
cascade composed of a MAPK and two upstream components, MAPK kinases (MAP2K or 
MKK) and MAPKK kinases (MAP3K) (185) (Figure 1.4). MAP3Ks are serine/threonine 
protein kinases that phosphorylate and activate MAP2Ks, whilst MAP2Ks are dual-
specificity protein kinases that phosphorylate the threonine and tyrosine residues of a 
conserved T-X-Y motif of the activation loop of MAPKs. The X residue is different in each 
class of MAPKs; it is glutamic acid for ERK, proline for JNK and glycine for p38 (185). 
48 
 
                    
Growth factors/environmental 
stress/bacterial fragments
MAPKK Kinase
(MAP3K)
MAPK Kinase 
(MAP2K or MKK e.g. MKK3/6)
MAPK
(ERKs, JNKs, p38)
Substrates
(proteins, transcription factors, 
downstream targets)
Cellular responses
(gene expression, apoptosis, actin re-
organization)
Stimuli
MAPK cascade
Responses
 
Figure 1.4. The Mitogen-Activated Protein Kinase (MAPK) pathway. The MAPK cascade consists of a three-tiered 
system of protein kinases – a MAPK (ERK, JNK and p38) and two upstream components, MAPK kinase (MAP2K) and 
MAPKK kinase (MAP3K).   
 
Circulating LPS has been linked to the development of ALI in critically ill patients 
and in experimental animal models (186). As mentioned earlier, LPS induces a wide 
range of responses in host cells including pro-inflammatory cytokine release upon 
interaction with appropriate recognition receptors. Ligation of the LPS receptor leads to 
the activation of several intracellular signalling pathways including the MAPK pathways 
(187-189). LPS-induced activation of these signalling pathways leads to the induction of 
an array of pro-inflammatory mediators including enzymes (COX-2, iNOS), eicosaniods, 
cytokines (TNF, IL-1β, IL-6) and chemokines (190) all of which have been implicated in 
the pathogenesis of sepsis. The p38 MAPK pathway, in particular, has been shown to be 
involved in the biosynthesis of cytokines especially in monocytes/macrophages (31, 
191). In this section, I will focus on the role of p38 MAPK pathway in the regulation of 
cytokine biosynthesis.  
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The p38 MAPK pathway 
p38 was initially identified as the molecular target of the pyridinyl imidazole inhibitors, 
that attenuate the production of inflammatory cytokines such as IL-1 and TNF in LPS-
stimulated human monocytes (191, 192), and as a major phosphokinase activated by 
LPS and inflammatory cytokines in mice (193). Four splice variants of p38 exist: α, β, δ 
and γ. Of the four variants, p38α is the most characterised and is expressed in most cell 
types. One of the best characterised functions of the p38 pathway is in the post-
transcriptional regulation of mRNAs containing adenine-uridine (AU)-rich elements 
(AREs) in their 3’ untranslated region (3’UTR) (194, 195). This pathway has been 
implicated in the regulation of mRNA stability of COX-2, TNF, IL-8, IL-6, and iNOS in 
macrophages in vitro (191, 196-199). 
MAPK-activated protein kinase 2 (MAPKAPK2, MK2) is the major downstream 
target of p38 that plays an important role in the posttranscriptional regulation of 
cytokine biosynthesis. Evidence for this has come from studies investigating the 
cytokine responses of MK2-deficient mice intraperitoneally injected with LPS, which 
exhibited considerably lower plasma levels of TNF, IL-6 and NO than those in wild type 
mice (200). In addition, cultured spleen cells from MK2-deficient mice produce 
significantly lower levels of TNF, IL-6, IL-1β than wild type animals (200). MK2 
regulates cytokines differently; either at the level of mRNA stability or at the level of 
translation. For example, IL-6 is regulated at the level of mRNA stability whereas TNF is 
regulated at the level of translation (201).  
Tristetraproline (TTP), a zinc finger protein, is also involved in the post-
transcriptional regulation of cytokine biosynthesis. Its expression is dependent on the 
activation of the p38 pathway, and it is a direct substrate for MK2 in vivo and in vitro 
(190, 202, 203). Its role has widely been studied in the biosynthesis of TNF in 
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macrophages. In the absence of inflammatory stimuli, TTP directly binds to the ARE of 
TNF mRNA and destabilizes it such that there is a rapid turnover of TNF, and thus 
modest/negligible amounts are secreted. Following stimulation of macrophages by LPS, 
TTP expression is upregulated and it becomes phosphorylated. In its phosphorylated 
form, it is inactive and unable to destabilize TNF. Consequently, TNF is secreted. The 
importance of TTP in TNF regulation comes from studies, which show that mice 
deficient in this protein have a systemic inflammatory syndrome that is characterised 
by excess circulating levels of TNF. The syndrome results from the increased stability of 
the TNF mRNA, and subsequent higher rates of secretion of the cytokine (204). 
MK2 can also regulate transcription through its action on NF-κB (205). Recent 
studies have shown that MK2 prolongs the nuclear retention of NF-κB by decreasing the 
synthesis of IκBα – the kinase involved in the export of NF-κB from the nucleus (206). In 
addition, MK2, in collaboration with its downstream substrate HSP27, prevents p38-
mediated phosphorylation of mitogen- and stress-activated kinase 1 (MSK1). This 
kinase is known to regulate transcription factors such as cyclic-AMP-response-element 
binding protein (CREB), and can directly phosphorylate the p65 component of NF-κB 
(207). A decrease in the phosphorylation of MSK1 by p38 results in a reduction of its 
activity, and a consequent suppression of NF-kB hyperphosphorylation (208). This 
prevents the premature export of NF-κB from the nucleus.  
In summary, the proposed mechanism for LPS-induced p38/MK2 cytokine 
biosynthesis (disregarding the NF-κB pathway) proceeds as thus: LPS induces 
activation (phosphorylation) of upstream kinases such as MKK3/6 which subsequently 
phosphorylate p38. Activated p38 in turn phosphorylates and activates MK2, which 
subsequently phosphorylates TTP (normally bound to the ARE of cytokine mRNA) 
resulting in the loss of its ability to destabilize cytokine mRNA. Accordingly, mRNA is 
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transcribed, translated and ultimately secreted (Figure 1.3). As this pathway plays such 
a crucial role in the regulation of cytokine biosynthesis, particularly in monocytes and 
macrophages, it could potentially be involved in regulating the differential cytokine 
responses of the mouse monocyte subsets. Determining the involvement of the 
p38/MK2 pathway in the regulation of cytokine biosynthesis in monocytes subsets 
could potentially provide therapeutic insights into the modulation, and/or targeting of 
individual monocyte subsets during inflammation.  
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Figure 1.5. Schematic representation of the p38/MK2 pathway in the regulation of cytokine biosynthesis. A 
variety of extracellular agonists including bacterial LPS, UV and oxidant stress activate upstream kinases (MKK3/6). 
Activated MKK3/6 phosphorylates and activates p38, which in turn activates MK2. TTP is phosphorylated by MK2 
and this prevents its binding to the AU-rich element (ARE) contained within the mRNA of various cytokines, thereby 
inhibiting the degradation of various transcripts such as TNF, COX-2, and IL-6 to allow protein translation and 
secretion. 
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Monocytes in sepsis-induced ALI 
Sepsis as a consequence of endotoxemia induces a rapid sequestration and 
accumulation of leukocytes to the lung in patients and in several animal models, leading 
to pulmonary capillary permeability and oedema (123, 209). In these models, 
monocytes are considered to contribute significantly to circulating levels of 
inflammatory cytokines, particularly TNF-α, IL-1β and IL-6, during endotoxemia (210, 
211). In addition, previous studies in patients with ARDS have shown that monocytes 
are recruited, in a CCL2-dependent manner, from the circulation to the alveolar 
compartment of the lung as early as 24 h, resulting in a significant expansion of the 
alveolar monocyte pool (130). The rapid sequestration of these monocytes into the 
alveolus in this model was significantly correlated with the severity of respiratory 
failure (130). Similarly, in an animal model of LPS-induced lung injury, it was shown 
that significant numbers of monocytes could be recruited to the lung in a CCL2-
dependent manner (212). Although these models show that monocytes are actively 
recruited to the lung during ALI, little is known of their direct functional contribution to 
the development of ALI. Moreover, the recent finding that monocytes exist as distinct 
subsets with different migratory patterns during resting and inflammatory conditions, 
adds further uncertainty about their roles.   
 Previous studies in our laboratory suggest that the numbers of inflammatory 
subset monocytes in the microvasculature increase rapidly in response to subclinical 
low doses of LPS through mobilisation of the bone marrow reservoir, and that they 
marginate to the microcirculation of the lungs and other organs in mice (105). Similarly 
to neutrophils, these lung-marginated monocytes can become ‘primed’ such that a 
substantially enhanced response is mounted to a secondary high dose LPS challenge 
(105). However, the mechanism by which monocytes become primed in vivo is not 
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defined. It is particularly unclear whether monocyte priming is a direct effect of low 
dose LPS stimulation or a direct effect of monocyte margination within the pulmonary 
microvasculature. Previous studies have also shown that, within the lung 
microvasculature, Gr-1high monocytes produce significantly higher levels of TNF than Gr-
1low monocytes, in an in vivo mouse model of ALI (105). Although this functional 
response ties in with their migratory properties during inflammatory conditions as 
previously described (163), other studies investigating monocyte function during in 
vitro LPS stimulation of whole blood have suggested that the Gr-1low monocytes produce 
higher levels of TNF. Due to this finding, it is uncertain how a particular 
microenvironment, and in this regard the lung microvasculature, influences the 
monocytes subset response. Recent data from in vivo studies done in our laboratory 
have demonstrated, using a 2-hit model of LPS priming followed by Zymosan challenge, 
that LPS pre-marginated monocytes contribute to zymonsan induced pulmonary 
microvascular permeability (105). However, it is equally unclear which monocyte 
subset plays the superior role in this model. In spite of these uncertainties, these and 
previously described data, provide some evidence that monocyte-endothelial 
interactions could potentially play a more important role than is appreciated for 
optimal expression of proinflammatory mediators, the propagation of the inflammatory 
response, and in the development of capillary permeability during ALI. 
 
 
Molecular basis of monocyte-endothelial interactions 
Interactions between leukocytes and the pulmonary endothelium is a crucial step in 
sepsis-associated pulmonary microvascular injury, as modifications in cell-cell adhesion 
initiate leukocyte sequestration into the lung parenchyma, and the subsequent 
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inflammatory response. A wealth of evidence has illustrated the key role of neutrophil-
pulmonary endothelial interactions in sepsis models both in humans and animals. It has 
been observed that neutrophil depletion attenuates endothelial dysfunction in an 
endotoxin-induced ALI rat model (213). However, more recently it has been shown that 
depletion of monocytes also results in a significant attenuation of endotoxin induced 
pulmonary inflammation in mice (105, 106). Tissue infiltration by circulating 
leukocytes mediated in part by chemokines and their associated receptors, occurs in 
three main steps: tethering/rolling, firm adherence and transmigration across the 
pulmonary endothelium (214). 
 The initial step, rolling is mediated by the selectin family of adhesion molecules 
and their sulphated, sialylated, fucosylated, glycoprotein ligands (215). The selectin 
family consists of three main molecules namely L-selectin, expressed by leukocytes, E-
selectin expressed exclusively by inflamed endothelial cells, and P-selectin expressed 
mainly by inflamed endothelial cells and activated platelets. P-selectin glycoprotein 
ligand 1 (PSGL1) is the ligand for all three selectins (216), and is expressed on 
leukocytes and on certain endothelial cells. It has been implicated as a crucial ligand for 
the adhesion of monocytes to the activated endothelium (217). Rolling occurs by the 
interaction of leukocyte expressed L-selectin and endothelial-expressed P- and E-
selectin with PSGL-1, CD44 or E-selectin-ligand-1 (ESL-1) (218). Whilst PSGL-1 and 
ESL-1 induce tethering and rolling of leukocytes on the endothelium, CD44 reduces 
their velocity subsequent to tethering through L-selectin (219). Although this 
mechanism of tethering and rolling occurs in most vascular beds, it does not necessarily 
apply to the lungs. Leukocytes tend to adhere to capillary endothelium independent of 
the above mentioned adhesion molecules through a process that involves deformation 
of their actin cytoskeleton due to the narrowness of the pulmonary capillaries (109). 
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However, increased P-selectin expression on the pulmonary endothelium appears to 
play an important role in the leukocyte recruitment occurring in the pulmonary 
microcirculation in a pancreatitis-induced model of lung inflammation (220). Elevated 
levels of E-selectin have also been observed in septic patients at risk for development of 
ARDS (221) 
 As tethering and rolling are transient, low affinity interactions, leukocytes may 
detach from the endothelium and re-enter the circulation (222). To prevent this, low 
affinity transient interactions of rolling become replaced by high affinity ones. These 
interactions are mediated through another family of adhesion molecules known as 
integrins (223) – heterodimeric receptors consisting of paired α and β chains. The β2 
(CD18) integrins are the main subset of integrins required for adhesion to other cells. In 
addition, monocytes also possess another integrin known as α4β1 (VLA-4) which 
contributes to stable adhesion (224). Of the four α chains constituting CD11a, CD11b, 
CD11c and CD11d that pair up with CD18, CD11a and CD11b are the most essential for 
leukocyte adhesion to the endothelium (224). Chemokines, mainly IL-8 for neutrophils 
and MCP-1 for monocytes and lipid mediators such as PAF (62, 225) expressed on 
endothelial cells induce a rapid increase in the binding affinity and avidity of leukocyte 
β2-integrins to trigger their arrest on endothelial cells (85, 226). Endothelial cells 
contribute to these processes through conformational changes in their actin 
cytoskeleton to form ‘docking structures’ (227) or ‘transmigratory cups’ (228) that 
contain leuckocyte integrin ligands, such as ICAM-1 and VCAM-1 (227). Firm adherence 
is then achieved by the ligation of leukocyte integrins CD11a/CD18 or CD11b/CD18 and 
VLA-4 with endothelial immunoglobulin adhesion molecules ICAM-1 and VCAM-1 
respectively (229). In a transgenic mouse model of sepsis-induced lung injury it was 
observed that chronic inactivation of CD11b by expression of an antagonist resulted in a 
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significant attenuation of lung neutrophil sequestration and pulmonary microvascular 
permeability (230) .  
After firm adherence to the vessel wall, chemokines (in concert with shear 
stress) further induce leukocytes to transmigrate though endothelial cells and their 
basement membranes, and through pericytes into the inflamed tissues (229). 
Endothelial cells redistribute junctional adhesion molecules such as vascular 
endothelial (VE-cadherin) which do not support leukocyte transmigration (231) and 
subsequently mobilize junctional adhesion molecules such as PECAM-1 (CD31) and 
CD99 (232, 233) for which leukocytes express ligands to the luminal surface to create 
an adhesive haptotactic gradient that guides leukocytes to junctions (222). Endothelial 
cells then transiently disengage their cell junctions to allow the leukocytes to cross 
(222, 234) into the interstitium.  
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1.5 The Endothelium 
The endothelium is a metabolically active, continuous monolayer of squamous cells that 
lines blood vessels, and in conjunction with the collagen-rich basement membrane not 
only separates, but also selectively connects the tissue micro-environment and blood, 
thus helping to maintain tissue homeostasis. Developmentally, endothelial cells arise 
from mesoderm via differentiation of angioblasts (235). They are typically small and 
contain relatively few mitochondria but are metabolically active. They also possess a 
significant amount of caveolae for macromolecular transport, and are important for a 
variety of physiological processes, including the maintenance of permeability, nutrient 
and leukocyte trafficking and regulation of vascular tone.  
The pulmonary microvasculature is designed as a high compliance, low 
resistance vascular bed to enable gas exchange of the entire circulating blood volume at 
baseline and under exertion (236). The main site of pulmonary gas exchange is the 
alveolar-capillary membrane, which is only 0.5 µm thick and consists of a layer of 
epithelium and endothelium separated by a thin basement membrane (237). As the 
pulmonary endothelium is a major component of this gas diffusion surface, its 
functional and structural integrity are crucial for adequate pulmonary and systemic 
cardiovascular homeostasis. Consequently, it is adapted to perform a number of 
functions that adequately match perfusion with ventilation (237). The development of a 
relatively impermeable endothelial layer is particularly important in the pulmonary 
microvasculature to prevent alveolar flooding under increased pressures (238, 239). 
However, under normal conditions, a small quantity of fluid passes between endothelial 
cells via the para-cellular route, under regulation by tight and adherens junctions (240). 
Pulmonary endothelial cells also carry out important metabolic functions similar to 
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endothelial cells of other vascular beds, including synthesis, and release of several 
vasoactive substances such as angiotensin II (AT II), NO and endothelin-1 (209). 
Pulmonary endothelial cells maintain an anti-adhesive and anti-coagulant surface to 
prevent platelet aggregation and clotting. They also regulate haemostasis by producing 
pro-thrombotic substances such as von Willebrand factor, and restrict coagulation by 
producing anti-thrombotic- (heparan sulphate, thrombomodulin), and fibrinolytic- 
(plasminogen activators) factors. Finally, they actively participate in host defence 
through the release and expression of various inflammatory mediators (209). It should 
be noted that these functions are not executed by each pulmonary endothelial cell to the 
same extent, as significant functional and structural heterogeneity exists between 
endothelial cells from different vascular segments within the lung. Indeed, comparing 
the bronchial and pulmonary circulation, differences can be seen with respect to cell 
shape, nuclear orientation, barrier properties, adhesion molecule expression, leukocyte 
trafficking, and responses to intracellular calcium (241). 
 
Heterogeneity of the endothelium 
Blood vessels include arteries, veins and microvessels, including arterioles, capillaries 
and postcapillary venules. The exchange of substances such as gases and nutrients, as 
well as interactions of leukocytes with vascular endothelium, occurs mainly within the 
capillary bed (242). It is widely accepted that, regardless of the vessel, the endothelium 
is essential for a variety of basic physiological processes, such as those mentioned 
above. However, it is less well appreciated that endothelial cell phenotypes are 
structurally and functionally heterogeneous between organs, and even within the 
vascular beds, of a given organ (242). Endothelial heterogeneity has been postulated to 
arise either from genetic or environmental factors. With regards to genetic factors, it 
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has been hypothesized that organ-specific phenotypes are preset before they migrate 
from the mesoderm to specific vascular beds. On the other hand, it is thought that 
soluble proteins and mediators, cell-cell communications, and the synthesis and 
organisation of matrix proteins, play a significant role in the composition of the 
microenvironment, that inadvertently determines the phenotype and properties of 
endothelial cells within a particular vascular bed. 
From a structural standpoint, endothelial cells from different vascular beds vary 
in size, shape and thickness. For example, in a study of rat blood vessels, pulmonary 
artery endothelial cells were found to be short and broad (30 x 14 µm), forming a 
rectangular shape, whereas endothelial cells of the pulmonary veins were found to be 
longer and broader (48 x 23 µm) and round in shape (243). Endothelium can either be 
continuous and fenestrated, or continuous and non-fenestrated, or discontinuous (242). 
Within the kidney, endothelium is discontinuous within glomerular capillaries and 
continuous, but fenestrated, within peritubular capillaries (237). 
Lung microvascular endothelium possesses a more impermeable barrier than 
pulmonary arteriole or venule endothelium; in vivo and in vitro studies have shown that 
lung microvascular endothelium are around 100-fold more impermeable to water than 
pulmonary arteriole or venular endothelium (238, 244). Under the same conditions, it 
was additionally demonstrated that thapsiagargin (an inhibitor of intracellular Ca2+ 
pumps) induced intercellular gap formation in in vitro cultured pulmonary artery 
endothelial cells, but did not induce gaps in cultured microvascular endothelial cells 
(244). Finally, glomerular and liver endothelia are organized such that they are semi-
permeable to allow the movement of fluids, whereas the brain endothelium is 
practically impermeable to fluids (237). In the lung and liver, leukocytes adhere to 
capillary endothelium independent of a selectin-mediated rolling mechanism, whereas 
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in the systemic circulation, leukocytes adhere to post-capillary venules in a selectin-
mediated fashion (108). Finally, in response to endotoxin, sheep and bovine pulmonary 
microvascular cells individually release greater levels of prostacyclin and prostaglandin 
E2 than their pulmonary artery endothelial cells in vitro (245). 
Endothelial cell gene expression also differs between blood vessel types and 
vascular beds. For example, the glycoprotein, von Willebrand factor (vWF), a stabilizing 
carrier for factor VIII, which is important for normal platelet adhesion and aggregation 
at sites of vascular injury, is heterogeneously distributed throughout the vascular tree. 
Expression of vWF has been demonstrated to be higher on the venous side of the 
circulation compared with arteries and arterioles (246). Furthermore, it was found that 
within the lungs of mice, tissue-type plasminogen activator was expressed on bronchial 
endothelial cells whereas it was absent on parenchymal endothelial cells (247). In terms 
of adhesion molecule expression, basal P-selectin expression is higher in the lung and 
mesentery in comparison to the heart and brain of mice(248). In a mouse model of 
endotoxemia however, P-selectin mRNA expression was increased 87-fold in the heart 
but only 12-fold in the lung, thus showing that vascular beds vary in their response to 
endotoxin (249). Finally, in a cecal ligation puncture (CLP) model of sepsis, ICAM-1 was 
highly induced in the lungs but VCAM-1 was not, despite the observation that other 
organs including the heart, liver and kidney had a significantly high expression VCAM-
1(250). 
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The endothelium in vitro 
Experimental in vivo studies on pulmonary ECs are not always easy to perform and 
permit little experimental manipulation. To overcome this, tissue culture models have 
been developed which have proven to be a useful tool, allowing investigation of 
biochemical and molecular events under standardized conditions. 
 Substantial amounts of our knowledge about endothelial cell functions come 
from in vitro experiments with HUVEC. These experiments, for example, have provided 
basic knowledge about antigenic proteins with which to identify and characterise 
endothelial cells both in vivo and during in vitro tissue culture. Some of these markers 
and their functions are summarized in Table 1.2. In addition, adhesion molecules and 
inflammatory mediators such as E-selectin and COX-2, now known to be upregulated 
during inflammation in vivo, were initially identified to be expressed by HUVECs in vitro 
(251). However, as microvascular endothelial cells differ from macrovascular ones, it 
has been important to establish microvascular endothelial cultures.  
 Although researchers agree that cells cultured in vitro may lose some of their 
tissue-specific properties (252), it is now clear that most in vivo responses are 
maintained in tissue culture models. This apparently occurs because cells retain a 
functional “memory” that is dependent upon their vascular bed of origin; a study by 
King et al, in 2003 (253), demonstrated this. In the rat lung in vivo, capillary endothelial 
cells specifically bind a lectin known as Griffonia simplicifolia that exclusively interacts 
with α-galactose. Rat pulmonary artery endothelial cells, in contrast, bind another lectin 
Helix pomatia, that exclusively interacts with α- and β-N-acetyl-galactosamine. Upon in 
vitro culture, each of the endothelial cells displayed their in vivo lectin-binding 
properties (253). In another study, alcohol-fed rats exhibited diminished anti-oxidant 
capacity, and cells isolated from these rats also exhibited similar diminished anti-
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oxidant capacity(254) . These results therefore illustrate that, the ability of endothelial 
cells to retain memory allows the use of in vitro cell culture models (especially when 
isolated from the appropriate vascular bed within the organ of interest) to investigate 
physiological and pathophysiological mechanisms in inflammation. 
 
 
Table 1.2. Cellular markers of the endothelium. Cellular antigens/markers present in the membrane define cells 
of endothelial lineage. Antigens including CD34, ICAM-1 & -2, Ve-cadherin, endoglin, and CD31 are constitutively 
expressed. While others including VCAM-1, E-selectin, p-selectin and ICAM-1 are upregulated during inflammation. 
 
 
 
 
Endothelial Markers Distribution Function 
CD34 Capillary endothelial cells 
(255) 
 - 
E-selectin Endothelial cells 
Ligand for leukocyte PSGL and 
upregulated during 
inflammation  
Endoglin Endothelial cells Accessory receptor for TGF-β 
(256) 
ICAM-1 Endothelial cells, epithelial 
cells 
Ligand for leukocyte integrins, 
constitutively expressed but 
upregulated during 
inflammation (257) 
ICAM-2 Endothelial cells Provides co-stimulatory signal 
for T cell aggregation and NK 
cell migration . 
P-selectin Endothelial cells, platelets Ligand for leukocyte PGSL, 
upregulated during 
inflammation (258) 
CD31 Endothelial cells, platelets, 
monocytes & neutrophils 
Regulates transmigration of 
leukocytes through the 
endothelium into the 
interstitium (259) 
VCAM-1 Endothelial cells, some 
macrophages 
Interacts with leukocyte β-2 
integrin VLA-4, upregulated 
upon inflammatory stimuli 
(258) 
Ve-Cadherin Endothelial cells Organisation of endothelial cell 
junctions and maintenance of 
barrier function (260, 261) 
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In vitro models of leukocyte-mediated endothelial injury 
To obtain a more precise understanding of leukocyte-endothelial cell interactions 
during inflammation, it has been necessary to utilise in vitro model systems. In these 
systems, leukocyte-endothelial cocultures have been used to determine the mechanisms 
involved in leukocyte-endothelial contact-dependent effect on inflammatory responses. 
The majority of these in vitro models have been developed by co-culturing leukocytes 
with human umbilical vein endothelial cells (HUVECs), which are macro-vascular 
endothelial cells (262-265). One of the reasons for this is that HUVECs are easy to obtain 
and maintain in culture. However, many pathologic processes occur at the 
microvascular level of organs, and as each vascular bed varies considerably within each 
organ, and even within the organ itself, it is unlikely that a read-out depictive of the 
organ being studied could be completely replicated by studying endothelium from a 
totally different organ. This finding is especially true for the lung due to its specific 
endothelial cell characteristics (241, 266). A desirable model system would therefore be 
based on coculture of primary pulmonary microvascular endothelial cells with primary 
leukocytes from the same species. The few in vitro studies that have used such models 
to elucidate the mechanisms of leukocyte-endothelial interactions in pulmonary 
microvascular injury have cocultured neutrophils with human pulmonary 
microvascular endothelial cells (HMVEC) (267, 268). These studies have established 
that pre-exposure of neutrophils to priming agents such as LPS increases its expression 
of surface-adhesive glycoproteins, which enhances margination to the endothelium and 
also further activates neutrophils to release cytotoxic agents that could potentially 
damage the activated endothelium (267). Also important, and consistent, is the finding 
that contact, mainly mediated through β2-integrin-ICAM interactions, augments both 
endothelial and neutrophil activation in response to inflammatory stimuli. Other in vitro 
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models of pulmonary microvascular injury have implicated VCAM-1 and/or other β2 
integrin ligands in endothelial cell damage (265). Furthermore, in vitro studies have 
demonstrated that that the incubation of unstimulated neutrophils with endothelial 
monolayers could induce endothelial cell cytolysis and detachment (269). Similar 
results have been found when endothelial cells are incubated with proteolytic enzymes 
including elastase and proteinase 3 (270), but these models, once again, have employed 
HUVECs, which may not truly represent the array of adhesion molecules present in the 
pulmonary microvascular endothelium. 
 In the context of ALI and to my knowledge, no in vitro studies have been done to 
determine the mechanisms involved in monocyte-pulmonary microvascular endothelial 
injury. Thus, to allow direct comparison between in vivo and in vitro findings, and to 
essentially obtain a closer representation of the mechanisms involved in monocyte-
mediated damage to the pulmonary microvascular endothelium; a coculture system of 
both these cells from the same species would be most ideal. Because of the relative 
difficulty in obtaining primary human tissue, as well as the difficulty in performing in 
vivo studies of organ injury in humans to correlate in vitro findings, mice are an ideal 
alternative because of their availability, and the fact that particular strains respond 
similarly to inflammatory stimuli. Unfortunately, the capacity to set up useful in vitro 
models using microvascular endothelium from mice is restricted because of the 
methods available to isolate and culture murine endothelial cells have not been totally 
successful. This is partly due to the amount of tissue available from a mouse as well as 
the difficulties in isolating pure populations of endothelial cells. Nevertheless, if such 
coculture systems could be established, in addition to getting a basic understanding of 
the molecular and biochemical signals that mediate these interactions, hybrid systems 
using endothelial cells and monocytes from genetically modified mice could be 
65 
 
developed. These could potentially further our understanding of monocyte-endothelial 
interactions through adhesion molecules, chemokines, inflammatory mediators, and 
signalling pathways. Moreover, we would be provided with a platform on which both 
our in vitro and in vivo findings in mice could be directly compared, and in this way, we 
would get a better understanding of the role of monocytes in sepsis-induced pulmonary 
microvascular injury. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
66 
 
1.6 Thesis Hypothesis, Objectives & Aims 
Hypothesis 
In view of the recent data from in vivo mouse models of endotoxin-induced ALI, I 
hypothesise that in mice and other species devoid of a resident population of PIM, 
monocytes are actively recruited to the lung in response to endotoxin during systemic 
bacterial infection, where they play a role in modulating early pulmonary inflammation 
events in a comparable manner to lung-marginated PIM in livestock animals. I also 
hypothesise that the p38/MK2 MAPK pathway plays an important role in regulating the 
inflammatory responses of the Gr-1high and Gr-1low monocyte subsets. 
 
Objectives & Aims 
The main objective of this PhD is to define the role of monocyte-endothelial interactions 
during pulmonary microvascular injury in response to endotoxin challenge using an in 
vitro monocyte-endothelial coculture model. The specific aims are: 
1. Develop a methodology for the isolation and culture of mouse lung 
endothelial cells (MLEC) 
2. Investigate priming and enhancement of the monocyte pro-inflammatory 
response through monocyte-endothelial interactions in vitro 
3. Investigate the role of the p38 MAPK pathway in the differential monocyte 
subset TNF responses 
4. Investigate the role of LPS-mediated TLR4 signalling for monocyte-
endothelial reciprocal activation. 
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Chapter 2: 
Methods 
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This chapter describes the methodologies and techniques used during this project, 
including protocols for isolating and culturing primary mouse lung endothelial cells, 
isolating mouse bone marrow and whole blood monocytes, developing in vitro 
monocyte-endothelial coculture models and, flow cytometric analysis. 
 The initial part of this project focused on isolating and culturing primary mouse 
lung endothelial cells. To this end, we developed an immuno-magnetic bead method 
using the MACS separation system with which we could obtain viable and high yields of 
endothelial cells. A general synopsis of the approach used and techniques involved in 
primary cell isolation and culture is described in the following section, with a more 
detailed description of the procedures provided in the results Chapter 3 dedicated to 
endothelial cells. The remainder of the methods used are described in full detail. 
 A flow cytometric protocol that has previously been developed in our laboratory 
was used to quantify expression of cell surface TNF on bone marrow monocytes and 
monocyte subsets in whole blood. The same protocol was modified and used for the 
quantification of intracellular cytokines and phospho-kinases in monocyte subsets. We 
also used flow cytometry for the characterization of our primary lung endothelial cells 
by quantifying constitutive and induced expression of surface adhesion molecules. The 
general concepts and gating strategies involved in flow cytometric analysis of adhesion 
molecules, surface and intracellular cytokines, as well as phospho-kinases will be 
described in the following sections but specific details for individual assays will be 
described in appropriate chapters. 
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2.1  Animals 
All protocols were performed in accordance with the Animals (Scientific Procedures) 
Act 1986, United Kingdom and had previously been reviewed and approved by the 
Home Office. Male wild-type (WT) C57BL/6 (Charles River Laboratories, Margate, UK) 
and TLR4-/- knockout (KO) (purchased from Oriental Yeast Co., Ltd, Tokyo, Japan) mice 
aged 4-6 weeks were used. 
 
2.2 Primary Lung Endothelial Cell Isolation and Culture 
Overview 
Cell culture is an important technique that is used by scientists in various fields of 
research to investigate biological properties and mechanisms that may prove difficult to 
study at the level of the intact organism using in vivo modelling systems. Primary 
endothelial cell cultures are usually initiated after direct isolation of endothelial cells 
from appropriate animal tissues. Primary cell cultures are advantageous because they 
retain most of the physiological and functional properties of the parent tissue. However, 
it is important that primary cultures are not maintained in culture for prolonged 
periods or else they lose their innately acquired functional properties.  
 Primary cultures are obtained either by disaggregating tissue mechanically or 
with the use of enzymes to produce a cell suspension from which some cells will adhere 
to a suitable surface, or by allowing cells to grow out from tissue explants. Different 
tissues may require specialised techniques, but generally there are important points 
that must be noted. Firstly, solid tissues should be chopped finely to optimise enzymatic 
digestion, which is a more gentle method than mechanical-only separation of 
parenchymal cells; secondly, the enzymes used for the disaggregation of the tissue must 
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be removed from the primary culture as their prolonged presence may result in cell 
death. Therefore, cells should be exposed to minimum amounts of enzyme, and for very 
short time periods to ensure minimal cell damage. Finally, the number of cells seeded 
per tissue culture vessel should be much higher than would normally be used for the 
subculture of an established cell line to maximize chances of cell propagation. The 
method we developed for the isolation of lung endothelial cells comprised three main 
steps: 
1. Acquisition of lungs from animals 
2. Enzymatic disaggregation of lung tissue 
3. Magnet-activated cell sorting (MACS) separation 
Once endothelial cells were isolated, they were seeded into flasks and allowed to grow 
until they reached confluence, after which they were sub-cultured and allowed to 
propagate. Endothelial cells were characterised morphologically and immunologically 
to confirm their vascular lineage. 
 
Acquisition of lungs from animals 
To initiate endothelial cell cultures, lung tissue was obtained from mice aged between 4-
6 weeks. Young animals were used to improve our chances of obtaining high yields of 
viable, proliferating endothelial cells. As animals age, their tissues become more 
resistant to enzymatic dispersion, and consequently it is increasingly difficult to obtain 
substantial amounts of viable proliferating cells. Several factors including the onset of 
differentiation, an increase in fibrous connective tissue, and a reduction in the pool of 
undifferentiated proliferating cells contribute to this. 
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Enzymatic lung tissue disaggregation 
The most frequently used enzymes for tissue disaggregation include trypsin, 
collagenase and dispase. Trypsin adversely affects cell viability especially when used for 
prolonged periods of time. Although collagenase has widely been used for the 
dispersion of lung tissue by other research groups, I found that it considerably reduced 
the viability of my lung endothelial cells. Dispase, however, was a milder yet effective 
digesting enzyme, and was found to produce high viability single cell suspensions.  
  
Magnet-activated cell sorting (MACS®) column separation system 
MACS separation is an antibody-based technique that relies on the presence of a 
magnetic field for the separation of various biological materials including human and 
animal cells. The Miltenyi MACS column separation system consists of a magnet, 
plunger, and a ferromagnetic-containing column (Figure 2.1).  
 
Column
Magnet
Ferro-magnetic spheres
Plunger
 
Figure 2.1. Magnet-Activated Cell Sorting (MACS® Technology). The MACS separation system consists of a 
magnet, plunger, and a ferro-magnetic containing column. The magnet provides a magnetic field, which holds 
magnetically labelled cells within the column. Once the column is removed from magnet, the plunger is used to expel 
the cells from the column. 
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MACS Columns 
The MACS column matrix is composed of ferromagnetic spheres, which are covered 
with a hydrophilic plastic coating to allow rapid and gentle separation of cells (Figure 
2.1). Columns exist in a variety of sizes including ‘MS’ and ‘LS’ that can retain different 
numbers of cells, and is optimized for both positive selection, and depletion, of cells. MS 
columns can hold up to 1×107 magnetically labelled cells from a cell suspension 
containing 2×108 total (magnetically labelled and unlabelled) cells, while LS columns 
can hold up to 1×108 magnetically labelled cells from a cell suspension containing 2×109 
total cells.  
 
Principle of MACS® Separation 
Cell suspensions are initially labelled with a biotinylated primary antibody, and 
subsequently labelled magnetically with streptavidin-conjugated micro-paramagnetic 
beads (Figure 2.2A). The cell suspension is then loaded on to a MACS® column which is 
placed in the magnetic field of a MACS separator (the magnet). The magnetically 
labelled cells are retained in the column while the unlabeled cells pass through (Figure 
2.2B). Upon removal of the column from the magnetic field, the magnetically retained 
cells can be eluted using a plunger (Figure 2.2C). In this way, both fractions, 
magnetically labelled and unlabelled, can be completely recovered. 
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A.  Magnetic labelling of cells
Antibody Antigen
Paramagnetic streptavidin 
microbead
Biotin Target cell
 
Cell suspension containing 
magnetically labelled (black) 
and unlabelled (red) cells
Magnet
Ferromagnetic spheres
B.  MACS separation of magnetically labelled cells 
Magnetically 
labelled cells
C.  Harvesting of  target cells
 
 
Figure 2.2. Principle of MACS separation. A. Cell suspensions are initially incubated with biotinylated-antibodies 
against specific antigens and subsequently with paramagnetic streptavidin microbeads. B. When the cell suspension 
is loaded into the column, cells bound to streptavidin microbeads are retained in the magnetic field generated by 
magnet and column matrix; unlabeled cells pass straight through. C. The magnetically bound cells are expelled using 
the plunger when the column is removed from the magnet,  
 
 
To obtain high purity endothelial cell cultures, we employed a two step MACS 
separation method that involved the initial depletion of leukocytes followed by the 
positive selection of endothelial cells. I used different combinations of columns for the 
depletion and enrichment steps until it was optimised for maximum purity and viability 
rates (Table 1). Leukocytes were identified and depleted on the basis of their high 
CD45+ expression while endothelial cells were positively selected and isolated on the 
basis of their high CD31+ expression. Leukocytes were initially depleted before positive 
selection for endothelial cells because they express moderate levels of the CD31 antigen. 
Therefore, primarily depleting these cells would improve the purity of MLEC cultures.  
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Table 2.1: Purity and viability of endothelial cells after MACS™ separation. Alterations in the size of columns 
used for depletion of leukocytes (CD45+) and isolation of endothelial cells (CD31+) as well repeated enrichment steps 
clearly improved purity. Using the LS column maximized CD45+ leukocyte depletion and yielded purer CD31+ isolates 
after positive selection with the MS column. *Final protocol. 
 
 
Establishment of mouse lung endothelial cell (MLEC) cultures 
To establish cultures, lung endothelial cells isolated using the MACS® separation system 
were re-suspended in complete growth medium and seeded into tissue culture flasks. 
As endothelial cells are typically adherent cells, tissue culture flasks (BD Falcon, Oxford, 
UK) were pre-coated with gelatin before the transfer of endothelial cell suspensions into 
them. Culture flasks were then placed in a standard 37˚C CO2 (5%) incubator.   
 
Subculture and Propagation of MLEC 
Once a culture has been initiated, it will require periodic medium changing, and 
monitoring with an inverted microscope on a daily basis to ensure they are growing 
adequately towards forming confluent monolayers. Once confluent, monolayers may be 
harvested by the use of a variety of proteases including dispase, collagenase or most 
commonly trypsin, by digesting the proteins in the cell membrane responsible for cell 
attachment to the surface of the tissue culture flask. Trypsin can digest functionally 
MACS™ separation protocol % Purity of  MLEC % Viability 
No purification ~8 ~86 
LS: CD31+ selection ~60 ~85 
 
LS: CD45+ depletion 
LS: CD31+ selection 
~74 ~80 
LS: CD45+ depletion 
MS: CD31+ selection 
~79 ~63-90 
*LS: CD45+ depletion 
MS: (x2):CD31+ selection 
~ 86–93 ~83-89 
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relevant endothelial cell membrane proteins, such as CD31 (271) so it is important to 
keep the time it is in contact with the cells to a minimum. After the cells detach, a 
serum-containing medium is added to inhibit further action of trypsin on cells. 
Detachment of cells with trypsin is generally more efficient if magnesium and calcium 
ions are removed from the medium. This can be achieved by using a trypsin containing 
the divalent cation chelator EDTA. 
  
Cell seeding concentration at subculture 
The ideal method of determining appropriate seeding densities is to perform a growth 
curve assay using different seeding concentrations, and from that determine the 
minimum concentration of cells that will produce confluent endothelial monolayers, 
within a time frame that is convenient for experimental continuity or the next 
subculture. However, it also convenient to determine seeding concentrations by using 
split ratios. This involves reducing the cell concentration at subculture for example by 
2-, 4- or 8-fold etc, ie, dividing cells obtained from one flask into two flasks to give a split 
ratio of 1:2, or from one flask into 4 flasks for a 1:4 split ratio. In this way, calculating 
the number of population doublings becomes easier (ie, a split ratio of 2 corresponds to 
1 population doubling, 4 to 2 and 8 to 3). In essence, a culture divided 4-fold requires 2 
doublings to return to the same density. I did not perform a growth curve assay in this 
project, instead I counted the cells obtained after each sub-culture and used split ratios 
to determine the seeding concentrations for subsequent sub-cultures. As such, I could 
determine the minimum number of cells required to obtain confluent cells within a 
certain time frame and thus maintain experimental continuity.  
After trypsinisation of monolayers, cells were re-suspended in culture media, 
and added to the counting chamber of a haemocytometer slide to determine cell 
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densities by light microscopy. I found that after the first subculture, approximately 1-2 × 
106 cells were obtained (from a 75-cm2 flask) and this was split at a ratio of 1:2 into a 
150-mm2 tissue culture flask (BD Falcon). Subsequent to this, each confluent 150-mm2 
flask containing approximately 7-10 × 106 cells was split at a ratio of 1:8.  Cells split at 
this ratio are confluent after 3 days in culture. 
  
Characterisation of lung endothelial cells 
Characterisation of a primary culture is important, not only for verifying its 
functionality and proving its lineage authenticity, but also to confirm that the cell 
culture has not become contaminated with other cells. Endothelial cells can be 
characterised morphologically using a phase-contrast microscope. They display a 
characteristic cobblestone appearance once confluent. In addition they can be 
characterised through their constitutive expression of specific surface antigenic 
markers, and also through their up-regulation of certain adhesion molecules after 
stimulation by inflammatory cytokines or bacterial LPS. 
 We characterised our endothelial cells by their morphological appearance, and 
also by their expression of constitutively expressed antigens including CD31, vascular-
endothelial (VE)-cadherin (CD144), endoglin (CD105), ICAM-1 (CD54) and ICAM-2 
(CD102). Their microvascular origin was also determined by their expression of CD34, a 
capillary endothelial cell antigen. vWF, a marker expressed mainly by human large 
vessel endothelial cells, and to a lesser degree by microvascular endothelial cells, could 
have additionally been used to confirm their endothelial lineage. However, the antibody 
for this antigen is not currently available for mouse cells. In addition to constitutively 
expressed markers, we stimulated endothelial cells with recombinant TNF (R&D 
systems, Abingdon UK) and LPS (Escherichia Coli 0111:B4, Autogen-Bioclear, 
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Nottingham, UK), and determined their up-regulation of the adhesion molecules ICAM-
1, VCAM-1 and E-selectin. 
 
 
2.3 Isolation of monocytes  
Overview 
During sepsis-induced lung injury in in-vivo mouse models, a high proportion of Gr-1high 
monocytes are recruited from the bone marrow reservoir into the lung where they 
produce high levels of TNF and contribute to the development of pulmonary oedema 
(105, 106, 160). To further assess the inflammatory responses of Gr-1high monocytes in 
vitro, bone marrow monocytes were isolated. Monocytes within the circulation consist 
of Gr-1high and Gr-1low subsets. To compare the inflammatory responses of each subset, 
PBMCs were isolated from whole blood. 
Male C57BL/6 mice aged between 8-12 weeks were used in all experiments. 
Bone marrow was obtained from mouse femur and tibias, and monocytes were 
positively selected and isolated on the basis of their CD115 expression using the MACS 
separation system. PBMCs were obtained from whole blood by density gradient 
centrifugation. 
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Bone marrow cell isolation and magnetic labelling of monocytes 
Mice were injected intravenously with 200 µL of heparin prior to being euthanised by 
isofluorane overdose. Mice were exsanguinated by cardiac puncture and their femurs 
and tibiae were carefully removed and cleaned to remove any adherent soft tissue. The 
tip of each bone was removed using a scalpel, and the bone marrow from the femur and 
tibia was harvested by inserting a syringe needle (27-guage) into one end of the bone 
and flushing through with purification buffer (HBSS [Invitrogen]) supplemented with 
0.1% BSA [Sigma], 2mM EDTA [Sigma]). The bone marrow cells were filtered through a 
40-µm nylon mesh filter (BD Falcon). The cell suspension was then triturated to form a 
single cell suspension that was centrifuged at 400 × g for 10 min. Pelleted cells were re-
suspended in 1 mL of red blood cell lysing buffer (Sigma), gently agitated for 2 min and 
centrifuged at 1400 rpm for 7 min. The cells were then re-suspended in 500 µLof 
purification buffer, incubated with biotin anti-mouse CD115 (BD bioscience) for 30 
mins at 4°C, centrifuged at 300 × g for 10 min and then re-suspended in fresh buffer. 
This was re-incubated at 4°C for 15 minswith streptavidin-conjugated microbeads 
(Miltenyi biotech, Surrey, UK), centrifuged and re-suspended in 500 µL of buffer. Finally, 
the labelled cells were separated using the MACS separation unit with an MS column. 
 
MACS separation of labelled CD115+ monocytes 
MS columns were prepared by rinsing through with 500µL of purification buffer. Cell 
suspensions (500 µL) containing labelled cells were loaded onto the column, and 
unlabeled cells passed through (effluent). After the cell suspension had gone though, MS 
columns were washed three times with 500 µL of purification buffer. The buffer was 
added each time once the column was empty. After washing, the column was removed 
from separator and placed in a 15 mL falcon tube. Purification buffer (1 mL) was added 
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to the column, and this was immediately flushed out by firmly applying the plunger. To 
increase the purity of this magnetically labelled fraction, it was passed over a second, 
freshly prepared MS column. 
 
PBMC isolation 
Peripheral blood (0.8–1.0 mL/mouse) was drawn via cardiac puncture into heparin 
containing syringes from isofluorane euthanised mice. The blood was overlaid on a 
sucrose solution, Histopaque-1083 (Sigma) and subjected to density gradient 
centrifugation (400 × g for 30 min at room temperature) (Figure 2.3). The opaque 
interface containing the mononuclear cells was carefully aspirated, washed three times 
in HBSS then re-suspended in RPMI 1640 supplemented with 10% fetal bovine serum 
(FBS, Invitrogen) and 1% Penicillin-Streptomycin-Glutamine (assay medium).  
 
Plasma layer
PBMC
Histopaque 1083 layer
Erythrocytes & granulocytes
 
 
Figure 2.3. Histopaque-1083 density gradient separation of whole blood. Heparinised whole blood was layered 
onto histopaque and centrifuged at 400 × g for 30 min at room temperature. PBMCs contained within the opaque 
interface were aspirated. 
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2.4 Cell stimulation assays 
Bone marrow monocyte assays 
Low-dose LPS priming of bone marrow Gr-1high monocytes for increased inflammatory 
(TNF) responsiveness to subsequent high-dose LPS challenge was investigated in bone 
marrow monocultures and during coculture with lung endothelial cells. Bone marrow 
monocytes were cultured either alone (monocultures) or with lung endothelial cells 
(cocultures) and stimulated with LPS. Monocyte TNF responses in monocultures and 
cocultures were assessed. 
 
Monoculture assays 
In monoculture experiments, monocytes (1×105 cells/tube) were suspended in 500µL 
of assay medium. Cells were incubated in low-adherence, polypropylene 
microcentrifuge tubes and pre-treated with buffer control (PBS, Sigma) or LPS at 
concentrations ranging from 0–10 ng/mL for 2 h at 37°C, washed three times with 
purification buffer and re-suspended in assay medium. Cells were then stimulated with 
PBS or 100 ng/mL LPS at 37°C for 1 h with or without 10 µM BB94 (British Biotech, 
Abingdon, UK), a hydroxamate-based metalloprotease inhibitor. BB94 was added to 
inhibit TNF-α converting enzyme (TACE) mediated membrane TNF (memTNF) 
cleavage, and thus allow its accumulation on the monocyte cell surface. 
 
Coculture assays 
To set up coculture experiments, lung endothelial cells (4 x 105 cells per well) were 
seeded into 24-well flat bottom gelatin-coated culture plates in complete growth 
medium. At this concentration, they formed a confluent monolayer after overnight 
81 
 
culture. Growth medium in culture plates was discarded and monolayers were washed 
twice with HBSS before the addition of assay medium. Monocyte suspensions containing 
1 x 105 cells were added to endothelial cell monolayers, and cells allowed to sediment 
and equilibrate for 2 h. Cocultures were pre-treated with PBS or LPS at concentrations 
of 0.1–10 ng/mL for 2 h at 37°C, washed three times with care taken not to remove non-
adherent cells with HBSS (0.1% BSA) and re-suspended in assay medium. Cocultures 
were then stimulated with PBS or 100 ng/mL LPS at 37°C for 1 h with or without 10 µM 
BB94.  
Levels of membrane TNF (memTNF) production by monocytes were determined 
by flow cytometry (see flow cytometry section) in mono- and coculture experiments. 
Soluble TNF (solTNF) production by monocytes was also investigated by ELISA, with 
incubations performed in the absence of BB94. 
 
Whole blood assays 
For analysis of leukocyte cytokine responses, it is generally believed that whole blood 
provides a more physiological representation of the in vivo milieu as it preserves the 
natural cell-cell interactions that occur normally, and also maintains the soluble factors 
in plasma at their physiological concentrations. The TNF profile of Gr-1high and Gr-1low 
monocytes within whole blood was determined. To determine memTNF production by 
monocyte subsets, 100 µL of heparinised whole blood was stimulated for 4 h in the 
presence of BB94. To measure intracellular TNF production, 100 µL of whole blood was 
stimulated for 4 h in the presence of 10 µg/mL Brefeldin A (BFA, Sigma). BFA allows 
intracellular accumulation of proteins by inhibiting the export of proteins from the 
endoplasmic reticulum (ER) to the Golgi.  
82 
 
PBMC assays 
To investigate the inflammatory responses of Gr-1high and Gr-1low monocytes in vitro, 
PBMCs (Gr-1high and Gr-1low monocytes) were cultured either alone (monocultures) or 
with lung endothelial cells (cocultures) and stimulated with LPS. Monocyte TNF 
responses, IL-6, COX-2, iNOS, MK2, and p38 activation were assessed in monocultures 
and cocultures. Flow cytometry was used to determine expression of all inflammatory 
mediators and phospho-kinases. 
 
Monoculture assays 
PBMC-only stimulations were performed under rotating, non-sedimenting conditions in 
polypropylene microcentrifuge Eppendorf tubes to prevent their adherence to tubes 
and thus approximate for circulating conditions in vivo. PBMCs (4 x 105/tube) were re-
suspended in assay medium and allowed to equilibrate for 2 h at 37°C prior to 
stimulation. After 2 h, cells were stimulated with either LPS at 100ng/mL or PBS as a 
control. To determine memTNF production by each monocyte subset, 10 µM BB94 was 
added to cultures (to prevent TACE induced memTNF cleavage) 1 h before cell harvest.  
To determine the contribution of p38 activation to memTNF biosynthesis, p38 
inhibitors SB203580 (10 µM) and SB202190 (5 µM) were added to cultures 30 min 
prior to stimulation. To assess intracellular TNF production by each monocyte subset, 
PBMCs were stimulated with either LPS at a concentration of 100 ng/mL or PBS as a 
control for 4 h, in the presence of 10 µg/mL BFA, to stop protein export. Phosphorylated 
p38 and MK2 expression in each monocyte subset was also determined. 
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Coculture assays 
To set up cocultures, lung endothelial cells (4 x 105 cells per well) were seeded into 24-
well flat bottom gelatin-coated culture plates in complete medium. After overnight 
culture, growth medium in culture plates were discarded, monolayers were washed and 
medium was replaced with assay medium. PBMC suspensions containing 4 x 105 cells 
were added to cocultures and allowed to settle and equilibrate. After 2 h, cells were 
stimulated with either LPS at 100 ng/mL or PBS as a control. To determine membrane-
bound TNF production by each monocyte subset, 10 µM BB94 was added to cultures 1 h 
before cell harvest. IL-6 production by each monocyte subset was determined after 4 h 
of LPS stimulation in the presence of BFA. Intracellular COX-2 and iNOS expression were 
also assessed in cocultures after 4 h of LPS stimulation. To determine the contribution 
of p38 activation to memTNF, IL-6, COX-2 and iNOS expression, p38 inhibitors 
SB203580 and SB202190 were added to cocultures 30 min prior to LPS stimulation. 
Phosphorylated p38 and MK2 in each monocyte subset was also determined.  
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2.5 Flow cytometry 
Overview 
Flow cytometry is a technique that uses immuno-fluorescence to measure and analyse 
multiple parameters of individual cells within single or heterogeneous populations. 
Cells are stained with fluorophore-conjugated antibodies specific for target antigens, 
and depending on the capacity of the flow cytometer, several different fluorescently 
labelled antibodies that recognise different antigens can be quantitated on a single cell 
simultaneously. The flow cytometer analyses a sample cell suspension by passing cells 
through a laser beam, and capturing the light that emerges from each cell as it passes 
through. From this, correlated data about individual cell size, granularity and 
fluorescence intensity can be collated. Flow cytometry is particularly useful for cytokine 
and phospho-kinase analysis of individual cells within small samples of heterogeneous 
populations that cannot be easily separated and analysed by other methods such as 
ELISA or Western blot.   
I used flow cytometry to characterise my primary lung endothelial cells by 
measuring their expression of various adhesion molecules. I also used this technique to 
assess the cytokine and kinase responses of Gr-1high and Gr-1low monocytes in whole 
blood, bone marrow/PBMC monoculture, and coculture models  
 
Preparation of cell suspensions for flow cytometry 
PBMCs in cocultures were detached from MLEC monolayers by repeated pipetting and 
transferred into 1.5 mL microfuge tubes. PBMCs in suspension and from cocultures 
were centrifuged at 500 × g for 5 min. Samples were kept on ice until ready for antibody 
staining. General staining protocols for identification of antigens on monocyte 
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subpopulations in bone marrow and PBMC samples are described below. Whole blood 
requires a slightly different staining protocol and will be described separately.   
 
Cell surface antigens/cytokine staining protocol 
For quantification of surface expressed antigens or cytokines, 50 µL of cell sample were 
incubated with appropriate concentrations of fluorophore-conjugated antibodies and 
incubated at 4°C for 30 min. Cells were washed with 4 mL of flow cytometer buffer (PBS 
supplemented with 2% FCS, 5mM EDTA (Sigma) and 0.1% sodium azide (sigma) at 500 
× g for 5 min to remove any excess unbound antibodies. Cells were then re-suspended 
in 300 µL of flow cytometer buffer followed by acquisition and analysis by flow 
cytometry. 
 
Intracellular staining protocol  
For quantification of intracellularly expressed cytokines in monocytes, cell suspensions 
were immediately fixed with BD cytofix/cytoperm (BD bioscience) after the stimulation 
period. For monocultures, BD cytofix/cytoperm was added directly into the culture 
tubes, for cocultures, BD cytofix/cytoperm was added to cells after they had been 
detached from endothelial monolayers in the tissue culture plates and transferred into 
Eppendorf tubes. After 5 min at 37°C, the cells were pelleted by centrifugation at 500 × 
g for 5 min, washed twice with 3mL of BD perm/wash (a saponin based buffer) and re-
suspended in 100 µL of perm/wash. Cells were incubated simultaneously with 
appropriate antibodies against surface- and intracellular antigens or their matched 
isotype control for 30 min at room temperature. Samples were washed twice in 3 mL of 
perm/wash at 500 × g for 5 min (BD bioscience) and re-suspended in 300 µL of PBS 
(2% FBS) followed by acquisition and analysis by flow cytometry. 
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Cell surface and intracellular staining protocol for whole blood 
For determination of membrane-expressed cytokines (memTNF) on monocytes, 50 µL 
of whole blood was incubated with antibodies against cell surface antigens and 
cytokines or its matched isotype control in the presence of BB94 for 30 min at 4°C. This 
was then washed with 4 mL of FACS wash buffer at 500 × g for 5 min and re-suspended 
completely by vortexing. BD lysing solution (1 mL) was added to the cell suspension for 
5 min at room temperature. This was then centrifuged at 500 × g for 5 min and then re-
suspended in 300 µL of FACS wash buffer followed by acquisition and analysis by flow 
cytometry 
For determination of intracellular TNF production in monocytes, 50 µl of whole 
blood was incubated with antibodies against cell surface antigens for 30 min at 4°C. 
Cells were washed with 4 mL of PBS supplemented with 2%FCS at 400 × g for 5 min, 
and re-suspended completely by vortexing. Red blood cell lysing buffer (1mL) was 
added to the cell suspension for 10 min at room temperature after which it was 
centrifuged at 500 ×  g for 5 min. Cells were then washed with 4 mLof PBS-2% FCS at 
300 × g for 5 min and re-suspended in 1 mL of BD cytofix/cytoperm and centrifuged 
immediately at 500 × g for 5 min. Cells were subsequently washed twice with 4 mL of 
BD perm/wash at 500 × g for 5 min. Cells were re-suspended in 100 µL of perm/wash 
buffer and then incubated with either anti-mouse TNF or its matched isotype control for 
30 min at 4°C. Cells were washed with 4 mL of perm/wash buffer and then re-
suspended in 300 µL of PBS-2%FCS followed by acquisition and analysis by flow 
cytometry. 
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Antibodies 
Different cell populations were identified based on size, granularity and expression of 
surface markers using the following fluorophore-conjugated rat anti-mouse monoclonal 
antibodies (unless stated otherwise): anti-F4/80 (clone: CI:A3-1, AbD Serotec), anti-
CD11b (clone: M1/70), anti-Gr-1 (clone: RB6-8C5), anti-TNF (clone: MP6-XT22), anti-
CD34 (clone: RAM34), anti-TLR4-MD2 (clone: MTS510) anti-phospho p38 MAPK 
(pT180/pY182) (Becton Dickinson Pharmingen, Oxford, UK); anti-endoglin (clone: 
MJ7/18), control rabbit IgG (eBioscience, Hatfield, UK); anti-IL-6 (clone: MP5-20F3) 
(Biolegend); rabbit polyclonal anti-phospho-MK2 (Thr334; clone: 27B7), control rabbit 
polyclonal (clone: DA1E) (Cell Signaling); anti-iNOS (clone: C-11) and anti-COX-2 (clone: 
C-29) (Santa Cruz Biotechnology, Heidelberg, Germany). 
 
Data acquisition and analysis 
Samples were acquired using a FACSCalibur™ flow cytometer (Becton Dickinson 
Biosciences, Oxford, UK). Acquisition was performed until at least 5,000 events were 
collected.  Data were analysed with CellQuest™ software (version 3.1, Becton Dickinson 
Biosciences) or FlowJo software (version 8.8.6, Tree Star, Ashland, Oregon, US) 
 
Identification of monocyte subsets for cytokine quantification 
Monocytes in PBMC cell suspensions were identified by their surface expression of 
CD11b and F4/80. Gr-1high and Gr-1low monocyte subpopulations were identified based 
on their relative expression of the Gr-1 antigen (Ly-6C & Ly-6G) (Figure 2.4). Monocytes 
in whole blood displayed identical phenotypes by flow cytometry (data not shown).  
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Figure 2.4. Identification of monocyte Gr-1high and Gr-1low subpopulations in PBMC using flow cytometry. Cell 
suspensions were stained with fluorescent-conjugated antibodies against CD11-b, F4/80 and Gr-1. Monocytes were 
identified by positive staining for CD11b and F4/80, and the subpopulations were differentiated on the basis of their 
relative Gr-1 expression. 
 
 
2.6 Enzyme-Linked Immunosorbent Assay (ELISA) 
Sandwich ELISA was used to quantify LPS-induced soluble TNF production by bone 
marrow Gr-1high monocytes in the supernatants of monocyte-only and monocyte-lung 
endothelial cocultures. 
 
Quantification of soluble TNF production by ELISA 
The concentrations of TNF-α in cell-free supernatants of the cultures were determined 
by sandwich ELISA. In brief, 96-multiwell plates were coated overnight with 1 µg/mL 
anti-mouse TNF-α antibody (R&D systems, Abingdon, UK) at 4°C. Between each 
incubation step, the plates were washed 4x with PBS supplemented with 0.01% Tween 
(Sigma). Standard titration curves were obtained by making serial dilutions of a known 
amount of recombinant mouse TNF-α (R&D Systems). Antibody-coated wells were 
A. PBMC 
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blocked with 1% BSA (in PBS) for 15 min at room temperature. After washing, TNF-α 
standards and test samples were added to the wells in triplicates and incubated for 2 h 
at RT. Plates were washed then incubated sequentially with biotinylated anti-mouse 
TNF-α and streptavidin conjugated horseradish peroxidase (HRP, R&D Systems). The 
substrate, TMB peroxidase (Sigma) was added and colour was allowed to develop in the 
dark. After 10 min the reaction was stopped with 1M sulphuric acid. The optical density 
of each well was measured by spectrophotometric measurements at an absorbance of 
450 nM using a MRX II microwell plate reader and the Revelation software (Dynex 
Technologies, UK) to analyse the generated data. 
 
 
2.7 Data Analysis 
Data are expressed as mean ± SD. Statistical analyses were carried out by student t-tests 
or ANOVA and Bonferroni tests where appropriate. A p value < 0.05 was considered 
significant. All statistical analyses were performed using Graphpad Prism software 
(version 4.0, GraphPad, La Jolla, USA). 
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Chapter 3: 
Isolation, culture & characterisation of 
mouse lung endothelial cells (MLEC) 
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Endothelial cells are heterogeneous between different organs and even within diverse 
vascular beds of the same organ. In order to study disease mechanisms using an in vitro 
system, it is important to culture endothelial cells from the organ of interest. Previous 
methods have been described for the isolation and culture of endothelial cells, which 
although have been successful for some investigators, have not been entirely successful 
for others especially because of contamination with other cell types including 
fibroblasts. 
 I initially attempted to culture lung endothelial cells using a method published by 
the Marelli-Berg group (271) but I encountered difficulties with this method. The main 
problems I had were related to viability and yield of endothelial cells at the point of 
isolation from lung tissue. This chapter describes the modifications, alterations and 
improvements I made to their method that enabled me to isolate, propagate and 
establish a primary lung endothelial culture.  
 The endothelial cells I propagated exhibited the typical ‘cobblestone’ 
morphology of the vascular endothelium. They also expressed typical endothelial 
markers including, CD31, VE-Cadherin, ICAM-1, ICAM-2 and endoglin. Their 
microvascular origin was verified through their expression (marginal) of the capillary 
endothelial marker CD34. E-selectin and VCAM-1 were not basally expressed but in 
response to LPS and TNF stimulation, they up-regulated their expression of E-selectin, 
ICAM-1 and VCAM-1. 
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3.1 Background 
The endothelium possesses several physiological, immunological and biosynthetic 
functions that are required for the maintenance of tissue homeostasis (272) It also plays 
a key role in dictating the immune response to systemic inflammation. It is now well 
recognised that considerable functional and structural heterogeneity exists, not only 
between endothelial cells from different organ sites, but also between macro- and 
microvascular endothelial cells derived from the same organ (237, 242). As such, each 
vascular bed responds to systemic inflammation in a unique way that is defined by both 
intrinsic (genetically pre-determined) and extrinsic (governed by the local 
microenvironment) factors.  
The capacity to isolate and culture endothelial cells has not only significantly 
increased our general understanding of vascular biology but has also provided a means 
by which to study the mechanisms involved in leukocyte-endothelial interactions. The 
mechanism of leukocyte migration into tissues at inflammatory sites has often been 
illustrated as a series of sequential adhesive steps that is initiated by selectin-dependent 
rolling/tethering on the endothelium. A vast majority of this knowledge has come from 
in vitro studies of leukocyte cocultures with macrovascular endothelium obtained from 
human arteries and veins, particularly human umbilical vein endothelial cells (HUVECs).  
In the lung, however, the main site of leukocyte migration is the microvasculature, 
which consists of a complex interconnecting network of short capillary segments (108). 
The selectin-dependent rolling mechanisms required to capture leukocytes from 
flowing blood within the macrovasculature are not necessary in the lung 
microvasculature. This is because the capillary vessels of the lung are so narrow that 
physical trapping is sufficient to stop leukocytes, which have a larger diameter. 
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Consequently, leukocytes have to deform in order to traverse the capillaries; this 
invariably prolongs their transit time and results in their increased retention within the 
lung microvasculature. In fact, in comparison to vessels of other vascular beds, the lung 
microvasculature contains ~50-fold more leukocytes under homeostatic conditions 
(111). Furthermore, research into the functional properties of lung endothelial cells 
using in vitro models has demonstrated that microvascular endothelial cells not only 
have a more impermeable barrier than their macrovascular equivalents (238, 244), they 
also produce greater levels of inflammatory mediators, such as prostaglandins, in 
response to bacterial LPS (245, 273). These findings indicate that the distinctive 
structural property and the characteristic mechanism, by which leukocytes sequester 
into the lung microvasculature, as well as the differential responses of the pulmonary 
microvascular endothelium to inflammatory stimuli, could play an important role in 
defining leukocyte inflammatory responses within the lung microvasculature. In view of 
this, the traditional use of HUVECs for the study of leukocyte-endothelial immune 
responses would be inappropriate for the study of leukocyte-lung endothelial 
responses, and thus, it is essential to isolate and culture endothelial cells from the lung 
to study its inflammatory responses in vitro. 
Previous techniques that have been described for isolating mouse lung 
endothelial cells (MLEC) have proven to be difficult due to the rapid overgrowth of 
contaminating cells such as fibroblasts and smooth muscle cells (274). Despite these 
draw backs, several investigators have devised other strategies to isolate and maintain 
these cells in culture. One method that has been used involves retrograde perfusion of 
the pulmonary vasculature with micro-carrier beads (275). Unfortunately, capillary 
endothelial cells engulf the micro-carrier beads in situ rather than adhere to it (274). 
Hence, this method does not allow for the isolation of capillary cells. Another modified 
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version of this technique involves in situ retrograde collagenase perfusion to ‘wash out’ 
lung endothelial cells (276) but this method invariably leads to a mixed population of 
large and microvascular endothelial cells. A method described by Marelli-Berg et al, 
2000 (271) seemed to provide good yields of viable endothelial cells. This method 
involved incubating minced lung tissue with collagenase and sieving (forcing tissue 
through sieve with syringe piston) the tissue to further dissociate undigested cells. The 
resulting cell suspension was further incubated in a trypsin/EDTA solution and washed. 
Endothelial cells were isolated on the basis of their CD31+ expression using the MACS™ 
separation system (as described earlier). Using this method, they isolated endothelial 
cells, which formed confluent monolayers within 14 days of culture and appeared to 
exhibit the characteristic cobblestone morphology of endothelial cells. Their cells also 
expressed typical endothelial antigens including ICAM-1, ICAM-2 and endoglin (271). 
Based on their success, I attempted to isolate and culture endothelial cells from the lung 
using their protocol. However, using this method, I was consistently unable to generate 
an endothelial cell culture. The main problems I encountered were: (1) dicing lung 
tissues using a scalpel followed by collagenase digestion and filtering resulted not in a 
suspension of single cells but rather a clump of cells, so that the yield of endothelial cells 
was modest; (2) the tissue dissociation protocol, particularly the sieving process and 
the subsequent prolonged exposure to trypsin/EDTA dramatically reduced the 
immediate number of viable cells, so that after the cell suspensions underwent MACS 
separation, the numbers of remaining viable cells were insignificant. Consequently, 
during cell culture there was no growth. On account of this, it was important to develop 
a method with which I could successfully isolate viable lung endothelial cells for in vitro 
culture. 
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3.2 Objectives & Aims 
The overall objective of this chapter was to establish a method for the isolation and 
culture of lung endothelial cells. I aimed to develop a method that utilised gentle tissue 
dissociation techniques that would ultimately provide:   
1.  High yields of viable endothelial cells  
2.  High purity lung endothelial cultures. 
 
3.3 Protocols 
Isolation and culture of MLEC 
Preparation of mice 
Two C57BL/6 male mice aged between 4-6 weeks were used per culture. The animals 
were euthanised by isofluorane overdose and exsanguinated by cardiac puncture. The 
fur and skin of the mice were sprayed with 70% ethanol until they were soaked 
through. The skin around the neck was picked up using a pair of forceps and de-gloved 
using a pair of scissors. The salivary glands were teased apart and the tissue 
surrounding the trachea was removed. A small incision was made in the trachea and an 
endotracheal tube was inserted; this was secured in place by tying it with a piece of 
thread. 1 mL of a 1 mg/mL solution of dispase (made up in Ca2+/Mg2+-free HBSS) was 
subsequently instilled through the endotracheal tube into the lungs. After 5 min, the rib 
cage was cut open and the lungs (without the heart) were carefully excised. The excised 
tissue was placed into a bijou (Sterlin, Caerphilly, UK) containing 5 mL of HBSS 
supplemented with 2.5% FCS (wash buffer). 
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Lung tissue dissociation 
Using clean sterile forceps, the lungs were transferred into a disposable 100-mm 
diameter tissue culture dish (Becton Dickinson, Falcon). 5 mL of wash buffer was added 
and the culture dish was carefully agitated to wash out excess red blood cells from the 
lungs. The lungs were then placed into a fresh, dry 100-mm diameter dish and finely 
minced with scissors. The minced tissues was transferred into a bijou containing 5 mL 
of pre-warmed dispase solution and incubated at 37°C with gentle agitation for 45 min. 
Using a 1mL pipette, the cell suspension was triturated (repeated pipetting) until 
tissues were totally dispersed to form a single cell suspension. The cell suspension was 
then filtered through a 40 µm cell strainer (Becton Dickinson, Falcon) into a fresh 50 mL 
falcon tube, and the sieve was rinsed with 20 mL of wash buffer. The cell suspension 
was centrifuged at 300 × g for 8 min at 4°C. The supernatant was discarded and re-
suspended in 1 mL of wash buffer and transferred into a 15 mL falcon tube. A small 
proportion of the cell suspension was incubated with a fluorophore-conjugated anti-
mouse CD31 mAb (Clone name Becton Dickinson, Pharmingen), and 7-
aminoactinomycin-D (7-AAD) (a plasma membrane impermeant fluorescent nuclear 
dye) to determine the viability rates of endothelial cells by flow cytometry (Figure 3.1). 
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Figure 3.1. Viability rates of pulmonary endothelial cells in dissociated lung tissue. Dispase digested lung 
tissues were finely minced with scissors and triturated to form a single cell suspension. Samples were incubated with 
fluorophore-conjugated antibodies and 7-AAD for flow cytometry. (A) MLECs were identified as high CD31+ 
expressing cells. (B) 97% of pulmonary endothelial cells did not absorb the fluorescent 7-AAD dye; these cells were 
identified as the viable MLEC population 
 
Magnetic labelling of CD45+ (leukocyte) cells 
To remove leukocytes, which express low to moderate levels of CD31, the cell 
suspension was incubated with biotinylated-CD45 antibodies (Becton Dickinson, 
Pharmingen) at a final concentration of 3 µg/mL for 30 min at 4°C. 10 mL of wash buffer 
was added to the tube and the cell suspension was centrifuged at 300 × g for 8 min at 
4°C to remove any excess antibody. The supernatant was discarded and the resulting 
pellet was re-suspended in 1 mL of wash buffer. The cell suspension was incubated with 
streptavidin-conjugated microbeads (Miltenyi Biotech) for 15 min at 4°C. 10 mL of wash 
buffer was added to the tube and it was centrifuged at 300 × g for 8 min at 4°C. The 
resulting pellet was re-suspended in 1 mL of wash buffer.   
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Depletion of CD45+ cells using the MACS™ separation unit 
The MACS™ separation unit was set up using an LS column as previously shown in the 
methods sections. The LS column was prepared by rinsing it with 3 mL of wash buffer.  
A fresh 50 mL falcon tube was used to collect subsequent flow-through. The 
magnetically labelled cell suspension was immediately applied onto the prepared LS 
column after which it was washed three times with 3 mL of wash buffer. The flow 
through containing endothelial cells (depleted of CD45+ cells) was collected and kept on 
ice until further processing. A small proportion of the flow-through was incubated with 
fluorophore-conjugated antibodies against CD31 and CD45 and analysed by flow 
cytometry to verify that the CD45+ population were depleted (Figure 3.2C). The LS 
column was removed from the separator (magnet), 3 mL of wash buffer was quickly 
added to the column and using the plunger, the CD45+ cells contained within the column 
were eluted. 
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Figure 3.2. Depletion of CD45+ cells using the MACS™ separation unit. Digested lung suspensions were 
simultaneously incubated with biotinylated-anti CD45 and streptavidin-conjugated microbeads. (A) Lung cell 
suspensions containing magnetically labelled CD45+ leukocytes and were loaded onto an LS column within the 
MACS™ separation system. (B) Magnetically labelled CD45+ cells were retained within the column (depleted). (C) 
Flow-through contained endothelial cells and were depleted of CD45+ cells. 
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Magnetic labelling of CD31+ (endothelial) cells 
The flow through (containing endothelial cells but depleted of leukocytes) from was 
centrifuged at 300 × g for 5 min at 4°C. The resulting pellet was re-suspended in 1mL of 
wash buffer, transferred into a fresh 15 mL falcon tube and incubated with biotinylated-
CD31 antibodies (Becton Dickinson, Pharmingen) at a final concentration of 3 µg/mL for 
30 min at 4°C. 10 mL of wash buffer was added to the tube and this was centrifuged at 
400 × g for 8 min at 4˚C. The supernatant was discarded and the pellet was re-
suspended in 1mL of wash buffer. The cell suspension was subsequently incubated with 
streptavidin-conjugated microbeads for 15 min at 4°C. 10 mL of wash buffer was added 
to the tube and it was centrifuged at 300 × g for 8 min at 4°C. The resulting pellet was 
re-suspended in 500 µL of wash buffer. 
 
Selection of CD31+ cells using the MACS™ separation unit 
The MACS™ separation unit was set up using an MS column. The MS column was 
prepared by rinsing it with 500 µL of wash buffer. A fresh 50 mL falcon tube was used to 
collect subsequent flow-through. The magnetically labelled cell suspension was 
immediately applied onto the prepared MS column after which it was washed three 
times with 500 µL of wash buffer. The MS column was removed from the separator, 1 
mL of wash buffer was quickly added to the column and using the plunger, the CD31+ 
cells contained within the column were eluted. The cell suspension was centrifuged at 
300 × g for 5 min at 4°C and resuspended in 500 µL of wash buffer. A fresh MS column 
was prepared and whole separation process repeated to increase the purity of the 
CD31+ cells. A small proportion of this cell suspension was kept for viability testing by 
flow cytometry (Figure 3.3) while the remaining was diluted in 10 mL of growth 
medium. 
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Figure 3.3.Viability rates of positively selected CD31+ endothelial cells. Cell suspensions that had been 
previously depleted of leukocytes (CD45+ cells) were simultaneously incubated with biotinylated-anti CD31 and 
streptavidin-conjugated microbeads. Cell suspensions were loaded onto an MS column within  the MACS™ separation 
system. Magnetically labelled CD31+ cells were retained within the column were eluted with a syringe piston and 
incubated with a streptavidin conjugate (to identify biotin positive cells) and 7-AAD. (A). 93% of the cells eluted from 
the column were biotin positive (CD31+) endothelial cells. (B). 84% of the CD31+ endothelial cells were viable. 
 
 
Preparation of growth medium 
Growth medium contains essential molecules, nutrients and supplements required for 
the propagation of cells. It is usually made up of a defined medium component with 
other components such as serum, growth factors, hormones and antibiotics added. The 
composition of the growth medium used for the culture of endothelial cells was adapted 
from Marelli Berg et al, 2000 (271) and was prepared under aseptic conditions. It 
consisted of the following components: Dulbecco’s modified Eagle’s medium (Sigma, 
Poole, UK), 1% non-essential amino acids (Sigma), 1% sodium pyruvate (Sigma), 
12U/mL heparin (Leo Laboratories, Buck, UK), 25mM HEPES (Invitrogen, Paisley, UK) , 
10% heat inactivated fetal calf serum (Invitrogen), 1% Penicillin-Streptomycin-
Glutamine (PSG, Invitrogen) and 50µg/mL endothelial cell growth supplement (Sigma). 
 
A B 
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Gelatin-coating of tissue culture flasks 
Coating tissue flasks with gelatin has been found to be beneficial for the culture of 
endothelial cells as they are adherent cells (277). A 2% stock type B gelatin solution 
(Sigma) was diluted in Ca2+/Mg2+-free PBS to a give a 0.1% solution. Gelatin (0.1%) 
solution was added to tissue culture flasks to cover the bottom of the flask. This was left 
for 1 h at room temperature in a tissue culture hood, after which excess gelatin was 
removed. 
 
Culturing of (CD31+ ) endothelial cells 
CD31+ cells isolated using the MACS™ unit were added to 10 mL of growth medium in 
gelatin-coated 75-mm3 tissue culture flasks. After overnight culture, growth medium 
was removed, and the cells were washed with 10 mL of HBSS to remove non-adherent 
cells and growth medium replaced. Growth medium was changed every 2–3 days. Once 
the cells reached confluence, they were removed from the flasks by trypsinisation and 
subcultured. 
 
Trypsinisation of lung endothelial cells 
Lung endothelial cells are adherent cells and trypsinisation was required for their sub-
culture. Growth media was removed from the flasks and the cells were washed twice in 
Ca2+/Mg2+-free HBSS to remove any traces of growth medium. 1 mL of pre-warmed 
trypsin-EDTA solution (Sigma) was subsequently added to the flasks and incubated for 
1–2 min at 37°C until the cells were rounded. The flask was also patted briefly to fully 
detach the cells from the flask. DMEM (supplemented with 10% FCS, 1% PSG and 25mM 
HEPES) was added to inactivate the trypsin. The cell suspension was briefly triturated, 
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transferred into a 15 mL falcon tube, and then centrifuged at 300 × g for 6 min. The 
resulting pellet was re-suspended in 1 mL of growth media. 
 
Subculture/in vitro propagation of endothelial cells 
Endothelial cells were re-suspended in 25 mL of growth medium and seeded into a 
gelatin-coated 150-mm3 tissue culture flask for propagation. At confluence they were 
detached by trypsinisation as described above and then split at a 1:4 ratio. The 
endothelial cell cultures were used for experiments until passage 8. 
 
Endothelial lineage characterisation 
Morphological appearance 
Endothelial cells were monitored daily until they reached confluence. Their 
morphological characteristics were investigated at confluence by observing them under 
an inverted phase-contrast microscope. 
 
Flow cytometric analysis of constitutive and inducible antigens  
MLEC were grown in gelatin-coated 24-multiwell culture plates. At confluence, the 
growth media was replaced with assay medium. Endothelial monolayers were then 
incubated with either recombinant TNF-α or LPS for 4 h. MLECs incubated in media 
containing PBS alone served as controls. For flow cytometric analysis, the cells were 
detached from the culture plates by trypsinisation and proteolysis was stopped by the 
addition of cold RPMI-10%FCS. Pelleted cells were re-suspended in fresh media, 50 µL 
of which was incubated for 30 min at 4˚C with fluorophore-conjugated anti-mouse 
monoclonal antibodies for CD31 (clone: MEC 13.3), E-selectin (clone: 10E9.6), ICAM-1 
(clone: 3E2), VCAM-1 (clone: 429), VE-cadherin (clone: eBioBV13), ICAM-2 (clone: 3C4), 
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CD34 (clone: RAM34) (Becton Dickinson, Pharmingen), and Endoglin (clone: MJ7/18) 
(eBioscience, Hatfield, UK) or their appropriate isotype-matched control. The stained 
cells were washed with 4 mL of flow cytometry buffer (PBS supplemented with 2mM 
EDTA, 2% FCS and 1% sodium azide) at 500 × g for 5 min. The cells were re-suspended 
in 300 µL of flow cytometry buffer and kept on ice until acquisition and analysis by flow 
cytometry. 
 
3.4 Characterisation of MLEC 
Morphological characteristics 
Over 90% of MLEC isolated by this method of CD45+ leukocyte depletion followed by 
CD31+ enrichment were viable. In culture, they formed monolayers that exhibited the 
characteristic cobblestone morphology with contact inhibition, depictive of the vascular 
endothelium (Figure 3.4).  
 
 
Figure 3.4. Endothelial cell morphology under a phase contrast microscope. Purified mouse endothelial cells 
were cultured in a DMEM based growth medium on gelatin-coated 75-mm3 tissue culture flasks. These cells grew as 
monolayers that exhibited the characteristic cobblestone morphology 
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Characterisation of surface marker expression 
(i) Constitutively expressed endothelial antigens 
The endothelial cell lineage was confirmed by staining MLECs at passage 1 or 2, and 
analysing them for cell surface expression of CD31, the endothelial specific marker that 
was used for the positive selection of this cell. More than 93% of these cells were 
positive for CD31; and although CD31 expression on mouse cells has previously been 
reported to be sensitive to trypsin treatment (271), we found that short incubation of 
the cells with trypsin was sufficient to detach them from culture plates without 
reducing their CD31 expression. This finding was consistent with studies by Lim et al 
(278) whose cells also retained high CD31 expression after short incubations with 
trypsin. In addition, the cells retained a high expression CD31 until passage 8 after 
which it progressively declined.  
Other typical cell surface markers constitutively expressed on endothelial cells 
including VE-cadherin, endoglin, ICAM-1 and ICAM-2 were highly expressed (Figure 
3.5). In addition, the cells expressed marginal levels of CD34, which has previously been 
shown to be expressed at higher levels on pulmonary capillary endothelial cells in vivo 
(279) (Figure 3.5). The expression of these markers further confirmed their endothelial 
lineage. 
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Figure 3.5. Phenotypic characterization of lung endothelial cells. Single-cell suspensions of MLEC were incubated 
with antibodies to VE-Cadherin, Endoglin, ICAM-1, ICAM-2, CD31 and CD34 as described in ‘methods’. Flow 
cytometric analysis showed that >90% of MLECs expressed CD31 as compared with the isotype control (filled 
histogram). Cells positive for CD31 were also positive for the other constitutively expressed markers. Values shown 
in parentheses are mean fluorescence intensity (MFI) for each test mAb with isotype control values subtracted. 
 
LPS- and TNF-α-induced expression of cell adhesion molecules 
Using flow cytometry, we examined the capacity of endothelial cells to up-regulate 
expression of the cell adhesion molecules ICAM-1, VCAM-1 and E-selectin following 
their stimulation with bacterial LPS or recombinant mouse TNF-α for periods up to 6 h.  
 ICAM-1 was constitutively expressed at high levels in MLEC but was further up-
regulated by LPS and TNF-α (Figure 3.6A and 3.6B) in a dose-dependent manner. 
Expression of VCAM-1 was very low in unstimulated MLEC but was significantly up-
regulated by LPS and TNF-α (Figure 3.6C and 3.6D) in a dose-dependent manner. 
Expression of E-selectin was very low or undetectable in unstimulated MLEC consistent 
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with our previous in vivo data (160). However, upon stimulation with LPS and TNF-α, E-
selectin expression was up-regulated (Figure 3.6E and 3.6F) in a dose-dependent 
manner.  
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Figure 3.6. Effects of various concentrations of LPS and TNF on the cellular expression of ICAM-1, VCAM-1 and 
E-selectin on MLEC.  MLEC (5×105 cells/well) were seeded into gelatin-coated 24-well tissue culture plates 
overnight and stimulated with LPS or TNF at the indicated concentrations. After 4 h, adhesion molecule up-regulation 
was measured by flow cytometry. Values are mean fluorescence intensity (MFI) with isotype control values 
subtracted. Data are expressed as mean ± SD of triplicate wells of three seperate experiments. **p<0.01 vs. 0h 
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Figure 3.7. LPS-induced up-regulation of E-selectin and VCAM-1 on MLEC. MLEC (5x105 cells/well) were seeded 
into gelatin-coated 24-well tissue culture plates and stimulated with LPS (100 ng/mL).  After 4 h the levels of each 
adhesion molecule was measured by flow cytometry. Representative histograms showing up-regulation of E-selectin 
and VCAM-1 (black line) compared with isotype-matched control Ab binding (filled histogram) on MLEC. Values 
shown in parentheses are mean fluorescence intensity (MFI) for each test mAb with isotype control values 
subtracted. 
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Time-course experiments indicated that LPS induced ICAM-1 up-regulation on MLEC 
was evident at 2 h, with expression reaching maximum levels by 4 h (Figure 3.8A). 
VCAM-1 expression was also rapidly induced in MLEC after exposure to LPS with 
protein levels peaking at 4 h (Figure 3.8B) after which it declined. E-selectin expression 
was induced in MLEC at 4 h. The response peaked at 2 h (Figure 3.8C) after which it 
rapidly reduced. In spite of this, E-selectin expression was still significantly higher at 4 h 
when compared with basal levels.  
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Figure 3.8. Kinetics of ICAM-1, VCAM-1 and E-selectin up-regulation. MLEC (5x105 cells/well) were seeded into 
gelatin-coated 24-well tissue culture plates overnight and stimulated with LPS (100 ng/mL). At each time point, the 
levels of each adhesion molecule were measured by flow cytometry. Values are represented as mean fluorescence 
intensity (MFI) with isotype control values subtracted. Data are expressed as means ± SD of triplicate wells of three 
separate experiments. *p<0.05 vs. 0h 
 
B A 
C 
111 
 
3.5 Discussion 
Considerable physiological and biochemical differences exist between endothelial cells 
of different organs and between macro- and micro-vessels within the same organ (237). 
Previous studies have shown that environmental signals greatly influence the 
phenotype of endothelial cells, and also that biomechanical stimuli such as laminar 
shear stress can differentially modulate the expression of diverse genes within these 
cells; thus defining their inflammatory responses. In light of this, it is ideal to isolate 
endothelial cells from the appropriate vessels within the organ of interest for in vitro 
studies. 
 A number of methods have been developed for the isolation of endothelial cells 
from the lungs of mice (271, 278, 280). The general features of these methods include 
the use of (i) relatively mature mice (aged between 8–10 weeks) (ii) mechanical 
homogenisation of lung tissue with further enzymatic digestion using collagenase and 
trypsin/EDTA treatment and, (iii) the use of magnetic bead sorting to directly isolate 
the ECs from digested lung cell suspensions. Based on the reported successes of these 
approaches, my initial method of collagenase digestion combined with the identification 
of CD31 using our flow cytometry method suggested I had a good basis to get high 
yields of lung endothelial cells with high viability rates. In my hands however, this 
approach was not suitable for establishing cultures for two important reasons; very low 
viability rates after tissue digestion and sub-optimal conditions, including cell source, 
for producing sustained growth and division of cells. Consequently, I modified the 
procedure and was successful in obtaining viable cells and stable growth in culture. The 
modifications I consider to have improved the method include:  
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(I) The use of younger animals (aged 4–6 weeks): Although I could isolate ECs from adult 
mice using my procedure, their growth in culture was unduly slow and they required a 
greater concentration of growth stimulant (150 µg/mL as opposed to 50–75 µg/mL for 
younger animals) and FCS (20% as opposed to 10% for younger animals) to propagate 
effectively. In addition they were more susceptible to fibroblast overgrowth. However, 
in view of the finding that cellular senescence and the potential for cell division of 
primary cultures depend on donor age, my observations are not totally unexpected 
(281).  
  
(II) The enzyme used for the tissue dissociation process: I used dispase instead of 
collagenase. Dispase (neutral protease) is a bacterial enzyme produced by Bacillus 
polymyxa and is considered to have a milder proteolytic action, especially because it 
preserves cell membrane integrity (282). 
 
 (III) The way in which the lungs were prepared and digested: The intra-tracheal 
instillation of dispase enabled the lungs to disintegrate easily and more completely. In 
addition, trituration as opposed to mechanical homogenisation to obtain single-cell lung 
suspensions after enzymatic dissociation reduced direct physical manipulation of lung 
tissue. In this way, stress to the endothelial cells was reduced and in effect their survival 
was increased. 
 
Endothelial cells are commonly identified by their high expression of the surface 
antigen CD31. However, this antigen is also expressed on leukocytes, albeit at lower 
levels. To ensure I cultured endothelial cells that were of as high purity as possible, I 
employed a two-step method of leukocyte depletion followed by endothelial cell 
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isolation (enrichment) using the Miltenyi MACS™ immuno-magnetic separation 
technique. I depleted leukocytes, identified as CD45+CD31+ cells (Figure 3.2) and then 
positively selected for endothelial cells, identified as CD31++ cells (Figure 3.3). I found 
further optimisation of purity could be obtained by careful selection of the types of 
magnetic columns (used in conjunction with the MACS™ unit) used and the number of 
times cell suspensions were applied. By using the LS –sized column for depletion of 
leukocytes and the MS column twice for positive selection of endothelial cells, I could 
obtain endothelial cells that were ~93% pure (Table 1, Figure 3.3). MLEC isolated by 
the method presented exhibited the classical cobblestone morphology by phase-
contrast microscopy. In addition to morphological appearance, their lineage was 
confirmed by constitutive expression of the markers CD31, ICAM-1, ICAM-2, VE-
cadherin and endoglin, which are typical of the vascular endothelium. However, in this 
project, it was important that we isolated and cultured endothelial cells from the lung 
microvasculature as it is the main site for leukocyte migration both during 
inflammatory and non-inflammatory conditions. It is likely that my endothelial cells are 
of mixed vascular bed origins, but as they expressed the microvascular endothelial 
marker, CD34, albeit at very low levels, we are inclined to believe that the majority of 
the endothelial cells are indeed of microvascular origin. This assumption can be made 
because previous studies have indicated that in in vitro cell culturing conditions, some 
genes usually expressed in lung tissue in vivo are either down-regulated or not 
expressed at all (283). In fact, expression of the CD34 marker, has been reported to be 
greatly reduced on in vitro cultured cells in comparison to cells in vivo (284). Consistent 
with this data CD34 expression levels on my cultured MLEC although lower, were 
comparable to that seen after whole tissue homogenization (data not shown). Further 
characterisation of pulmonary endothelial markers will be required to quantify 
114 
 
microvascular endothelia in primary MLEC cultures. Candidate markers include vWF 
(large vessels) and binding of the lectin Griffonia simplicifolia (capillaries). 
MLEC cells in culture expressed low to negligible levels of E-selectin, P-selectin 
and VCAM-1, consistent with data from other in vitro cultures of mouse lung endothelial 
cells (278) and in vivo expression levels (160). However, on exposure to bacterial LPS or 
recombinant mouse TNF, they up-regulated their surface expression of these adhesion 
molecules, further confirming their endothelial origin. In response to TNF stimulation, 
E-selectin and VCAM-1 were induced by 4 h after which they progressively declined, 
consistent with previous in vivo studies (285). A peak induction of both adhesion 
molecules was observed at 4 h in vivo after which they rapidly declined(285). Although 
ICAM-1 was constitutively expressed, it was also further up-regulated upon treatment 
of endothelial monolayers with either LPS or TNF. Our cells, in comparison to those 
obtained by Marelli-Berg et al (271) expressed much higher levels of CD31, ICAM-1 and 
ICAM-2 albeit lower levels of VCAM-1. In fact, I found my endothelial cell characteristics 
to be more similar to those obtained by Lim et al (278), who purified their cells using a 
dynal bead method; these cells had high expression levels of the aforementioned 
adhesion molecules but lower expression levels of VE-cadherin. Finally, the phenotype 
of my MLEC did not show a marked drift or switch in terms of expression of constitutive 
antigens and responses to LPS or TNF-α during in vitro subculture or passaging up to 
passage 8. After this however, their responsiveness to LPS was greatly reduced.  
 In summary, I have successfully isolated, cultured and propagated endothelial 
cells from mouse lungs. My data suggests that these endothelial cells can retain most of 
their phenotypic and functional properties for several generations when they are 
subcultured in vitro. My ability to develop a reliable method to isolate endothelial cells 
from the lungs which retain some of their organ-specific functions in vitro will be a 
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useful tool to elucidate the genetic contributions and molecular mechanisms that 
mediate endothelial cell-leukocyte interactions and their roles towards the 
pathogenesis and progression of various conditions. 
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Chapter 4: 
Priming and enhancement of the 
monocyte pro-inflammatory response 
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SUMMARY 
‘Two-hit’ models of ALI/ARDS have been proposed in which a first insult sensitises or 
‘primes’ the cells of the inflammatory network and, a secondary insult results in the 
elaboration of the inflammatory response. Based on these models, studies in our group 
have previously shown that low-dose (subclinical) LPS administration in an in vivo 
mouse model induces the mobilization and margination of bone marrow monocytes to 
the pulmonary microvasculature without substantial levels of systemic inflammation. 
However, these newly marginated monocytes appear to be in a primed state; because 
upon secondary LPS challenge, they express significantly high levels of TNF in situ 
within the pulmonary vasculature. In these models, it is unclear whether the primed 
state of these bone marrow derived monocytes is a direct effect of low-level LPS 
stimulation or, a result of monocyte margination with the endothelium (i.e. prolonged 
endothelium contact induces monocyte priming) or, a combination of both low-level 
LPS stimulation and margination to the endothelium. In this chapter, using a model of 
LPS-stimulated enriched bone marrow monocytes alone, or with MLEC in coculture, I 
investigated these alternative mechanisms of monocyte priming. 
 The results indicated that bone marrow monocytes cultured alone could be 
primed by low dose LPS such that upon secondary high dose LPS challenge they 
produced higher levels of memTNF. However, when monocytes were cocultured with 
pulmonary endothelial cells and then stimulated with a single high dose of LPS, they 
produced around ten-fold more TNF than monocytes cultured alone. LPS pre-treatment 
of cocultures did not further increase the monocyte TNF response. 
 These results suggested that the priming exhibited by lung-marginated 
monocytes in vivo after primary low-dose LPS challenge, could be the result of 
prolonged contact between newly mobilised bone marrow monocytes and the 
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pulmonary endothelium. However, direct effects of LPS pre-exposure on bone marrow 
monocytes and/or the pulmonary endothelium should not be ruled out at this stage.  
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4.1 Background 
Priming refers to the phenomenon in which prior exposure of a cell to stimuli or agonist 
alters its response to secondary stimuli (286). Leukocytes can be primed by a wide 
variety of agonists including LPS, cytokines and chemokines that may be present during 
an inflammatory response. In several in vitro and in vivo models, these priming agents 
have been shown to enhance the microbicidal function of leukocytes through increased 
release of injurious mediators such as ROS, elastase and TNF in response to subsequent 
inflammatory stimuli (267, 287-292).  
Animal models of sepsis-related ALI often involve a single high dose of LPS or the 
more progressive development of systemic inflammation through controlled infusion of 
LPS (293). However, administration of LPS alone does not completely mimic the 
pulmonary effects of bacteremia or endotoxemia, hence, the use of more complex 
models such as an ongoing peritonitis, such as in the cecal ligation and puncture (CLP) 
model (294). Although these CLP models are regarded as the gold standard, as they 
produce most of the clinical features of sepsis-induced ALI, their variability and the un-
controllable, complex nature of the immune response, makes it difficult to interpret 
(295). In addition, clinical data suggest that ALI is rarely present at the time of hospital 
admission; instead, it develops over a period of hours to days in patients with 
underlying conditions such as pneumonia, sepsis or trauma after a second bout of 
inflammatory stimuli (296-298). To this end, other models propose “2-hit” models in 
which two distinct insults imposed sequentially on the lungs result in the development 
of ALI/ARDS. Although these models oversimplify the complex inflammatory events of 
sepsis-related ALI into just two independent serial injuries, they have often been found 
useful to simulate the essential pathophysiologies observed in clinical ALI (290, 299).  
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The first event in ALI/ARDS which may be an endotoxemia or bacteraemia, 
causes activation of the pulmonary endothelium through up-regulated expression of 
adhesion molecules and chemokine release that prime leukocytes, changing their 
phenotype to adhesive, and inducing their “margination,” partly through β-2-integrin-
ICAM-1 interactions in different vascular beds (267, 287, 290, 300). Based on this, both 
endothelial cell adhesion molecules and leukocyte ligands, especially of the selectin 
family, have been reported to be essential in the development of leukocyte-mediated 
acute lung injury (301). However, the lung contains several narrow capillaries that 
entrap leukocytes and makes them unable to transit the pulmonary microvasculature, 
resulting in leukocyte margination and direct contact to the endothelium, without the 
need for selectin-mediated adhesion (108). As such, this prolonged contact of 
leukocytes with the endothelium could, in itself, modify or enhance leukocyte responses 
to secondary challenges. The second insult, which could be a further endotoxemia, 
shock or haemorrhage, causes the activation of these adherent leukocytes, inducing 
their release of cytotoxic agents and ROS, NO-metabolites, cytokines and other 
inflammatory mediators at the points of leukocyte-endothelial cell contact, culminating 
in endothelial cell damage, capillary leak and pulmonary injury. Although the roles of 
neutrophils in these two-hit models are well established (267) , the roles of monocytes 
are not clearly defined. 
 Monocytes consist of at least two distinct subpopulations which in mice have 
been described as “Gr-1high” and “Gr-1low” subsets. The immature bone marrow derived 
Gr-1high subset is recruited into local sites of inflammation and injury, and is referred to 
as the ‘inflammatory’ subset, while the Gr-1low subset is a precursor of resident tissue 
macrophages and is referred to as the ‘resident’ subset (163, 302). In various in vivo 
models of acute inflammation, the inflammatory subset Gr-1high monocytes have been 
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shown to produce greater amounts of inflammatory mediators, including TNF and iNOS 
than their resident counterparts (166, 168). We have shown in our previous studies, 
using a 2-hit model of ALI, that, in response to subclinical low doses of LPS, the numbers 
of inflammatory Gr-1high monocytes in the pulmonary microvasculature increases 
rapidly through mobilisation of the bone marrow reservoir (105). Furthermore, these 
‘lung-marginated’ monocytes appear to be in a primed state because they respond 
vigorously to secondary LPS challenge by expressing much higher levels of TNF-α than 
monocytes in mice challenged with a single dose of LPS (105). In previous studies 
comparing the inflammatory responses of lung-marginated monocytes and circulating 
monocytes to single-dose LPS challenge, it was observed that lung-marginated 
monocytes expressed significantly higher levels of TNF than circulating monocytes. 
Thus suggesting that monocyte contact with the lung could potentially enhance their 
responsiveness to LPS stimulation. In view of these data, it is unclear whether the in vivo 
primed state and subsequent enhanced TNF responsiveness of the Gr-1high bone-
marrow derived monocytes is a direct effect of LPS pre-treatment (priming) on the 
monocytes, or a result of monocyte ‘margination’ (adherence) with the microvascular 
endothelium or a combination of LPS priming and adherence to the microvascular 
endothelium. Using enriched bone marrow monocytes to represent the major 
population of newly marginated monocytes in vivo, I investigated the direct effects of 
low-dose LPS pre-treatment on LPS-induced monocyte TNF expression and the possible 
augmentation of this response by coculture with primary pulmonary cells.  
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4.2 Aims 
Using an in vitro coculture model of lung endothelial cells and bone marrow Gr-1high 
monocytes, I investigated: 
1. The effect of low-dose LPS pre-treatment (priming) on monocyte TNF response 
to subsequent LPS challenge 
2. The effect of monocyte coculture with MLEC on the monocyte TNF response to 
LPS challenge 
 
4.3 Methods  
To assess monocyte priming by LPS, bone marrow CD115 (M-CSF receptor)-positive 
monocytes were used. Enriched monocytes were pre-treated with PBS vehicle or LPS at 
concentrations ranging from 0.1–10 ng/mL for 2 h at 37°C in Eppendorf tubes. Cells 
were subsequently incubated with PBS or stimulated with LPS at 100 ng/mL or for 1 h 
at 37°C with BB94 (10 µM) to inhibit memTNF cleavage and thus quantify TNF 
production by cells using flow cytometry. MemTNF expression was only measured at 1 
h after secondary LPS challenge because time course experiments with bone marrow 
monocytes showed peak expression at this time point after which it was difficult to 
detect above baseline. To determine solTNF production, cultures were pre-treated with 
LPS (0.1–10 ng/mL) for 2 h and subsequently stimulated with LPS at 100 ng/mL for 4 h. 
Total solTNF levels were measured in culture supernatants by ELISA after 6 h. 
To determine the effect of prolonged endothelial contact on monocyte TNF 
response, bone marrow monocytes were added to, and allowed to ‘equilibrate’ with, 
confluent monolayers of endothelial prior to treatment. The same LPS treatment 
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protocols as used in monocultures were applied in cocultures and, memTNF and solTNF 
production were measured 
 
4.4 Results 
Identification of bone marrow Gr-1high monocytes 
Monocytes were enriched using the MACS separation technique. Although monocyte 
preparations were only approximately 50% pure, they could be easily identified and 
distinguished from other cells by 4-colour flow cytometry. In cocultures, monocytes 
could be differentiated from endothelial cells on the basis of their CD11b expression.  
Gr-1 high bone marrow monocytes were identified as low side scatter, CD11b+ and 
F4/80+, Gr1+ cells (gate R2) (Figure 4.1B).  
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Bone marrow only culture 
                
 
 
Bone marrow-lung endothelial coculture 
                   
 
 
Figure 4.1. Identification of Gr-1high monocytes in monocyte only- and monocyte-MLEC cocultures using flow 
cytometry. Monocytes from cocultures were detached from endothelial monolayers by repeated pipetting. 
Monocytes from monocultures and cocultures were incubated with fluorescent-conjugated antibodies for analysis by 
flow cytometry. Gr-1high Monocytes were identified as CD11-b positive gate (R1), low side scatter and F4/80 and Gr-1 
positive (gate R2) events. 
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LPS priming of bone marrow monocytes for enhanced TNF production 
To evaluate the effect of LPS priming on monocyte TNF production in response to 
subsequent LPS challenge, monocytes were initially treated with lower doses of LPS at 
concentrations in the range 0.1–10 ng/mL for 2 h and subsequently challenged with a 
higher dose of LPS at a concentration of 100 ng/mL. The monocyte pro-inflammatory 
response was assessed by measuring the levels of surface memTNF at 1 h or solTNF at 4 
h after the secondary LPS treatment. Priming monocytes with LPS at concentrations of 1 
and 10 ng/mL followed by secondary LPS produced a significant increase in memTNF 
expression on monocytes, whereas memTNF levels after a single high dose LPS without 
pre-treatment was negligible (Figure 4.2) with similar to levels in unstimulated 
monocytes (data not shown). Analysis of solTNF production at 4 h after secondary LPS 
(100 ng/mL) treatment showed that there was no significant difference in total solTNF 
by enriched monocytes primed with 1 and 10 ng/mL of LPS in comparison to non-
primed enriched cultures (Figure 4.3). There was however a significant reduction in 
solTNF production by monocytes promed with 0.1 ng/mL LPS (Figure 4.3). SolTNF 
production in untreated cultures was negligible (data not shown). These resulted 
suggested that pre-treatment may accelerate (memTNF) rather than enhance TNF 
production because overall levels produced over 6 h (solTNF) were unchanged.  
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Figure 4.2. Low-dose LPS priming of bone marrow monocytes enhances early memTNF production. Bone 
marrow monocytes were treated with low concentrations of LPS as indicated. After 2 h, primed monocytes were re-
challenged with 100 ng/mL LPS for 1 h and analysed for expression of memTNF by flow cytometry. Representative 
histograms showing levels of memTNF expression (black line) compared with isotype-matched control Ab binding 
(filled histogram), on bone marrow monocytes after single (A) or two-hit (B) LPS challenge. (C) Levels of memTNF on 
monocytes were expressed as the geometric mean of fluorescent intensity (MFI) with values of isotype control 
subtracted. Data are expressed as mean ± SD of three separate experiments. *p<0.05; ***p<0.001 vs. single 100 
ng/mL LPS treatment 
 
 
 
A.  Non-primed B.  Primed 
C. 
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Figure 4.3. Low-dose LPS priming of bone marrow monocytes does not increase solTNF production. Bone 
marrow monocytes were treated with low concentrations of LPS as indicated. After 2 h, primed monocytes were re-
challenged with 100 ng/mL LPS for 4 h and analysed for expression of solTNF by ELISA. Data are expressed as mean 
± SD of three separate experiments. **p<0.01 vs. single 100 ng/mL LPS treatment 
 
 
 
Coculture-dependent enhancement of memTNF and solTNF production 
by monocytes after single-hit high dose LPS 
To evaluate the effect of prolonged endothelial contact on monocyte TNF production, 
bone marrow monocytes were cultured in low-adherence polypropylene Eppendorf 
tubes alone (monoculture) or with endothelial monolayers for 2 h at 37°C before being 
stimulated with a single high (100 ng/mL) dose of LPS for 1 h in the presence of 10 µM 
BB94. Monocytes stimulated alone expressed low levels of memTNF; however, during 
coculture with endothelial cells, there was a considerable increase in memTNF 
expression on monocytes (Figure 4.4A). In addition, total solTNF production as 
measured by ELISA indicated that monocytes in coculture with endothelial cells 
produced significantly more TNF after 4 h of LPS stimulation in comparison to 
monocultured monocytes (Figure 4.5). Mem- and solTNF production in endothelial-only 
cultures were negligible both basally and upon LPS stimulation (data not shown). 
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Figure 4.4. memTNF expression on bone marrow monocytes in monoculture and during cocultures with 
MLEC monolayers. Monocytes were cultured either alone (monoculture) or with endothelial monolayers 
(cocultures) for 2 h and treated with PBS (buffer control). After 2 h, mono- and cocultures were stimulated with 100 
ng/mL LPS for 1 h. Cells in cocultures were harvested by repeated pipetting. Monocytes from both mono- and 
cocultures were analysed for memTNF production by flow cytometry. MemTNF expression was significantly higher 
on monocytes in cocultures. Representative histograms showing levels of memTNF expression (black line) compared 
with isotype-matched control Ab binding (filled histogram), on bone marrow monocytes incubated alone (A) or 
during coculture with endothelial cells (B) LPS challenge. (C) Levels of memTNF on monocytes were expressed as the 
geometric mean of fluorescent intensity (MFI) with values of isotype control subtracted. Data are expressed as mean 
± SD of three separate experiments. ***p<0.001  
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Figure 4.5. solTNF production in bone marrow monocyte monocultures and during cocultures with MLEC 
monolayers. Bone marrow monocytes were cultured either alone or with endothelial monolayers for 2 h and treated 
with PBS (buffer control). After 2 h, mono- and cocultures were stimulated with 100 ng/mL LPS for 4 h. After a total 
of 6 h incubation, the amount of sol TNF produced was assessed by ELISA. Monocytes in cocultures expressed 
significantly higher levels of solTNF. Data are expressed as mean ± SD of four separate experiments.  *p<0.01  
 
 
LPS priming of monocyte-endothelial coculture for enhanced TNF 
expression 
To evaluate the effect of LPS priming on monocyte TNF production in cocultures in 
response to subsequent LPS challenge, monocyte-endothelial cocultures were treated 
with lower doses of LPS at concentrations of 0.1–10 ng/mL for 2 h and subsequently 
challenged with a higher dose of LPS at a concentration of 100 ng/mL. The monocyte 
pro-inflammatory response was assessed by measuring the levels of surface memTNF 
expression at 1h after the secondary LPS treatment. There was no significant difference 
in monocyte memTNF expression between cocultures treated with the single high dose 
LPS (non-primed) and those that had been initially primed with low (0.1 or 1 ng/ml) 
dose LPS. In addition, pre-treatment of cocultures with 10 ng/mL LPS resulted in a 
significant reduction in monocyte memTNF expression (Figure 4.6). Mem and solTNF 
production in endothelial-only cultures were negligible both basally and upon LPS 
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stimulation (data not shown). The results therefore indicate that in coculture, LPS pre-
treatment does not prime bone marrow monocytes towards an enhanced response to 
secondary septic stimuli. 
 
 
 
 
Figure 4.6. Low-dose LPS priming of cocultures does not enhance monocyte memTNF production. Bone 
marrow monocytes-lung endothelial cocultures were treated with low concentrations of LPS as indicated. After 2 h, 
pre-treated cocultures were re-challenged with 100 ng/mL LPS for 1 h. Monocytes were harvested from cocultures 
by repeated pipetting and analysed for memTNF expression by flow cytometry. Data are expressed as mean ± SD of 
three separate experiments. ***p<0.001 vs. single 100 ng/mL LPS treatment 
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4.5 Discussion 
Animal studies have adopted a 2-hit model for studying the mechanisms involved in the 
pathogenesis of sepsis induced ALI/ARDS as they are able to simulate some of the 
essential local and systemic inflammatory responses observed clinically (290, 299, 
303). The mechanism of ALI in some of these models relates to the effects of LPS pre-
treatment on leukocyte-endothelial cell interactions (267). LPS is known to prime 
leukocytes, a process that enhances the release of injurious and inflammatory 
mediators in response to secondary stimulus (288). LPS also directly activates 
endothelial cells and up-regulates adhesion molecule expression on both leukocytes and 
endothelial cells in vitro, which allows for firm adherence of leukocytes to endothelial 
cells (304, 305). Within the in vivo system, it is likely that after LPS pre-treatment, these 
mechanisms result in the priming and sequestration of leukocytes to the pulmonary 
endothelium, so that upon subsequent stimulation, an enhanced release of 
inflammatory mediators (ROS, cytokines) would lead to endothelial damage and 
eventual ALI (267). Within the lung however, the presence of narrow capillaries leads to 
the prolonged retention of leukocytes within the lung microvasculature and invariably, 
their interaction with endothelial cells (108). This event in itself could prime leukocytes 
for an enhanced responsiveness to inflammatory insult. Although the roles of 
neutrophils in these models have been established, the roles of monocytes have not 
been clearly defined. 
Previous studies in our group using 2-hit models of acute lung injury have 
indicated that, during sub-acute endotoxemia, monocytes are mobilized from the bone 
marrow which preferentially marginate to the lung micro-circulation, appearing to be in 
a primed state, as they respond vigorously to secondary LPS challenge by expressing 
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high levels of TNF. These pre-marginated monocytes also confer a state of latent 
priming to the lungs themselves with increased susceptibility to zymosan-induced acute 
lung injury that was shown to be dependent on the production of PAF and ceramide by 
monocytes (105). Although, whether enhanced TNF production was additionally 
responsible for this effect has not been investigated (105). In spite of this, in this model 
(and in other 2-hit models of leukocyte mediated lung injury), it is unclear whether the 
apparent primed state of the monocytes is (i) a direct consequence of low-dose LPS pre-
treatment (direct priming) or (ii) augmentation of monocyte responsiveness by 
adherence/margination to the pulmonary endothelium (indirect priming) or (iii) a 
combination of both effects. To address these questions, I evaluated TNF responses with 
2-hit LPS stimulus of bone marrow monocytes in monoculture and coculture with 
MLEC. The results demonstrated that the most substantial increase in monocyte 
responsiveness was evident with monocyte-endothelial coculture and without the need 
for LPS pre-treatment.   
 
Rationale for the use of bone marrow monocytes 
Monocytes isolated from the bone marrow were used in these studies.  We used these 
monocytes because we could obtain high numbers of monocytes and also our previous 
studies had indicated that subclinical endotoxemia induced substantial mobilization of 
monocytes from the bone marrow reservoir and their margination into the lung 
microcirculation (105). In addition, the mobilised population are largely of the Gr-1high 
subset of monocytes, which respond vigorously to secondary LPS challenge by 
expressing higher levels of TNF in comparison to their Gr-1low counterparts (105). Bone 
marrow monocytes were isolated on the basis of their expression of the 
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monocyte/macrophage lineage marker CD115 using the Miltenyi MACS™ immuno-
magnetic separation technique (described in chapter 2).  
 
LPS priming of monocytes 
Monocytes were pre-treated with lower doses of LPS and then challenged with a higher 
dose of LPS in the presence of BB94. Hence, there is an accumulation of memTNF on the 
monocytes and as such an amplified signal which corresponds to TNF production by 
each monocyte is obtained. MemTNF expression on primed cells was compared with 
that on cells that had only received the secondary high dose, and consistent with the in 
vivo data, primed cells expressed significantly higher levels of memTNF as shown by the 
flow cytometry data. Time course experiments indicated that TNF production by 
monocytes peaked at 1 h after secondary LPS treatment and declined dramatically 
afterwards. As bone marrow monocyte preparations used in experiments were around 
50% pure, other non-monocytic cells including neutrophils and NK cells could have 
been present in the isolates. Although these cells could potentially contribute to TNF 
responses measured, the flow cytometry detection method allowed us to gate 
specifically on TNF expressing monocytic cells, and thus allows us to ascribe TNF 
signals to them. In addition, gating on the other non-monocytic cells showed that these 
cells produced negligible levels of TNF. When the total solTNF produced by bone 
marrow cells over a 6 h incubation period was measured, it was observed that cells that 
had not been pre-treated with LPS produced solTNF at levels comparable to those that 
were pre-treated with LPS at 1 and 10 ng/mL. However, when pre-treated with 0.1 
ng/mL LPS, solTNF production by these cells was considerably lower than non-pre-
treated monocytes. The optimum conditions for priming have been ascribed, but are not 
limited to factors including temporal relations (vulnerable window in which priming 
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occurs), crosstalk between various signal transduction pathways, and the magnitude of 
the primary stimulus (306). It is possible in this scenario that monocytes stimulated 
with 0.1 ng/mL LPS are tolerised rather than primed towards an enhanced TNF 
response upon further LPS stimulation. This suggestion is supported by other studies in 
which monocytes have been pre-treated with LPS and subsequently exposed to a 
secondary LPS challenge, and a similar reduction in solTNF production has been 
reported (212, 307, 308). This ‘hypo-responsiveness’ is thought to be LPS-specific, as 
re-exposure of LPS-primed monocytes to other stimulus, such as PMA or zymosan, 
induces enhanced solTNF production (309, 310). Other authors have suggested this LPS 
induced tolerance is associated with a decrease in LPS-induced TNF mRNA and also 
with a decreased G protein function (311). In addition, the decrease in TNF mRNA is 
thought to occur as a result of suppression in NF-kB and MAPK family activation (312). 
Reduced protein kinase C (PKC) activation as well as defective phosphorylation of ERK 
½, has also been implicated in endotoxin-induced hypo-responsiveness of monocytes in 
vitro (313-315). Because we measured memTNF expression on monocytes at only one 
time point (1 h post secondary LPS), the increased expression of memTNF as seen by 
FACS in LPS pre-treated monocytes could be related to kinetic differences in the 
response to primary and secondary LPS treatment. This means that on re-exposure to 
LPS, primed monocytes initially produce TNF rapidly (over the first hour in this case) 
but over an extended period of time, the rate of production decreases such that the total 
solTNF produced by primed monocytes is not necessarily more than that produced by 
un-primed monocytes. To confirm this interpretation, further investigation of the 
kinetics of TNF expression in the in vitro system will be required; solTNF production 
will have to be measured over various time points (hourly for instance) and a transient 
priming effect may be evident which diminishes as time progresses. Nevertheless, the 
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more acute expression of TNF produced by low-level LPS pre-exposure could represent 
a physiologically significant process that inadvertently accelerates the cytokine 
response cascade, leading to a more severe inflammatory response. 
 
Endothelium induced priming of monocytes 
In the previous in vivo studies, an enhanced TNF response to secondary LPS challenge 
was demonstrated in lung-marginated monocyte at 2h after the primary low dose LPS 
(160). Monocyte-only assays were performed in eppendorf tubes that were slowly 
rotated to maintain cells in suspension and to minimise their adherence to plastic 
surfaces, whilst monocyte-endothelial co-culture assays were performed in 24-well 
gelatin coated plates. Although assay conditions for monocytes in monocultures and 
cocultures were not perfectly matched, it was important to maintain monocyte-only 
cultures in non-adherent, rotating conditions so as to approximate for circulating (but  
not marginated within the microcirculation) cells in vivo.  
 
To simulate the in vivo protocol/conditions, monocytes were allowed to settle and have 
contact with the endothelial monolayer for 2 h prior to LPS treatment and measurement 
of the TNF response. Previous in vitro studies have shown that resting monocytes are 
more adhesive to endothelial cells if co-incubated for a minimum of 1.5 – 2 h (316). 
When monocyte-endothelial cocultures were treated with a single high dose of LPS, 
they produced significantly higher amounts of solTNF over a 4 h period than monocytes 
treated with the same LPS dose but cultured alone. Endothelial cells did not contribute 
significantly to total solTNF in monocyte-endothelial cocultures as detected levels in 
endothelial-only cultures were negligible. MemTNF expression was also higher on 
monocytes in coculture with endothelial cells than on monocytes cultured alone. One 
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explanation for this enhancement is monocyte contact with endothelial cells. Previous 
coculture studies of kupffer cells with hepatocytes show a similar augmentation in TNF 
production in comparison to monocultures of either cell type upon LPS stimulation 
(317, 318). In addition, other studies have indicated that monocyte adherence induces 
transcription of TNF mRNA, even without stimulation, but this does not lead to solTNF 
production (319, 320). However, upon LPS stimulation, there is a rapid release of 
solTNF over half of which is produced within the first 60 min of stimulation and peaks 
by 90 min (319). These data could further explain the 12-fold difference in memTNF 
expression between cocultured and monocultured monocytes over an hour. ie contact 
with endothelium  induces transcription of TNF mRNA in monocytes such that upon LPS 
stimulation, a rapid production of TNF ensues. 
 
LPS priming of monocyte-endothelial cocultures 
Having demonstrated that monocytes on their own could be primed to enhance early 
expression of TNF at 1 h, and that contact with the endothelium further significantly 
increased monocyte TNF at this time point, we wanted to determine if pre-treating 
these cocultures with LPS could even further increase monocyte TNF production. Pre-
treating cocultures with LPS at concentrations of 0.1 and 1 ng/mL did not further 
increase memTNF above the levels expressed by monocytes receiving only the single 
high dose of LPS, suggesting that LPS pre-treatment may not be responsible for the 
enhanced mem- and solTNF production by monocytes. Rather, prolonged monocyte 
contact with the endothelium induced a latent state of priming such that further 
exposure to septic stimuli induced an enhanced monocyte TNF response.   
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Interpretation 
Relating this finding to the in vivo system, we can postulate that LPS pre-treatment may 
be more important for the mobilization and margination of monocytes to the pulmonary 
microcirculation rather than for direct monocyte priming. Prolonged contact of 
monocytes with the endothelium may then result in the priming of the newly mobilized 
and marginated monocytes such that secondary high dose LPS induces a significant 
increase in memTNF expression by these monocytes. This increased responsiveness of 
monocytes to inflammatory stimuli during contact with the pulmonary endothelium 
suggests that monocytes contribute significantly to local-cell mediated effects such as 
the induction of capillary permeability and leakage within the microvasculature in vivo, 
culminating in the development of ALI.  
 
Future Directions 
In determining the priming and enhancement of the monocyte inflammatory response, I 
have focused on elucidating the effects of ‘resting’ endothelium on monocyte responses. 
It will be interesting to determine the effects of LPS pre-activated endothelium on 
monocyte priming and their subsequent response to secondary LPS challenge. In this 
way we can determine if release of endothelial factors such as chemokines further 
enhance the monocyte inflammatory response. Cell-cell interactions between 
endothelial cells and monocytes may also play a crucial role in the increased monocyte 
inflammatory response. Specific cell-contact dependent interactions responsible for 
augmented responses have been described, with interactions between leukocyte β1 & 2 
integrins and endothelial ICAM-1 in human pulmonary microvascular endothelial cells 
(HPMVEC) considered of major importance (267, 321, 322). Other studies have also 
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implicated VCAM-1 and VLA-4 to be important in cross-talk, although these studies have 
used HUVECs (265, 323), and as mentioned earlier, this may not be a true depiction of 
the pulmonary endothelium. Investigating the contribution of adhesion molecules in 
monocyte-pulmonary endothelial interactions will further enhance our knowledge and 
understanding of the mechanisms involved in producing the enhanced monocyte 
inflammatory response. Finally, the effect of monocyte TNF responses on pulmonary 
endothelial cell activation/injury has not been studied. It will be interesting to 
determine if monocytes can induce pulmonary endothelial activation through 
prostaglandin, chemokine and cytokine release and more importantly, directly induce 
endothelial permeability, a hallmark of pulmonary inflammation and/or ALI. 
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Chapter 5: 
Heterogeneous TNF responses of 
mouse monocyte subsets to LPS and 
their modulation by the pulmonary 
endothelium 
 
 
 
 
140 
 
Summary 
Monocyte subsets were originally identified in humans as CD14+CD16- and CD14-CD16+ 
subpopulations. Recent studies in mice have indicated that at least two monocyte 
subsets exist in mice known as Gr-1high and Gr-1low monocytes. Based on their 
chemokine receptor expression, Gr-1high monocytes are considered orthologs of human 
CD14+CD16- monocytes while Gr-1low monocytes are considered orthologs of CD14-
CD16+ monocytes. 
 Previous studies investigating the TNF responses of human monocytes in vitro in 
whole blood have indicated that the CD14-CD16+ produce higher levels of TNF upon 
stimulation by LPS. More recent studies investigating monocyte subset responses in 
mice have also indicated that Gr-1low monocytes produce higher levels of TNF in whole 
blood, similar to their human orthologs. However our previous in vivo studies have 
indicated that Gr-1high monocytes produce higher levels of TNF within the pulmonary 
microvasculature. To reconcile these differences, we studied the TNF responses of 
monocyte subsets within whole blood, in isolated peripheral blood mononuclear cells 
(PBMC) and in PBMC-endothelial cell cocultures upon stimulation with LPS. 
 These studies that indicate within whole blood, Gr-1low monocytes indeed are 
higher producers of intracellular and membrane-bound TNF. However, in isolated 
PBMC, Gr-1high monocytes produce higher levels of intracellular and membrane-bound 
TNF.  In cocultures, Gr-1high still produce higher levels of TNF, but the level of TNF 
production is 15-20-fold greater in cocultures than in PBMC only cultures. Although the 
monocyte subset responses in PBMCs are not consistent with those in whole blood, they 
are consistent with our previous in vivo data (105). This suggests that the PBMC 
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preparation, especially when cocultured with endothelial cells, may be a better system 
with which to replicate in vivo inflammatory responses. 
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5.1 Background 
It is widely accepted that the recruitment of inflammatory cells into infected tissues is a 
requisite for ensuring host survival to infection. Consequently, in response to 
inflammatory stimuli, monocytes, as well as other leukocytes, are released from the 
bone marrow into the blood, from where they transmigrate into tissues to carry out 
their effector functions, which include the phagocytosis of foreign material, and the 
production of pro-inflammatory cytokines, including TNF, IL-1 and IL-6 (163, 324). 
 Circulating monocytes are composed of a heterogeneous population of cells that 
exist as functionally and phenotypically distinct subsets in humans, rats, and other 
species. In mice, two main subsets known as Gr-1high and Gr-1low monocytes exist, which 
are distinguished phenotypically on the basis of their respective CCR2+CX3CR1-CD62L+ 
and CCR2-CX3CR1+CD62L- expression profiles (145). Previous in vitro studies 
investigating the functional properties of each monocyte subset in whole blood have 
suggested that Gr-1low monocytes express higher levels of intracellular TNF in response 
bacterial LPS stimulation (325). Although these data are consistent with studies of 
human monocytes in that their counterparts, CD14+CD16+, also produce higher levels of 
TNF in response to bacterial LPS (154), our previous in vivo studies have indicated that 
within the microvasculature, marginated Gr-1high monocytes express significantly 
higher levels of TNF than their Gr-1low counterparts (105). Moreover, other studies 
investigating the functional properties of these subsets at local sites of inflammation 
within the gut, the healing myocardium, and skeletal muscle, have also illustrated the 
superior capacity of the Gr-1high subset to express TNF and IL-1β (43, 166, 168, 326).  
 In view of these findings and in order to reconcile the differences between (i) our 
in vivo results and the ex vivo result in whole blood, and (ii) to also determine if contact 
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with pulmonary endothelium in vivo modifies monocyte subset responses, I set up an in 
vitro coculture model of blood monocytes and lung endothelial cells to closely replicate 
the in vivo system where monocytes are marginated within the lung microvasculature. 
 
5.2 Aims 
In this chapter, I investigated the TNF expression profiles of Gr-1high and Gr-1low 
monocytes in mouse whole blood, peripheral blood mononuclear cells (PBMC) and in 
monocyte-lung endothelial cocultures. There were two main aims: 
1.  Investigate the TNF expression profile of monocyte subsets in LPS-treated 
whole blood and in PBMC monocultures by flow cytometric quantification of 
intracellular and memTNF production. 
2. Investigate the TNF expression profile of monocyte subsets in LPS-treated 
monocyte (PBMC)-endothelial cocultures to determine if coculture modifies 
the TNF response of each monocyte subset. 
 
5.3 Methods 
Whole blood 
Mice were euthanised by isoflurane overdose and exsanguinated by cardiac puncture. 
Heparinised whole blood was incubated with buffer control (PBS) or stimulated with 
100 ng/mL LPS for 4 h in a 37°C water bath (static). It should be noted that heparin has 
the potential to reduce monocyte responses to LPS (327). To determine memTNF 
production, 10 µM BB94 (to prevent cleavage of membrane bound TNF) was added 1 h 
before harvest and for intracellular TNF measurement, 10 µg/mL BFA was included to 
stop protein export and secretion. BFA is an inhibitor of intracellular protein transport 
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and is used routinely to measure intracellular expression of proteins normally secreted, 
such as TNF. Incubation of cells with BFA leads to a blockade of protein transport to the 
Golgi complex, and an accumulation of proteins in the endoplasmic reticulum. After 
fixation and permeabilisation, the levels of proteins retained within individual cells over 
several hours can be quantified by flow cytometry. 
 
PBMC-only (monocultures) & PBMC-lung endothelial cocultures 
PBMCs were isolated from heparinised whole blood by density gradient centrifugation 
using Histopaque-1083 as described in chapter 2. For monoculture assays, PBMCs were 
incubated alone in microcentrifuge Eppendorf tubes (4×105/tube) with cells maintained 
in suspension by rotation to simulate in vivo circulatory conditions. For coculture 
assays, PBMCs (4×105) were added to confluent endothelial cell monolayers 
(4×105/well) in 24-well tissue culture plates. Mono- and cocultures were equilibrated 
for 2 h at 37°C before stimulation with 100 ng/mL LPS for 4 h. For memTNF 
measurement, 10 µM BB94 was added to cultures 1 h before harvest, for intracellular 
TNF measurement (PBMC monocultures), 10 µg/mL brefeldin A was included in 
cultures. For intracellular TNF analysis, cells were initially fixed, then subsequently 
permeabilised prior to flow cytometric analysis. 
 
5.4 Results 
Identification of blood monocyte subsets 
I used our four-colour flow cytometry-based method to identify each monocyte subset 
either within whole blood or PBMC samples (Figure 5.1A & B respectively). In whole 
blood, monocytes were identified as CD11b positive cells (gate R1); within the gated 
145 
 
CD11b population, monocytes were distinguished from neutrophils and NK cells in 
whole blood on the basis of their F4/80+ expression. Monocytes were thus identified as 
CD11b+F4/80+ cells, and differentiation between individual subsets was established by 
staining for Gr-1 expression. Gr-1high (gate R2) and Gr-1low (gate R3). The same method 
was used for the identification of monocyte subpopulations in PBMC samples.   
            
 
                         
 
 
                          
 
Figure 5.1. Identification of monocyte Gr-1high and Gr-1low subpopulations in whole blood and PBMC using 
flow cytometry. (A) Whole blood was incubated with fluorescent-conjugated antibodies for flow cytometry. 
Neutrophil and monocyte subpopulations were identified by positive staining for CD11b (gate R1). Monocytes were 
identified as CD11b+F4/80+ events, and their subsets were defined as either Gr-1high (gate R2) or Gr-1low (gate R3) 
PBMCs in cocultures were harvested by repeated pipetting. (B) PBMC cell suspensions in mono and cocultures were 
stained with fluorescent-conjugated for flow-cytometry. Monocytes were identified by positive staining for CD11b 
(gate R1) and F4/80 and their subsets were defined as either Gr-1high (gate R2) or Gr-1low (gate R3). 
R1 
A.  Whole blood 
B.  PBMC 
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TNF production in monocyte subsets in whole blood 
Heparinised whole blood was stimulated with LPS (100 ng/mL) over a 4 h period in the 
presence of BFA to prevent protein export and secretion. Fixed and permeabilised cells 
were incubated with antibodies against TNF (or isotype matched control). In 
unstimulated cells, there was no detectable expression of memTNF on either monocyte 
subset. There was a weak expression of TNF in both subsets by 1 h (Figure 5.2). At 2 h, 
there was a substantial increase in TNF expression in both subsets but Gr-1high 
monocytes expressed significantly higher levels of TNF than Gr-1low monocytes. While 
the levels of TNF subsequently decreased progressively over time in the Gr-1high subset, 
the levels in Gr-1low continued to increase such that by the 4 h endpoint, they expressed 
considerably higher levels than Gr-1high monocytes, consistent with the previous 
analysis of intracellular expression of subsets in whole (325). 
 To determine if intracellular levels of TNF were predictive of TNF exported to 
the membrane, exported and secreted, I measured TNF expressed on the membrane of 
monocyte subsets in the presence of a more selective inhibitor of TNF secretion, BB94. I 
found that TNF was induced by 1 h in both subsets but no difference was seen in 
expression levels (Figure 5.3). Levels of TNF in Gr-1high monocytes progressively 
declined after 1 h whereas, levels in Gr-1low peaked at 2 h and were significantly higher 
in comparison to Gr-1high monocytes. After 2 h however, TNF expression levels also 
declined in Gr-1low monocytes. These results suggest that in whole blood, Gr-1low 
monocytes are higher producers of TNF in response to LPS stimulation, as detected by 
both intracellular and memTNF methods. Overall these results are consistent with data 
obtained by Burke and colleagues (325). However, the duration of TNF expression in 
the presence of BB94 appeared to be much shorter than that of intracellular TNF with 
BFA treatment, and the levels reached with the latter method were considerably higher.  
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Figure 5.2. Kinetics of intracellular TNF production in Gr-1high and Gr-1low monocytes in whole blood. Whole 
blood was stimulated with LPS at 100 ng/mL in the presence of brefeldin A over a 4 h period. At each time point, cells 
were immediately fixed and intracellularly stained for CD11b, F4/80, Gr-1 and TNF (or isotype control) and analysed 
by flow cytometry. Gr-1high monocytes expressed significantly higher levels of TNF in comparison to Gr-1low 
monocytes at 2 h whereas the opposite was true at 4 h. Data are expressed as mean ± SD for four separate experiment 
(*p < 0.01, **p < 0.001).  
 
 
 
Figure 5.3. Kinetics of memTNF production in Gr-1high and Gr-1low monocytes in whole blood. Heparinised 
whole blood was stimulated with 100 ng/mL LPS over a 4 h period in the presence of BB94 as indicated (1 h prior to 
sample harvest to prevent memTNF cleavage). At each time point, cells were surface stained for CD11b, F4/80, Gr-1 
and TNF (or isotype control) and analysed by flow cytometry. Gr-1low monocytes expressed significantly higher levels 
of TNF at 2 h in comparison to Gr-1high monocytes. Data are expressed as mean ± SD for four separate experiments 
(*** p < 0.001, *p < 0.05) 
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Intracellular TNF expression in monocyte subsets in PBMC 
PBMCs were stimulated with LPS (100 ng/mL) over a 4 h period in the presence of BFA 
to prevent protein export and secretion. TNF was detected as previously described. By 1 
h, there was a low expression of TNF in both subsets, but this increased substantially 
between 2 and 4 h in the Gr-1high subset. Although the levels of TNF were highest in Gr-
1high monocytes at all time points measured, the difference in expression was only 
statistically significant at the 3- and 4 h time points (Figure 5.4). 
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Figure 5.4. Kinetics of intracellular TNF production in Gr-1high and Gr-1low monocytes. PBMCs were stimulated 
with LPS at 100 ng/mL in the presence of brefeldin A over a 4 h period. At each time point, cells were immediately 
fixed and intracellularly stained for CD11b, F4/80, Gr-1 and TNF (or isotype control) and analysed by flow cytometry. 
Gr-1high monocytes expressed significantly higher levels of TNF at 3 and 4 h in comparison to Gr-1low monocytes. Data 
are expressed as mean ± SD for four separate experiments (* p < 0.05, **p < 0.01) 
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Expression of memTNF in monocyte subsets in PBMC only and PBMC-
endothelial coculture 
To investigate monocyte subset responses during coculture with primary MLEC, PBMC-
only incubations were performed as controls. PBMC-only stimulations were performed 
in micro-centrifuge eppendorf tubes, which were slowly rotated to maintain cells in 
suspension to minimise adherence to plastic surfaces. After a 2 h equilibration period to 
allow for monocyte-endothelial contact, PBMC-MLEC cocultures were stimulated with 
LPS (100ng/mL) with BB94 used as before. In PBMC- only cultures, memTNF 
expression in unstimulated monocytes was negligible but at 1 and 2 h after LPS 
treatment, monocyte TNF production was approximately 4-fold higher in Gr-1high 
monocytes than Gr-1low monocytes (Figure 5.5). Levels of TNF decreased over time in 
both subsets, with no significant difference in expression levels seen between Gr-1high 
and Gr-1low after 2 h (Figure 5.5). 
 In monocyte-endothelial cocultures, there was also a negelible expression levels 
of memTNF in unstimulated cells but there was a 15-20-fold increase in TNF production 
by both monocyte subsets at 1 h post-LPS treatment in comparison to PBMC only 
cultures. However, Gr-1high monocytes still expressed significantly higher levels of TNF 
than the Gr-1low subset (Figure 5.6 and 5.7). The increased expression was evident in 
the profile of memTNF, with most Gr-1high monocytes displaying high memTNF levels in 
coculture at 1 h, and only a portion positive in monoculture with intermediate levels. 
Similar to the PBMC only cultures, TNF production decreased over time, but there was 
no significant difference in TNF expression between Gr-1high and Gr-1low monocytes 
after 1 h. In the presence of cycloheximide - an inhibitor of protein synthesis, memTNF 
expression on both monocyte subsets was completely inhibited (data not shown). 
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Figure 5.5. Kinetics of memTNF production in Gr-1high and Gr-1low monocyte subsets in PBMC only cultures.  
PBMCs were stimulated with LPS at 100 ng/mL over a 4 h period in the presence of BB94 as indicated (1 h prior to 
sample harvest to prevent memTNF cleavage) under rotating conditions in Eppendorf microcentrifuge tubes. At each 
time point, cells were surface stained for CD11b, F4/80, Gr-1 and TNF (or isotype control) and analysed by flow 
cytometry. Gr-1high monocytes expressed significantly higher levels of TNF at 1 and 2 h in comparison to Gr-1low 
monocytes. Data are expressed as mean ± SD for four separate experiments (*** p < 0.001, *p < 0.05) 
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Figure 5.6. Kinetics of memTNF production in Gr-1high and Gr-1low monocyte subsets in PBMC-MLEC 
cocultures.  Cocultures were stimulated with LPS (100 ng/ml) over a 4 hour period in the presence of BB94 as 
indicated (1 h prior to sample harvest to prevent memTNF cleavage).  Monocytes in coculture were harvested by 
repeated pipetting.  At each time point, cells were surface stained for CD11b, F4/80, Gr-1 and TNF (or isotype 
control) and analysed by flow cytometry.  Gr-1high monocytes expressed significantly higher levels of TNF at 1h in 
comparison to Gr-1low monocytes.  Data are expressed as mean ± SD for four separate experiments (*** p < 0.001) 
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Figure 5.7. Representative histograms showing membrane TNF production on Gr-1high and Gr-1low monocytes 
in PBMC only cultures (A) and in PBMC-MLEC cocultures (B). PBMCs from mono- and cocultures were treated 
with LPS (100 ng/mL) in the presence of BB94 and analysed for expression of memTNF by flow cytometry. Levels of 
membrane TNF (black line) compared with isotype matched control Ab binding (filled histogram). Coculture 
significantly enhances TNF production by monocytes and also increases the proportion of monocytes that respond to 
LPS. 
 
 
 
 
 
 
 
 
 
A.  PBMC-only culture 
B.  PBMC-MLEC Coculture 
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5.5 Discussion 
TNF production by inflammatory cells, particularly monocytes, is an important 
response to septic stimuli that is essential for ensuring host survival to infection. Gr-
1high and Gr-1low monocytes are the two main subsets of monocytes that exist in mouse 
blood. Previous in vivo studies have demonstrated that, due to their high expression of 
the CCR2 receptor, Gr-1high monocytes are preferentially recruited to sites of 
inflammation in a CCL2-dependent manner, where they express significantly higher 
levels of TNF than Gr-1low monocytes (105, 166-168). However, a recent ex vivo study 
monitoring intracellular TNF responses in whole blood has indicated otherwise (325). 
In order to reconcile these differences, the objective of the present study was two-fold; 
first I aimed to determine the TNF expression profile of Gr-1high and Gr-1low monocytes 
in response to LPS stimulation in whole blood and PBMC only cultures, and secondly to 
investigate how the response is modulated during coculture with lung endothelial cells, 
as this would give a close representation of the monocyte-endothelial contact that 
occurs as a result of margination within the microvasculature during systemic 
inflammation in vivo. 
 
Intracellular & memTNF production in whole blood & PBMC-only 
cultures 
Intracellular cytokine staining is a flow cytometry-based assay that is widely used for 
the detection of cytokines within a specific cell (328, 329). Protein export inhibitors, 
particularly BFA, which prevent cytokine secretion and their accumulation within the 
ER, are commonly employed to facilitate intracellular cytokine measurement (328, 
329). The use of such inhibitors in cell cultures results in the measurement of 
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accumulated cytokines over time rather than the production of cytokines at a given time 
point. I used this technique to determine TNF production by monocyte subsets in whole 
blood and PBMC cultures, but instead of measuring expression at a single endpoint, I 
also performed an analysis of the response kinetics. 
Analysis of intracellular TNF production in whole blood indicated that Gr-1low 
monocytes were higher producers of TNF at the 4 h endpoint (Figure 5.2). This result is 
in line with previous studies done by the Burke group which show that Gr-1low 
monocytes are higher producers of TNF at 4 h (325), and also with other ex vivo studies 
which show that, Gr-1low monocytes produce higher levels of TNF in the peritoneum 
(178). Furthermore, they are consistent with studies done in human whole blood, which 
show that the CD14-CD16+ monocytes (Gr-1low counterparts) are major producers of 
TNF. Although the subset response at 4 h does not correlate with other ex vivo studies 
done by Nahrendorf et al and Rydstrom et al, the data at 2 h, which show that Gr-1high 
monocytes are higher producers of intracellular TNF is in line with them (166, 168). 
The PBMC data that indicate the Gr-1high monocytes produce higher levels of 
intracellular TNF (Figure 5.4) are also consistent with these previous in vivo studies. 
The PBMC data is additionally in line with previous studies done using human PBMCs, 
which show that the CD14+CD16- monocytes (Gr-1high counterparts) are higher 
producers of TNF (330). However, comparison with the human monocyte subset data 
further suggests, that the context in which monocytes are stimulated in vitro, may be 
important in defining their responses.  
 MemTNF is a bioactive form of TNF, initially produced before it is cleaved to its 
soluble form (331). The BB94 TACE inhibition based measurement of memTNF, 
minimizes interferences with intracellular regulatory mechanisms involved in TNF 
trafficking and transport (that is associated with BFA) that could potentially influence 
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the levels of TNF produced by a cell. Analysis of memTNF in whole blood showed that 
Gr-1low monocytes were higher producers of TNF whereas in PBMCs, Gr-1high monocytes 
were higher producers. The higher expression of memTNF on Gr-1high monocytes in 
PBMCs is consistent with previous in vivo studies done in our group (105). However, 
comparing the overall levels of memTNF produced by monocyte subsets, both in whole 
blood and in PBMC cultures, with intracellular levels, it is apparent from my data that 
the levels of memTNF are significantly lower than intracellular levels. In addition, 
memTNF expression was short-lived, peaking at 1 h and declining thereafter. This 
kinetic is comparable to that exhibited by lung-marginated monocytes in vivo, which 
show a peak memTNF expression at 30 min that progressively declines afterwards 
(160). It is also comparable to other in vitro studies by Solomon et al who show a peak 
expression of memTNF on monocytes at 1 h post LPS stimulation (181). The monocytic 
response to LPS may thus be an acute, rather than a prolonged one. Studies 
investigating the kinetics of memTNF production in monocytes have shown that in the 
absence of metalloprotease inhibitors, memTNF expression in vitro has a half-life of 
approximately 30 min, which is extended to 60 min in the presence of such inhibitors. 
However, after this time point, memTNF becomes internalised and rapidly degraded, 
thus preventing its prolonged and continuous accumulation on monocytes (181). This 
result suggests that the use of BF A indeed artificially amplifies and prolongs TNF 
production. It could also potentially alter cytokine production by each monocyte subset, 
and as such, may not accurately reflect their ‘natural’ behaviour to inflammatory 
stimuli. This suggestion is supported by studies which show that BFA induces a stress 
response in cells that is associated with an increased p38 and NF-κB activity, leading to 
increased transcriptional activation of pro-inflammatory molecules (332). This 
mechanism could potentially play an important role in the amplified and prolonged 
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expression of intracellular TNF. Hence, measuring memTNF (which does not interfere 
with normal intracellular processes) could provide a more physiological representation 
of monocyte subset inflammatory responses.  
 Within each culture system, intracellular and memTNF production by each 
subset is consistent. ie in whole blood, Gr-1low monocytes produce higher levels of both 
intracellular and memTNF whereas in PBMC, Gr-1high monocytes produce higher levels 
of both intracellular and memTNF. The exact reason for this ‘switch’ in subset response 
between whole blood and PBMC has not been investigated. The use of whole blood for 
cytokine analysis is considered to provide a more physiological representation of the in 
vivo circulatory milieu, preserving the cellular and soluble constituent of blood at their 
normal levels (333, 334). The presence of PMN, RBCs and soluble factors, including anti-
inflammatory mediators in whole blood perhaps, exerts modulatory effects on each 
subset that defines the pattern of their response but may not necessarily reflect their 
inherent ability to produce cytokines. Immunoregulatory systems such as the CD200 
and CD200 receptor (CD200R) within whole blood could potentially contribute to the 
reduced capacity of monocytes to respond to inflammatory stimuli, and thus produce 
appreciable amounts of memTNF. Previous studies have shown that interactions of 
CD200 with CD200R (strongly expressed on myeloid cells including monocytes) results 
in a transmission of inhibitory signals that inadvertently results in the downregulation 
of myeloid cell responses (335). It has been suggested that isolating PBMCs from whole 
blood could perturb the intrinsic balance that exists in normal blood, such that cytokine 
responses of inflammatory cells are altered (333, 334). However, since the pattern of 
monocyte subset responses in PBMC is consistent with those observed in in vivo studies, 
the PBMC culture may be a better system with which the monocyte subset inflammatory 
responses to LPS could be investigated. In spite of this, studies are currently in progress 
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in our laboratory to determine the mechanisms that contribute to the differences in 
subset responses between whole blood and PBMCs. 
 
memTNF production in PBMC-lung endothelial cocultures 
Comparisons of cytokine production levels in whole blood after LPS stimulation ex vivo 
with levels during endotoxemia in vivo have shown that the cytokine quantities in the in 
vivo system are much greater than those in whole blood (336). The higher cytokine 
levels in vivo are apparently due to the fact that tissue residing cells, either resident 
(such as macrophages) or marginated leukocytes within the microvasculature, are the 
main sources and propagators of inflammatory cytokines (337). The greater plasma 
concentration of cytokines in vivo may be a result of a ‘spill-over’ from these local sites 
within the vascular compartment, thus suggesting that the whole blood, and potentially 
the PBMC cultures perhaps do not directly represent in vivo conditions (338). In view of 
these findings and to closely depict in vivo settings, we cocultured PBMCs with 
endothelial cells and measured their cytokine responses. MemTNF was not detected in 
unstimulated monocytes, suggesting that monocytes do not contain presynthesised 
stores of TNF. Upon stimulation with LPS however, there was a significant increase in 
TNF expression by both monocyte subsets that was completely abrograted in the 
presence of cyclohexamide (data not shown). This indicates that the observed LPS-
induced TNF expression in Gr-1high and Gr-1low monocytes was a result of de novo TNF 
protein synthesis. We additionally found that TNF production by Gr-1high and Gr-1low 
monocytes in coculture with endothelial cells were increased by approximately 15-20-
fold at 1 h in comparison to expression levels in PBMC only cultures. Moreover, flow 
cytometry histograms indicated that, in cocultures, a greater percentage of monocytes 
respond to LPS stimulation than in monocultures. This potentially contributes to the 
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increased TNF responses (Figure 5.8). The enhancement in TNF production by the 
monocyte subsets is consistent with other studies which have shown that leukocyte 
culture with endothelial cells augments their inflammatory responses (339). It also 
supports previous data showing lung-marginated monocytes to be more responsive to 
bacterial LPS than circulating monocytes (160). Irrespective of the enhanced TNF 
expression by both subsets during coculture, Gr-1high monocytes still expressed around 
3-fold more TNF than their Gr-1low counterpart at 1 h;this is also consistent with 
previous in vivo data which show that  lung marginated Gr-1high monocytes to be higher 
producers of TNF as opposed to Gr-1low monocytes (105). Our data further shows that 
the intrinsic difference in monocyte subset TNF response is maintained during 
coculture when compared with PBMC monocultures. In view of the discrepancy that 
also exists between the inflammatory responses of human monocytes to inflammatory 
stimuli under different in vitro conditions, it may also be important to coculture them 
with endothelial cells (from the organ of interest) to determine how they modulate their 
inflammatory responses. It will also be important to correlate these findings with ex 
vivo studies. 
 
 
Interpretation 
Although in vitro stimulated whole-blood and PBMC cultures are extensively used as 
important models to elucidate monocytic cytokine responses especially to bacterial LPS, 
care should be taken when extrapolating data from in vitro studies to in vivo models 
both in animals and in patients. While in vitro whole blood and PBMC cultures may give 
an indication of cytokine responses, it does not necessarily represent the degree and 
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pattern of cytokine release as it occurs in vivo. Consequently, it is important to correlate 
in vitro with in vivo findings where possible.   
The mechanisms of assay-dependent inversion of subset response pattern are 
unclear, but as the pattern of monocyte subset TNF response in PBMCs in vitro correlate 
with their responses in vivo, it may be a better system with which to investigate their 
responses in vitro. In view of the high propensity of monocytes to marginate to the 
pulmonary capillaries when activated in vivo (105, 160, 337), the coculture setting with 
lung endothelial cells in vitro seems optimal to simulate the TNF responses of 
monocytes in vivo, especially within the pulmonary microcirculation.   
Using this system, I have found that Gr-1high monocytes produce considerably 
greater quantities of TNF than Gr-1low monocytes upon bacterial LPS stimulation in 
vitro. This coculture model provides a platform for analysis of underlying mechanisms 
regulating such responses, and this forms the subject of the next chapter.  
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Chapter 6: 
p38 MAPK regulation of monocyte 
subset inflammatory responses 
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Summary 
The p38/MK2 pathway has been shown to play a critical role in the regulation of LPS-
induced cytokine biosynthesis especially in monocytes and macrophages. LPS activates 
the p38/MK2 pathway in monocytes/macrophages through their TLR4/MD-2 
receptors. In the previous chapter I found that Gr-1high monocytes express significantly 
higher levels of TNF than Gr-1low monocytes, especially during coculture with 
endothelial cells. In this chapter, I investigated the p38/MK2 pathway as a mechanism 
for the differential cytokine responses of the monocyte subsets. I also investigated if 
other p38/MK2 regulated genes, namely IL-6, COX-2 and iNOS, were differentially 
expressed in the subsets. 
 My results indicated that, upon LPS stimulation, the p38/MK2 pathway was 
preferentially activated in the Gr-1high subset. In addition, Gr-1high monocytes expressed 
significantly higher levels of IL-6, COX-2 and iNOS than Gr-1low monocytes. Furthermore, 
in the presence of p38 inhibitors, there was a significant attenuation of TNF, IL-6, COX-2 
and iNOS expression in Gr-1high monocytes.  
 These results indicate that the p38/MK2 pathway may be a key determinant of 
the heterogeneous inflammatory responses of the monocyte subsets. 
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6.1 Background 
The p38 MAPK pathway has been long recognized as an important component of the 
signal transduction system that transcriptionally and post-transcriptionally regulates 
various pro-inflammatory mediators (193). It plays essential roles in regulating the 
biosynthesis of cytokines such as IL-1β, TNF-α and IL-6 (193), and in the induction of 
enzymes, including COX-2 (340) and iNOS (341).  
Stress conditions, bacterial LPS or cytokines activate p38 through its upstream 
kinases, MKK6 and MKK3. Activated p38 subsequently phosphorylates its downstream 
substrates, which include MK2, (342), MSK 1 and 2 (343), and p38 regulated/activated 
kinase (PRAK) (344). Activated p38 can also initiate the assembly of transcription 
factors including NF-κB, activating transcription factor (ATF)-2 and activator protein-1 
(AP-1) which are involved in regulating gene expression of various inflammatory 
mediators (345). Data from knockout studies suggest that the major post-
transcriptional effects of p38 MAPK on cytokine biosynthesis are mediated by MK2 
(346), as mice deficient in MK2 display impaired TNF-α and IL-6 production in vivo 
upon LPS stimulation, and increased resistance to endotoxic shock (200, 347).  
In the previous chapter, I demonstrated that during coculture with pulmonary 
endothelial cells, Gr-1high monocytes produce greater levels of TNF in comparison to the 
Gr-1low subset upon bacterial LPS stimulation. However, the mechanisms underlying 
heterogeneity in monocyte subset pro-inflammatory cytokine responses are not known. 
In this chapter, using my in vitro mouse PBMC-endothelial cell cocultures, I investigated 
the expression levels of TLR4/MD-2, p38, and MK2 as a mechanism for the 
heterogeneous monocyte subset inflammatory response to LPS. 
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6.2 Aims 
In this chapter, I aimed to investigate the p38/MK2 pathway as a mechanism for the 
differential cytokine production observed in Gr-1high and Gr-1low monocytes using my 
established coculture system. The four main aims were to: 
1. Determine the expression levels of TLR4/MD-2 on monocyte subets 
2.  Investigate p38 and MK2 activation in LPS-treated cocultures 
3. Investigate the effect of p38 inhibition on TNF responses in each monocyte 
subset  
4. Investigate the expression patterns of other p38/MK2 regulated genes (IL-6, 
COX-2 and iNOS) in Gr-1high  and Gr-1low monocytes 
 
6.3 Methods 
PBMCs (4×105 cells) were either added to confluent lung endothelial monolayers 
cultured in 24-well tissue culture plates (4×105/well) or incubated alone in Eppendorf 
microcentrifuge tubes with cells maintained in suspension by rotation at 37°C. Cultures 
were allowed to equilibrate for 2 h prior to stimulation with 100 ng/mL LPS. Surface 
expression of TLR4/MD-2 was measured on each monocyte subset in untreated 
cocultures. Intracellular phospho-p38 and MK2 were determined at 15 min intervals 
over 60 min post LPS treatment by flow cytometry. MemTNF was determined at the 
peak of expression, 1 h after LPS stimulation, in the presence of 10 µM BB94. COX-2, 
iNOS and IL-6 (in the presence of 10 µg/mL BFA) were determined after 4 h of LPS 
stimulation by intracellular staining and flow cytometry.  
To determine the effect of p38 inhibition on TNF, IL-6, COX-2 or iNOS production, 
the p38 inhibitors SB203580 (10 µM) or SB202190 (5 µM) were added to cultures 30 
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min prior to stimulation with LPS. Intracellular levels of phospho-proteins, memTNF, IL-
6, COX-2 and iNOS were determined by flow cytometry as described in chapter 2. 
 
6.4 Results 
TLR4/MD-2 expression on monocyte subsets 
In the previous chapter, I demonstrated that Gr-1high monocytes express significantly 
higher levels of TNF than Gr-1low monocytes in LPS stimulated PBMC-only and PBMC-
MLEC cocultures, consistent with the previously observed in vivo pattern of expression 
(105). The TLR4/MD-2 complex is the signalling receptor through which LPS mediates 
its effects. To assess its potential influence on monocyte subset responses, flow 
cytometry was used to examine the expression levels in each subset prior to LPS 
stimulation. Figure 6.1 demonstrates that there was no difference in the mean 
fluorescence of TLR4/MD2 expressed per cell between Gr-1high and Gr-1low monocytes. 
Therefore, the increased capacity of the Gr-1high monocytes to produce TNF is not 
related to the TLR4/MD-2 expression levels. 
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Figure 6.1. TLR4/MD-2 expression on Gr-1high and Gr-1low monocytes in PBMC-MLEC cocultures. PBMCs were 
cocultured with lung endothelial monolayers for 2 h without stimulation. PBMCs were harvested from cocultures by 
repeated pipetting and incubated with fluorescent-conjugated antibodies against CD11b, F4/80, Gr-1 and TLR4-MD2 
(or its matched isotype control). There was no difference in TLR4 expression between Gr-1high and Gr-1low monocytes. 
n=4 
 
 
LPS-induced p38/MK2 pathway activation in monocyte subsets 
To evaluate p38/MK2 pathway activation in monocyte subsets in the PBMC-endothelial 
coculture model, I used quantitative flow cytometric analysis of protein 
phosphorylation, an optimal approach for measuring kinase activation at the level of 
individual cells, when the cells of interest are scarce in number or difficult to isolate 
without affecting their phenotype (348).  
 Increased quantities of phospho-p38 in Gr-1high monocytes were observed at 15 
min post-LPS treatment and remained higher at 30 min. In comparison, phospho-p38 
increases in Gr-1low monocytes were much lower, with almost negligible increases 
evident at 15 min (Figure 6.2). LPS-induced phosphorylation of MK2 was evaluated 
under the same conditions. As with phospho-p38, levels of phospho-MK2 were higher at 
15 and 30 min post LPS in Gr-1high monocytes, and while increases in phospho-MK2 
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were detectable in Gr-1low monocytes, these were modest in comparison to the Gr-1high 
subset (Figure 6.3). 
 In PBMC-only incubations, LPS induced increases in phospho-p38 and phospho-
MK2 were higher in Gr-1high than Gr-1low monocytes, but their overall levels were lower 
than in coculture models, consistent with the TNF production data (Figure 6.4A &B) 
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Figure 6.2. Kinetics of LPS-induced phospho-p38 expression in Gr-1high and Gr-1low monocytes during 
coculture with MLEC. PBMC-MLEC cocultures were stimulated with PBS (buffer control) or LPS at 100 ng/mL over 
60 min. At each time point, PBMCs were harvested from cocultures by repeated pipetting and cells were immediately 
fixed and intracellularly stained with antibodies against CD11b, Gr-1, F4/80 and phospho-p38 (or isotype control) 
and analysed by flow cytometry. Representative histograms showing levels of phospho-p38 expression (black line) 
compared with isotype-matched control Ab binding (filled histogram), on Gr-1high (A) and Gr-1low (B) monocytes. (C) 
Levels of phospho-p38 on monocytes were expressed as the geometric mean of fluorescent intensity (MFI) with 
values of isotype control subtracted. Gr-1high monocytes expressed significantly higher levels of phospho-p38 than Gr-
1low monocytes at 15 and 30 min. Data are expressed as mean ± SD of three separate experiments. ***p<0.001  
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Figure 6.3. Kinetics of LPS-induced phospho-MK2 expression in Gr-1high and Gr-1low monocytes during 
coculture with MLEC. PBMC-MLEC cocultures were stimulated with LPS at 100 ng/mL over 60 min. At each time 
point, PBMCs were harvested from cocultures by repeated pipetting and cells were immediately fixed and 
intracellularly stained with antibodies against CD11b, Gr-1, F4/80 and phospho-MK2 (or isotype control) and 
analysed by flow cytometry. Representative histograms showing levels of phospho-MK2 expression (black line) 
compared with isotype-matched control Ab binding (filled histogram), on Gr-1high (A) and Gr-1low (B) monocytes. (C) 
Levels of phospho-MK2 on monocytes were expressed as the geometric mean of fluorescent intensity (MFI) with 
values of isotype control subtracted. Gr-1high monocytes expressed significantly higher levels of phospho-MK2 than 
Gr-1low monocytes at 15 and 30 min. Data are expressed as mean ± SD for four separate experiments.  ***p < 0.001 
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Figure 6.4. Kinetics of LPS-induced phospho-p38 and -MK2 expression in Gr-1high and Gr-1low monocytes in 
PBMC-only cultures. PBMCs were stimulated with LPS at 100 ng/mL over 60 min. At each time point, cells were 
immediately fixed and intracellularly stained with antibodies against CD11b, Gr-1, F4/80 and phospho-p38 or 
phospho-MK2 and analysed by flow cytometry. (A) Levels of phospho-p38 on monocytes were expressed as the 
geometric mean of fluorescent intensity (MFI) with values of isotype subtracted. (B) Levels of phospho-MK2 on 
monocytes were expressed as the geometric mean of fluorescent intensity (MFI) with values of isotype subtracted. 
Gr-1high monocytes expressed significantly higher levels of phospho-p38 and phospho-MK2 than Gr-1low monocytes at 
15 and 30 min. Data are expressed as mean ± SD for four separate experiments.  ***p < 0.001 
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Effect of p38 inhibition on monocyte subset TNF production 
To evaluate if p38 activity was necessary for TNF production in both the Gr-1high and Gr-
1low monocytes, I pre-treated PBMC-MLEC cocultures with two selective p38 inhibitors, 
SB203580 and SB202190, before stimulation with LPS (100 ng/mL). MemTNF 
production on each monocyte subset was measured at peak production, 1 h post LPS 
treatment. Complete inhibition of TNF was observed in both Gr-1high and Gr-1low 
monocytes in the presence of SB203580 (Figure 6.5A). With SB202190, there was 
approximately ~98 and 65% reduction in TNF production in Gr-1high and Gr-1low 
monocytes, respectively (Figure 6.5B).  
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Figure 6.5 Attenuation of memTNF production in Gr-1high and Gr-1low monocytes by inhibition of p38 
activation. PBMC-MLEC cocultures were stimulated with LPS at 100 ng/mL for 1 h in the presence of BB94 (10µM) 
with vehicle (DMS0) or p38 inhibitors: A. SB203580 (10µM) or B. SB 202190 (5µM). PBMCs were harvested from 
cocultures by repeated pipetting and cells were incubated with fluorescent-conjugated antibodies against CD11b, 
F4/80 Gr-1 and TNF (or its matched isotype control). Levels of memTNF are expressed as mean fluorescence 
intensity (MFI) with values of isotype control subtracted. (A) SB203580 completely ablated TNF production by both 
monocyte subsets (B) SB202190 significantly inhibited TNF production by both monocyte subsets. Data are 
expressed as mean ± SD of three separate experiments. ** p < 0.01, *** p < 0.001 
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LPS-induced expression of p38/MK2 regulated genes in monocyte 
subsets 
To evaluate whether other cytokines regulated by the p38/MK2 pathway are 
differentially expressed between the monocyte subsets, I assessed the levels of IL-6, a 
pro-inflammatory cytokine whose expression is regulated in an MK2-dependent 
manner (349). PBMC-MLEC cocultures were stimulated with LPS (100 ng/mL), with or 
without SB203580 for 4 h, in the presence of BFA, an inhibitor of protein export. In 
comparison to control levels, there was a significant increase in IL-6 expression in both 
monocyte subsets. However, Gr-1high monocytes expressed considerably higher levels of 
intracellular IL-6 than Gr-1low monocytes, and in the presence of the inhibitor there was 
a significant but incomplete attenuation in its expression in both monocyte subsets 
(Figure 6.6). 
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Figure 6.6. LPS-induced IL-6 expression in Gr-1high and Gr-1low monocytes and its attenuation by p38 
inhibition. PBMC-MLEC cocultures were stimulated with LPS (100 ng/mL) with or without vehicle (DMS0) or the 
p38 inhibitor SB203580 (10µM) in the presence of brefeldin A (10 µg/mL). After 4h PBMCs were harvested from 
cocultures by repeated pipetting and cells were immediately fixed and incubated with antibodies against CD11b, Gr-
1, F4/80 and IL-6 (or isotype control) and analysed by flow cytometry. Levels are expressed as mean fluorescence 
intensity (MFI) with isotype control subtracted. Data are expressed as mean ± SD of four separate experiments. *p < 
0.05, **p < 0.01, ***p < 0.001  
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The inflammatory enzymes COX-2 and iNOS have been reported to be post-
transcriptionally regulated by the p38/MK2 pathway. To determine if these enzymes 
were also differentially regulated between the monocyte subsets, I stimulated PBMC-
MLEC cocultures with LPS (100 ng/mL) with or without SB203580 for 4 h and 
measured their expression levels. Intracellular COX-2 levels were considerably 
increased by LPS treatment in Gr-1high monocytes, but only negligible increases were 
observed in Gr-1low monocytes (Figure 6.7A) A similar pattern for iNOS levels were 
exhibited with its up-regulation much more marked in the Gr-1high subset than the Gr-
1low subset (Figure 6.7B). Inhibition of p38 activation significantly reduced up-
regulation of both mediators in Gr-1high monocytes, but as with IL-6, only a partial 
attenuation was observed. 
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Figure 6.7. LPS-induced COX-2 and iNOS expression in Gr-1high and Gr-1low monocytes and its attenuation by 
p38 inhibition. PBMC-MLEC cocultures were stimulated with LPS (100 ng/mL) with or without vehicle (DMS0) or 
the p38 inhibitor SB203580 (10µM). After 4 h PBMCs were harvested from cocultures by repeated pipetting and cells 
were immediately fixed and incubated with antibodies against CD11b, Gr-1, F4/80 and  (A) COX-2 or (B) iNOS (or 
isotype control) and analysed by flow cytometry. Levels are expressed as mean fluorescence intensity (MFI) with 
isotype control subtracted. Data are expressed as mean ± SD of four separate experiments.     *p < 0.05, **p < 0.01 
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6.5 Discussion 
Recent studies investigating the roles of monocyte subsets in sepsis and ventilator-
associated models of acute lung injury have shown that the Gr-1high subset exhibits a 
more pro-inflammatory potential due to its elevated numbers in the lung micro-
circulation, and its increased release of pro-inflammatory cytokines in comparison to 
the Gr-1low subset (105, 106). Data from my in vitro coculture studies of PBMCs and 
MLEC have further supported the role of Gr-1high monocytes as the pro-inflammatory 
subset as they produce significantly higher levels of TNF than the Gr-1low monocytes. 
However, the mechanisms regulating the differential cytokine production between the 
monocyte subsets have not been explored. LPS signals through the TLR4/MD-2 complex 
and potently stimulates the MAPK pathway in monocytes and macrophages, and many 
reports have demonstrated that the p38/MK2 signalling pathway regulates the 
biosynthesis of pro-inflammatory cytokines and enzymes at a posttranscriptional level 
(346). In this chapter, I investigated the p38/MK2 pathway as a mechanism for the 
heterogeneous inflammatory responses observed between Gr-1high and Gr-1low 
monocytes.  
 To explore the mechanism of augmented LPS-dependent TNF elaboration in Gr-
1high monocytes, expression of TLR4/MD2 complex was initially examined because it is 
the signalling complex through which LPS transduces its stimulatory effects. My 
findings demonstrate that Gr-1high monocytes do not show a significant difference in 
surface receptors relevant to LPS recognition when compared with Gr-1low monocytes. 
This suggests that the increased capacity of Gr-1high monocytes to respond to LPS is not 
related to the TLR4/MD-2 complex. These results are consistent with studies 
investigating TLR4 expression in human monocyte subsets, where no differences in 
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expression levels have been observed (154). Conflicting results have, however, been 
obtained in other studies which have found that the CD14-CD16+ (Gr-1low equivalent) 
subset expresses higher levels of TLR4 than the classical CD14+CD16- subset (Gr1high 
equivalent) (155, 350). To further confirm my findings, it may be important to 
determine the intracellular levels of TLR4/MD-2 receptors in each monocyte subset 
because other studies have suggested that higher levels of TLR4 are present within the 
Golgi apparatus of monocytes in comparison to the surface membrane (351). It has also 
been suggested that these intracellular TLR4 have the capacity to rapidly cycle to the 
cell surface and mediate LPS signalling (351). If present, differences in intracellular 
levels could thus potentially influence the response of each subset to LPS stimulation. 
A variety of methods, including Western blotting and in vitro kinase assays have 
been described to detect phospho-kinase activation. Western blotting is an immuno-
based technique which relies on the use of specific antibodies to recognize the kinase of 
interest (352). In the case of kinase assays, immuno-precipitated proteins are incubated 
with certain substrates to measure their enzymatic activity as quantified by the uptake 
of 32P into the substrate (353). Both these techniques require large amounts of sample 
and more importantly, the use of whole cell lysates. As a result, they are not adequate 
for use when only small amount of sample containing mixed cell populations are 
available. Confocal-immuno-fluorescence-based techniques which allow the detection of 
kinase activity in specific cells provides an alternative to the former techniques; 
however, its limitation is that it is not quantitative and may inadvertently result in 
subjective interpretation. These limitations can be overcome by flow cytometry, a 
highly sensitive technique that provides a means by which kinase activity in specific cell 
populations can be quantitatively measured within a mixed population. This is done 
with the use of various antibodies directed against specific-cell surface markers and the 
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phospho-kinase of interest. This technique is especially useful when limited amounts of 
samples are available and avoids any potential phenotypic changes produced by 
isolation of individual cell populations. Several authors have now successfully used flow 
cytometry for the investigation of kinase activation in various signalling pathways (354-
357). 
Flow cytometric analysis, using phospho-specific antibodies, indicated that LPS 
induced rapid phosphorylation of p38 in Gr-1high monocytes with an apparent peak at 
15 min. Comparing the levels of phosphorylated p38 in Gr-1high monocytes with those in 
Gr-1low monocytes revealed that Gr-1high monocytes expressed considerably higher 
levels. As with p38, there was also significantly higher levels of LPS induced 
phosphorylated MK2 in Gr-1high monocytes in comparison to Gr-1low monocytes. The 
higher expression of these phospho-kinases in Gr-1high monocytes could thus be directly 
responsible for their greater capacity to produce TNF, as well as IL-6, COX-2 and iNOS. 
These results are consistent with other studies which have shown augmented TNF 
release by macrophages as a direct result of increased phosphorylated p38 activity 
(358). Although we have not measured the non-phosphorylated expression levels of 
p38 and MK2, a recent flow cytometric study by Zhao et al showed no apparent 
heterogeneity of constitutive p38 or MK2 among CD11b+ monocytes in response to 
anisomysin stimulation (359). In addition, previous studies in macrophages have 
indicated that LPS activation does not markedly modify the constitutive expression of 
these kinases (360).   
To determine the role of these kinases in LPS-induced production of pro-
inflammatory mediators, we examined the effect of two selective p38 inhibitors, 
SB203580 and SB202190 on the production of TNF, IL-6, COX-2 and iNOS in Gr-1high and 
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Gr-1low monocytes. Pre-treatment of PBMC-MLEC cocultures with SB203580 completely 
ablated LPS-induced TNF production in Gr-1high monocytes and markedly inhibited 
(~92) it in Gr-1low monocytes. With SB202190, TNF was inhibited by approximately 98 
and 65% in Gr-1high and Gr-1low monocytes respectively. There was also a partial 
attenuation of IL-6, iNOS and COX-2 in Gr-1high monocytes in the presence of SB203580. 
The near complete ablation of TNF expression in Gr-1high monocytes, as opposed to the 
Gr-1low monocytes, suggest that enhanced signalling through the p38 pathway is a 
principal determinant of acute TNF expression in the Gr-1high subset.  Recent studies 
investigating signalling pathways that regulate pro-inflammatory cytokine release in 
cells of the monocytic lineage have indicated that regulation of cytokine release changes 
from being a more predominant p38 MAPK-mediated effect in monocytes to a more 
ERK-dependent effect after differentiation to a macrophage phenotype (361). As 
depletion and repopulation studies in mice have suggested that Gr-1low monocytes 
constitute a more mature monocyte subpopulation which replenishes tissue resident 
macrophages (163), the incomplete inhibition of TNF production in the Gr-1low subset 
could potentially be a result of a small contribution of the ERK pathway in the early 
response.  
Previous studies in human monocytes have shown that both the ERK and p38 
pathway play a role in regulating TNF, IL-6 and COX-2 mRNA biosynthesis (352, 362, 
363); inhibition of either kinase results in a significant attenuation of these mediators, 
whereas inhibition of both kinases results in a near complete ablation of  their 
production (352, 362, 363). In the presence of SB203580, I observed a significant 
attenuation of iNOS in Gr-1high monocytes. Unlike IL-6 and COX-2, the iNOS was 
attenuated to levels which were comparable to those of control, suggesting that p38 
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may be the key pathway regulating its expression. These results are consistent with 
other studies done in macrophages which have shown that the ERK pathway is not 
required for the induction of iNOS expression (353). These data additionally suggests 
that the induction of different mediators may be dependent on specific signal 
transduction pathways. In light of these data, further studies will have to be done to 
investigate the role of the ERK pathway in the regulation of monocyte subset 
inflammatory responses. It will be important to determine if phospho-ERK is 
differentially activated in each monocyte subset and if this contributes to their 
heterogeneous LPS-induced inflammatory responses. In spite of this, our findings 
indicate an overall clear association between preferential p38 activation and enhanced 
p38-dependent TNF, IL-6, iNOS and COX-2 expression in Gr-1high monocytes.  
From these results, conclusions cannot be drawn about the exact point in the 
signal transduction pathway at which differences in activating signals result in the 
heterogeneous responses of the monocyte subset. One can speculate however, that 
differences in activating signals leading to the heterogeneous responses of monocyte 
subsets occurs upstream of p38 but distal to the recognition of LPS by the TLR4-MD2 
complex. Other kinases upstream of p38, including apoptosis signal-regulating kinase 1 
(ASK1), which has been shown to be required for LPS-induced activation of p38, could 
potentially play a role in determining the monocyte subset responses (364). However, 
previous studies have indicated that chemokines including MCP-1 can also induce 
activation of MAPKs in monocytes (365, 366). An alternative mechanism for differential 
subset responses could therefore be based on interactions between monocytes and 
endothelium producing co-stimulatory effects that differ between each subset. It is 
possible that preferential activation of adhesion molecules, such as integrins and 
chemokines, could modify the activation levels of MAPKs leading to increased 
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inflammatory responses of a particular subset. For instance, preferential activation of 
CCR2 expressing Gr-1high monocytes through MCP-1 could contribute to the increased 
responsiveness of these monocytes, both in tissues in vivo and during in vitro culture 
with endothelial cells. However, although integrin engagement is known to induce 
cytokine expression, differential expression of β1 and β2 integrins on monocyte subsets 
has not been observed in previous characterisation studies (163). Further studies will 
have to be carried out to investigate the role of these mechanisms in regulating 
monocyte subset responses. 
In summary, I have shown that LPS induces differential activation of the 
p38/MK2 pathway in mice monocyte subsets, which is not related to their expression 
levels of the TLR4/MD-2 complex. The differential activation of this pathway appears to 
be a major determinant of heterogeneity in pro-inflammatory mediator release between 
the mice monocyte subsets during LPS-induced pulmonary inflammation. By measuring 
intracellular kinase activation, a significant amount of information can be gained on 
how subsets are programmed to respond to septic stimuli. Future work could 
potentially involve the determination of phospho-kinase activity in monocyte subsets in 
whole blood, to determine if this predicts/determines their inflammatory responses to 
LPS. Finally, the determination of phospho-kinase activity in human monocytes could 
provide insights to the signalling mechanisms regulating their heterogeneous 
responses.   
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Chapter 7: 
Preliminary work 
LPS-mediated TLR4 signalling for 
monocyte-endothelial reciprocal 
activation 
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7.1 Background 
Sepsis induced lung injury has largely been attributed to the presence of circulating LPS.  
In experimental models, systemic injection of bacterial LPS closely mimics some of the 
clinical manifestations of lung injury.  Toll-like receptor (TLR)-4 plays an important role 
in the pathogenesis of lung injury as it is critical for the recognition of LPS by leukocytes 
and other cells including endothelial cells (30).   
There is sufficient evidence to suggest that endothelial cells can respond avidly 
to LPS in vitro. LPS induces the up-regulation of a number of adhesion molecules, 
including ICAM-1, VCAM-1 and E-selectin, and chemokines in endothelial cells (367, 
368), which are capable of  inducing leukocyte adhesion, and emigration in vitro (369). 
LPS also directly activates monocytes and induces their production of inflammatory 
cytokines including TNF and IL-1 in vitro (370) . These cytokines have been shown to be 
capable of inducing endothelial activation through adhesion molecule expression and 
their release of chemokines and prostaglandins (273, 371). 
A considerable part of the lung response to LPS has been attributed to cytokines, 
particularly TNF, as systemic administration of TNF in experimental models induces 
lung-mediated responses that are similar to those elicited by LPS (372). Since TLR4 is 
expressed on leukocytes, particularly macrophages and monocytes, it is conceivable 
that LPS recognition by leukocytes triggers the release of cytokines that in turn affect 
the lung. In support of this, our group has previously demonstrated, using an in vivo 
mouse model of endotoxemia, that lung marginated monocytes can induce endothelial 
activation, as evidenced by cell adhesion molecule up-regulation through TNF-mediated 
signalling (105, 160). In spite of this, it is also quite likely in this system that adhesion 
molecule up-regulation occurs via a direct effect of LPS on endothelium. As a result, it is 
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unclear if during the local inflammatory response in vivo, endothelial cell activation is a 
direct effect of LPS or an indirect effect of monocyte activation. In addition, recent 
studies have indicated that LPS-induced activation of endothelial cells is sufficient to 
induce the sequestration of leukocytes to the lung (113). However, it is unknown if 
activated endothelial cells can directly induce cytokine production in monocytes. In this 
preliminary study, the aim was to develop an in vitro coculture model of LPS responsive 
and unresponsive (chimera) monocytes and endothelial cells to determine how indirect 
LPS signalling could mediate the activation of the inflammatory response. Based on the 
results from these experiments, we would be provided a platform to further investigate 
how the activated status of each cell contributes to the inflammatory response. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
183 
 
7.2 Aims 
I initially cultured lung endothelial cells from TLR4-/- (LPS unresponsive) animals using 
the same method described in chapter 3. Using a chimeric system of LPS unresponsive 
(TLR4-/-) and LPS responsive (TLR4+/+) endothelial cells and monocytes, I aimed to 
investigate whether: 
1. LPS-treated TLR4+/+ monocytes could induce adhesion molecule up-
regulation  on TLR4-/- lung endothelial cells and if this was dependent on TNF 
signalling 
2. LPS-treated TLR4+/+ endothelial cells could induce TNF production in TLR-/- 
monocytes. 
 
7.3 Methods 
Adhesion molecule up-regulation on LPS unresponsive endothelial cells 
TLR4+/+ PBMCs (4×105) were added to TLR4-/- endothelial monolayers (4×105/well) 
cultured in 24-well gelatin coated tissue culture plates. The cocultures were stimulated 
with 100 ng/mL LPS for 4 h with or without 10 µg/mL anti-TNF monoclonal antibodies.  
Adhesion molecule up-regulation was determined on endothelial cells by flow 
cytometry. 
 
TNF expression in LPS unresponsive monocytes 
TLR4-/- PBMCs (4×105) were added to TLR4+/+ endothelial monolayers (4×105/well) 
cultured in 24-well gelatin coated tissue culture plates. The cocultures were stimulated 
with 100 ng/mL LPS for 4 h with or without 10 µM BB94. MemTNF production was 
determined in monocytes by flow cytometry. 
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7.4 Results 
Functional characterization of TLR4-/- endothelium 
Using my previous immuno-magnetic bead technique of CD45+ leukocyte depletion, 
followed by CD31+ selection (described in chapter 3), I isolated endothelial cells from 
TLR4-/- mice. I confirmed their endothelial lineage by determining their expression of 
constitutively expressed markers (ICAM-1, ICAM-2, VE-Cadherin, Endoglin and CD31), 
and found they expressed similar levels to wild type cells (data not shown).   
To confirm that these cells were responsive to inflammatory stimuli other than 
LPS, I treated endothelial monolayers (4×105 cells) with either LPS or TNF (100 ng/mL) 
for 4 h. ICAM-1, VCAM-1 and E-selectin expression as assessed by flow cytometry, 
revealed that these molecules were up-regulated upon TNF stimulation but were 
unresponsive to LPS, as expected (Figure 7.1) 
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Figure 7.1. TNF induced adhesion molecule expression on TLR4-/- MLEC. MLEC cultures were stimulated with 
LPS or TNF (100 ng/mL) for 4 h. Endothelial cells were detached from culture plates by brief trypsinisation and 
incubated with fluorescent-conjugated antibodies. MLEC were unresponsive to LPS as expected but TNF induced an 
up-regulation in (A) ICAM-1 (B) VCAM-1 and (C) E-selectin. Levels are expressed as mean fluorescence intensity 
(MFI) with isotype control subtracted. Data are expressed as the mean of triplicate wells of two separate 
experiments. 
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Functional assessment of TLR4 chimera cocultures 
To assess monocyte-dependent endothelial activation, I cocultured PBMCs (4×105) from 
TLR4+/+ (LPS responsive, wild-type) mice with TLR4-/- (LPS un-responsive, knockout) 
endothelial monolayers (5×105) and stimulated them with LPS (100 ng/mL) for 4 h 
with or without anti-TNF monoclonal antibody (clone TN3-19.12) antibodies to 
determine the contribution of TNF-mediated signalling to endothelial activation. I found 
significant increases in ICAM-1 and VCAM-1 expression on pulmonary endothelial cells 
at 4h post LPS stimulation. In the presence of anti-TNF antibodies, only moderate 
reductions were seen in the expression of ICAM-1 (Figure 7.2A) but there was a 
significant reduction in VCAM-1 expression (Figure 7.2B). 
Alternatively, to assess endothelial induced monocyte activation, I cocultured 
TLR4+/+ endothelium with TLR4-/- PBMCs and stimulated them with LPS (100 ng/mL) 
for 4h in the presence of BB94. I found that at 4 h post LPS stimulation, there was a 
significant increase in TNF expression on Gr-1high monocytes whereas only modest 
increases were observed in Gr-1low monocytes (Figure 7.3). Prior to the 4 h time point, 
there were only marginal increases in TNF expression which were not significantly 
different from baseline level 
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Figure 7.2. Monocyte induced ICAM-1 and VCAM-1 up-regulation on TLR4-/- MLEC. TLR4+/+PBMCs and TLR4-/- 
MLEC cocultures were stimulated with LPS (100 ng/mL) for 4 h without or without anti-TNF antibodies. Endothelial 
cells were detached from culture plates by brief trypsinisation.  Endothelial cells were incubated with fluorescent-
conjugated antibodies against ICAM-1 and VCAM-1 or matched isotype control and assessed by flow cytometry. (A) 
Monocytes induced a significant up-regulation of ICAM-1 which was not inhibited in the presence of anti-TNF 
antibodies (B) Monocytes induced a significant up-regulation of VCAM-1 which was significantly inhibited in the 
presence of anti-TNF antibodies. Adhesion molecule expression levels are expressed as mean fluorescence intensity 
(MFI) with isotype control subtracted. Data are expressed as mean ± SD of triplicate wells of four separate 
experiments (* p < 0.05; ** p < 0.01) 
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Figure 7.3. LPS-induced endothelial mediated activation of monocyte subsets. TLR4-/- PBMCs – TLR4+/+ MLEC 
cocultures were stimulated with LPS (100 ng/mL) over a 4 h period in the presence of BB94 as indicated. At each 
time point, PBMCs were harvested from cocultures by repeated pipetting and cells were surface stained for CD11b, 
F4/80, Gr-1 and TNF (or isotype control) and analysed by flow cytometry. Endothelial cells induced the expression of 
TNF in Gr-1high monocytes at 4 h which was significantly higher than in Gr-1low monocytes. Levels are expressed as 
mean fluorescence intensity (MFI) with isotype control subtracted. Data are expressed as mean ± SD of triplicate 
wells of four separate experiments. (*** p < 0.001) 
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7.5 Discussion 
TLR4 signalling is a key mechanism by which the innate immune system recognises 
bacterial LPS, initiating a potent inflammatory response (373). Other studies have 
demonstrated the clear roles for TLR4 signalling on immune cells including monocytes 
(370). In addition, it has long been known that leukocyte activation and priming play an 
important role in the early response to sepsis. The high expression of TLR4 on 
leukocytes, especially macrophages and monocytes provides a premise on which to 
infer that activation of these cells may drive the early inflammatory response. However, 
recent studies have indicated that LPS directly activates lung endothelial cells through 
TLR4 to induce the activation and recruitment of leukocytes to the pulmonary 
microcirculation (113). Thus, indicating that activation of endothelial cells is also 
important to drive the inflammatory response. In the present study, my aim was to 
investigate if indirect LPS-mediated reciprocal activation between monocyte and 
endothelial cells could occur. To this end, I created alternate chimeric cocultures of LPS 
responsive and unresponsive, PBMC and lung endothelial cells. 
 To initially confirm that TLR4-/- endothelial cells were responsive to 
inflammatory stimuli other than LPS, I treated MLEC monolayers with LPS and TNF.  
Flow cytometric analysis revealed that these cells were unresponsive to LPS but up-
regulated their expression of ICAM-1, VCAM-1 and E-selectin, similar to wild-type cells, 
upon stimulation with TNF.   
Various in vitro studies have established the role of monocyte TNF-induced 
endothelial activation using HuVEC cell lines. Here, I demonstrated that monocytes 
could directly induce activation of endothelial cells via TNF signalling, consistent with 
our previous in vivo findings (160). I showed that monocyte-induced VCAM-1 
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expression on endothelial cells was dependent on TNF; however, up-regulation of 
ICAM-1 expression seemed to be independent of TNF, suggesting that other monocyte 
cytokines, such as IL-1β or other mediators, may be involved. Further studies will have 
to be carried out to extensively characterise the molecular and signalling mechanisms 
involved in monocyte mediated pulmonary endothelial activation. 
In analysing the monocyte response induced indirectly by LPS-activated MLEC, I 
focused primarily on TNF expression as an indicator of the monocyte response. Here, I 
demonstrated a role for TLR4 on endothelial cells in the initiation of cytokine release in 
monocytes, as they induced late activation of Gr-1high monocytes which occurred at 4 h 
post LPS stimulation of endothelial cells. This finding indicates that indirect activation 
of monocytes by septic stimuli may be capable of prolonging the microvascular 
inflammatory response, and furthermore the pattern of subset response heterogeneity 
could be determined independently of the monocyte TLR4 signalling pathway. It also 
suggests that Gr-1high monocytes may be more responsive to other mediators such as 
chemokines produced by the endothelium. Although I have not explored the 
mechanisms involved in the observed endothelial-mediated monocyte activation, 
previous studies have indicated that release of chemokines such as MCP-1 can induce 
β2 integrin activation in monocytes (374) which would result in the activation of ERK 
MAPK pathway (365) and the subsequent release of TNF (352). Furthermore, an MCP-
1-induced mechanism of TNF in the monocytes could explain the higher expression of 
TNF on the Gr-1high subset, as opposed to the Gr-1low subset, considering that Gr-1high 
monocytes express high levels of the CCR2 receptor (163), the ligand for MCP-1. 
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Chapter 8: 
Summary 
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Sepsis, usually a consequence of bacterial infections is an important cause of mortality 
in patients in intensive care units. Bacterial products such as LPS induce uncontrolled 
activation of cells and mediators of the innate immune system which ultimately results 
in dysfunction of various organs. A consistent finding in septic patients and in 
experimental models of sepsis is, that regardless of the organ in which sepsis originates, 
the lungs are generally the first to fail (375). Consequently, acute lung injury (ALI) is a 
frequent complication of sepsis. The rapid sequestration and margination of leukocytes, 
particularly neutrophils, within the narrow lung capillaries, and their focal release of 
potent inflammatory mediators, is a key reason for this occurrence. Monocytes, which 
exist as at least two distinct subsets, also marginate to the lungs during sepsis and 
possess the capacity to produce a wide range of pro-inflammatory mediators have not 
been extensively studied in the pathophysiology of ALI. In addition, although monocyte 
subsets have been shown to exhibit differential cytokine responses to inflammatory 
stimuli, the signalling mechanism governing their inflammatory responses have not 
been investigated. To address the contribution of monocytes to the pathophysiology of 
ALI, I developed an in vitro monocyte-endothelial coculture model by initially isolating 
and culturing lung endothelial cells from mice, and culturing them with isolated primary 
monocytes from the same mouse species. With this model, I investigated the priming 
and enhancement of inflammatory response through monocyte-endothelial 
interactions, the heterogeneous inflammatory responses of monocytes subsets and the 
mechanisms regulating them. This summary chapter will discuss my major findings and 
discuss their implications. 
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8.1 Isolation & culture of MLEC 
To set up an in vitro model, it was important to establish a primary culture of lung 
endothelial cells. In light of the fact that endothelial cells from different organs, and even 
from different vascular beds within the same organ, exhibit heterogeneous functional 
properties, my first aim was to culture endothelial cells derived exclusively from the 
lung. In chapter 3, I developed a method for isolating and culturing primary MLEC. I 
successfully isolated MLEC which exhibited the ‘cobblestone’ morphology, typical of 
vascular endothelial cells. Their endothelial origin was confirmed by their high 
expression of endothelial-specific markers, including CD31, ICAM-2, Endoglin and VE-
Cadherin, while their microvascular origin was confirmed by their expression of CD34. 
Furthermore, on exposure to inflammatory stimuli, including LPS and TNF, MLECs up-
regulated their cell surface expression of ICAM-1, VCAM-1 and E-selectin. These cells 
were maintained in culture for several generations without losing any of their 
phenotypic and functional properties. The ability to isolate endothelial cells from the 
lung has provided our group a means by which to isolate endothelial cells, not only from 
wild type but also from genetically modified, animals to study the roles of particular 
genes and/or receptors in the development of ALI. Further studies should also consider 
heterogeneity in the microvascular and larger vessel endothelial cells, with respect to 
interactions with monocytes and modulation of their pro-inflammatory phenotype. 
 
8.2 Priming and enhancement of the monocyte pro-inflammatory response 
As I was able to successfully culture and propagate primary lung endothelial cells, in 
chapter 4, I developed a monocyte-endothelial coculture model to investigate the effects 
of LPS priming and, the effects of endothelial contact on monocyte TNF response. I 
found that prolonged contact of monocytes with the endothelium results in a marked 
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enhancement of the inflammatory response to LPS stimulation, consistent with our in 
vivo data where low dose LPS induces monocyte margination to the lung endothelium 
and enhanced TNF production in response to secondary LPS. It is unclear at present 
how these findings are directly related to the clinical setting, but there is evidence to 
suggest that an increased recruitment of immature monocytes to the lungs also takes 
place in humans during sepsis-induced ARDS (130), and that a rapid and prolonged 
withdrawal of monocytes from the circulating pool is a feature of volunteer response to 
LPS injection. One can speculate that monocyte-endothelial cell interactions potentially 
play key roles in the pathogenesis of ARDS in humans. Accumulation of these 
inflammatory cells in the lungs of patients with ARDS may contribute to the disease 
process through an amplified production of oxidants, cytokines and other mediators.  
The increased responsiveness of monocytes to inflammatory stimuli during contact 
with the pulmonary endothelium could therefore mean that monocytes contribute 
significantly to local-cell mediated effects such as the induction of capillary permeability 
and leakage within the microvasculature in vivo, culminating in the development of ALI.  
The interaction of monocytes with other sequestered leukocytes, in particular 
neutrophils, could be a crucial element in this process of organ injury. 
  
8.3  Heterogeneous responses of monocyte subsets & regulation by the 
p38/MK2 pathway 
In chapters 5 and 6, I investigated the inflammatory cytokine profiles of Gr-1high and Gr-
1low monocytes in response to LPS stimulation in vitro. I found that the Gr-1high subset 
produces significantly higher levels of TNF than Gr-1low subset and the optimal 
responses of these subsets are exhibited during coculture with pulmonary endothelial 
cells. In addition, the higher inflammatory response of the Gr-1high subset is not limited 
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to TNF, but in fact, covers a broad spectrum of inflammatory mediators, including IL-6, 
iNOS and COX-2, indicating the wider role they may have in microvascular inflammation 
and the significance of the subset heterogeneity in the pathogenesis of ALI and sepsis.  
In terms of chemokine receptor expression, CD14+CD16- monocytes are the 
human orthologues of Gr-1high mouse monocytes due to their high expression of CCR2, 
whileCD14- CD16+ monocytes are Gr-1low orthologues due to their high expression of 
CX3CR1 (376). As previously described, CD14-CD16+ are known to be higher producers 
of TNF in vitro (154). The cytokine profiles of these monocytes at inflammatory sites 
have not been investigated in vivo, so at present, it is unclear if the in vitro findings are a 
true depiction of the in vivo responses. Previous studies have investigated the 
production of inflammatory mediators by these human subsets during coculture with 
TNF/IFN- γ –activated HuVECs. In this setting, the CD14-CD16+ monocytes have been 
shown to be higher producers of IL-6 (377). However, this effect was attributed to the 
increased expression of CX3CL1 (fractalkine) on the endothelium (377). Ligation of 
CX3CR1 in monocytes by CX3CL1 induces MAPK activation and triggers production of 
various mediators, including TNF (378-380). In other models of inflammation, the 
increased expression of fractalkine has been shown to mediate the recruitment of CD14-
CD16+ monocytes. This suggests that monocyte subset recruitment during inflammation 
is dependent on the pattern of chemokine expression in tissues. Although at present it is 
unknown which subset is preferentially recruited to the lung, previous studies have 
indicated that monocytes are recruited to the lungs in a CCL2-dependent manner during 
ARDS (130). Based on the chemokine receptor expression, one can speculate, that 
similarly to Gr-1high monocytes in mice, CD14+CD16- monocytes are preferentially 
recruited to the lungs where they also produce higher levels of inflammatory mediators. 
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This speculation, however, has to be formally demonstrated both through in vitro 
coculture systems of monocytes with human lung endothelial cells and in vivo. 
Subsequent to the findings in chapter 5, that the Gr-1high monocytes express 
significantly higher levels of TNF than the Gr-1low monocytes, especially during 
coculture with lung endothelial cells, I proceeded to determine the mechanisms 
underlying the heterogeneous monocyte subset pro-inflammatory responses. In chapter 
6, I investigated the role of the p38/MK2 pathway in regulating the differential 
responses of the monocyte subsets. I showed that the p38/MK2 pathway, which is 
known to be an important regulator of cytokine biosynthesis, is preferentially activated 
in the Gr-1high subset, and its inhibition results in a significant attenuation in the 
production of inflammatory mediators. Preliminary in vivo studies done in our group 
have also shown that the p38/MK2 pathway is preferentially activated in the Gr-1high 
subset (data not shown). These data thus suggests that the p38/MK2 pathway is a 
mechanism for the increased capacity of the Gr-1high subset to produce higher levels of 
inflammatory mediators.   
 Previous experimental studies characterising the influence of p38 MAPK 
signalling in sepsis induced lung injury in vivo, have shown that its inhibition  
significantly attenuates the recruitment of leukocytes into the lung, their production of 
cytokines and the severity of pulmonary oedema (381). These results suggests that 
selective, cell-specific targeting of p38 MAPK activation in Gr-1high monocytes, could 
potentially be a means by which to modulate and reduce the severity of sepsis induced 
ALI. In the clinical setting, p38 MAPK could serve as a therapeutic target, however, its 
inhibition in humans results in adverse effects, such as hepatotoxicity and joint pain 
(382, 383). In these studies, however, p38 has been given orally and in a non-selective 
manner. Once the roles of human monocyte subsets in ALI have been established, such 
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cell-target based approaches could potentially be investigated. Although an alternative 
method could be to target molecules downstream of p38, such as MK2, which has a 
limited number of substrates in comparison to p38 and could regulate some p38 
functions whilst leaving others intact. At present, inhibitors for MK2 are currently being 
developed but in future, they could be of potential benefit in the modulation of 
inflammatory monocyte responses during ALI. 
 
8.4   Future directions 
Building on our findings on endothelial-coculture dependent enhancement of TNF 
production by Gr-1high monocytes, further experiments will be carried out to obtain a 
more precise understanding of the mechanisms involved. Adhesion molecule blocking 
experiments could be performed to establish whether the coculture altered responses 
are cell contact-dependent and consistent with mechanisms described using other 
leukocyte-endothelial coculture systems (265, 267). 
The coculture model could also be used to investigate the role of TNF signalling 
in monocyte-mediated pulmonary endothelial activation in vitro. As I have developed a 
method for the isolation of MLEC, this method could be used to isolate MLEC from TNF 
receptor single and double knockout (KO) mice and used in cocultures. The role of 
contact-dependent membrane TNF signalling may also be determined with cell culture 
semi-permeable inserts or by using monocytes from TNF knock-in (TNF KI) mice, which 
are deficient in memTNF cleavage and express only memTNF without releasing solTNF. 
Microarray analysis of gene expression could potentially be used to pinpoint the 
level in the signal transduction pathway at which heterogeneity of LPS-induced p38 
MAPK pathway activation arises in monocytes. This type of characterisation is 
analogous to the recent study by Ingersoll et al (384), which compared human and 
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mouse monocyte subset phenotype by microarray analysis and discovered around 100 
more genes that are conserved between human and mouse monocyte subsets, which 
could be used to further characterise the functional properties of each subset in both 
species during homeostatic and inflammatory conditions. However, the subset 
heterogeneity pattern in mice and perhaps humans, appears to be context-dependent 
i.e. the pattern in whole blood is reversed in PBMC monoculture and coculture. 
Therefore attention to environment-dependent factors is essential, but could also 
provide insights into the non-LPS pathways producing monocyte activation and 
heterogeneous responses, as demonstrated in the chimera experiments in chapter 7. 
For the most part of this PhD, I focused on the direct effects of LPS on monocyte 
pro-inflammatory cytokine responses and its modulation by the lung endothelium. 
TLR4 is the main receptor through which LPS signals to induce cell activation. Having 
previously demonstrated that the endothelium could induce a state of latent priming in 
monocytes, I developed a chimera model of LPS responsive (TLR4+/+) and LPS 
unresponsive (TLR4-/-) cocultures to evaluate monocyte-endothelial reciprocal 
activation; specifically, to assess modulation of monocyte responses through the 
indirect effects of LPS-mediated endothelial activation, as well as to determine indirect 
induction of endothelial responses by LPS-activated monocytes. In my preliminary 
studies, I found that LPS-activated endothelial cells could induce late production of TNF 
in Gr-1high monocytes. I also found that LPS-activated monocytes could induce the up-
regulation of ICAM-1, VCAM-1 and E-selectin in endothelial cells. I found that up-
regulation of VCAM-1 was dependent on TNF whereas ICAM-1 up-regulation was only 
marginally dependent on TNF. As these are preliminarystudies , it is difficult to draw 
any firm conclusions, but previous monocyte-endothelial coculture experiments in our 
group using the b.End5 brain endothelioma cell line have demonstrated a major role for 
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TNF signalling in the up-regulation of adhesion molecule expression (160). Although 
these results support a key role for monocytes in local-cell mediated effects, further 
studies will have to be carried out to determine the contribution of other molecules, 
including integrins, as well as other pro-inflammatory cytokines, such as IL-1β, in 
mediating monocyte-endothelial interactions during lung inflammation.  
 
8.5 Concluding remarks 
In this project, I successfully isolated and cultured lung endothelial cells with which I 
developed an in vitro model of monocyte-endothelial interactions. With this model, I 
found that prolonged contact of monocytes with the endothelium induces a latent state 
of priming to monocytes such that they respond vigorously to inflammatory stimuli. 
Thus, contact with the endothelium is essential for optimal responses of monocytes. I 
also found that the Gr-1high subset of monocytes produces higher levels of inflammatory 
mediators than their Gr-1low counterparts, especially during coculture with the 
pulmonary endothelium. Furthermore, the p38/MK2 pathway which has been shown to 
be a regulator of a diverse range of inflammatory mediators, was preferentially 
activated in the Gr-1high subset, and inhibition of this pathway resulted in a significant 
attention of inflammatory mediator release.  
Taking all the results together, I can conclude that monocytes, especially the Gr-
1high subset produce a significant amount of the pro-inflammatory cytokines TNF and IL-
6, and express high levels of the inflammatory enzymes COX-2 and iNOS, especially 
during contact with the pulmonary endothelium. In addition, the p38 MAPK pathway is 
a critical determinant of the inflammatory mediator response exhibited by the 
monocyte subsets. The production of these key mediators by Gr-1high monocytes 
suggests a central role for them in the evolution and propagation of sepsis-associated 
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ALI. By identifying p38/MK2 as a core regulator of the monocyte subset pro-
inflammatory response, further insights may be gained into the development of cell-
specific, target based approaches to modulate local generation of pro-inflammatory 
mediators and thus control the evolution of organ injury. As research into mouse 
monocyte subset biology progresses, further understanding about their functional roles 
in ALI will be gained. With this knowledge, insights about the potential roles of human 
monocyte subsets in ALI would be obtained.  From these data, therapies to modulate 
their responses can be developed. 
 This thesis further elucidates the role of monocytes in ALI, which has until 
recently received little attention. With respect to basic monocyte biology, the findings 
help clarify the mechanisms of priming and subset response heterogeneity, 
substantiated by the linkage of ex vivo observation to the in vivo situation. The data 
clarifies some of the contact-dependent mechanisms regulating the inflammatory 
responses of monocyte subsets during ALI and also highlights the central role the 
p38/MK2 pathway plays in regulating monocyte subset responses. Finally, the method 
of primary lung coculture, and the elucidation of basic monocyte-endothelial 
interactions has enabled, could have extensive future applications for studying roles of 
various cellular and molecular interactions in the pathogenesis of ALI. 
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